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Abstract 
 
P53 protein that has been referred to as the “guardian of genome”. It acts to suppress tumour 
development through mechanisms involving cell cycle arrest, DNA repair, senescence and 
apoptosis. Loss of the tumour-suppressive activity in p53 is a frequent event, occurring in 
more than 50% of all types of human cancers, mostly via point mutations. This very common 
genetic event is often associated with trans-dominant suppression of the wild type (wt) p53 or 
gain of oncogenic function independent of the wt protein. A wide range of p53 mutations are 
frequently found in the “hot spot” region responsible for promoting carcinogenesis. In the 
current study, two mutations, located at amino-acid 175 and 273 of the protein, were selected 
due to the two opposite effects they have on the protein conformation. Indeed, mutation at 
position 175 linearises the protein completely whereas mutation at position 273 retains the 3D 
structure of the protein but abolishes the DNA binding site. In both cases the protein loses its 
tumour suppressor characteristic. We hypothesise that these two mutants will be processed 
differently and give rise to a different peptide repertoire but maybe with some peptides in 
common. Therefore, HHDII/DR1 mice were immunised with the cDNA of either of these 
mutants and responses against predicted peptides were assessed ex-vivo using ELISpot assays. 
Responses against p53-193-201 was shown to be mutation specific and was not therefore 
pursued. On the other hand responses against peptides p53-322-329 (class I) and p53-249-264 
(class II) could be detected in both the groups and were chosen for further study. Importantly 
the sequence of these peptides are the same in both human and murine p53 sequences. A 
vaccination strategy was developed using anti-CD-40 antibody and CpG TLR agonist to 
enhance the immunogenicity of the selected p53 peptides in the in vivo system. The developed 
strategy successfully demonstrated prolonged survival of the MC38 (naturally express mutated 
 xii 
 
p53) cell-induced tumour bearer C57BL/6 mice in therapeutic vaccination setting and was 
found to be associated with enhanced tumour-infiltrating CD8+ lymphocytes (TILs).  
Prostate cancer (PrCa) is one of the most predominant types of cancer in the UK male 
population with high morbidity and mortality. Although studied for a long time and having a 
FDA approved PrCa vaccine (PROVENGE®), due to limitations of the vaccine a robust, and 
patient specific treatment for PrCa still remains to be determined. P53 is found to be 
overexpressed and/or mutated in the PrCa and is associated with advanced stage of cancer and 
age of the patient. In the current study, p53-322-329 (class I) and p53-249-264 (class II) 
peptides showed immunogenic responses in the patients with various grades of PrCa when 
assessed using different functional assays. Collectively, identified p53 class I and class II 
peptides appear to be highly relevant in the context of the PrCa vaccine development. 
Assessing the p53 mutation status in the cancer patient is essential in the development and 
success of the immunotherapy. 
Chapter 1: Introduction                                                    
1 
 
Chapter 1 Introduction 
1.1 Cancer 
Cancer is one of the principal reasons of death worldwide 
(http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx), which is projected to reach up to 
12 million by 2030 (www.who.int/cancer/en). Number of deaths recorded in 2008 due to 
cancer were found to be more than AIDS, tuberculosis and malaria combined 
(www.who.int/cancer/en). According to Cancer Research UK statistics, 2010, it was 
reported that a total of 157,275 deaths from cancer occurred in the UK with 46% of deaths 
caused due to lung, colorectal, breast and prostate cancers.  
1.2 What is cancer? 
 
Cancer was first described, in the latter half of nineteenth century and beginning of the 
twentieth century, as the conversion of normal cells, giving rise to descendant cells 
forming neoplastic tumour masses (Weinberg, 2007). Cancer is a complex disease in which 
normal cells no longer respond to the regulatory signals of cell proliferation, 
differentiation, survival and cell death leading to the accumulation of the cells within the 
tissue, where inflammation occurs, causing tissue damage 
(www.nature.com/subjects/cancer). These tumour can be local (benign and noninvasive) or 
malignant, leading to metastasis in later stages. Any cell type in the body is capable of 
undergoing malignant transformation (Zingade, 2001). Cancers are mainly of epithelial 
origin giving rise to carcinomas, which may be either squamous cell carcinomas (from 
protective cell layers) or adenocarcinomas (from secretory epithelia) (Bickers and Lowy, 
1989). Non-epithelial malignant tumours include: hematopoietic cancers (originates from 
circulatory and immune system cells), sarcomas (from mesenchymal cells), 
neuroectodermal tumours (from nervous system components), and for some other types of 
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tumours, a loss of tissue-specific characters give rise to anaplastic carcinomas (Preston-
Martin et al., 1990). Cancer progresses through various stages and grades from benign to 
metastatic. Benign tumours can be categorised into hyperplastic (normal tissue appearance 
but with abundant cell number) or metaplastic (displacement of normal cells mostly) and 
dysplastic tumours is a transition state between benign and malignant e.g., polyps, 
adenomas, warts, papillomas which are classified benign but cytologically abnormal cells 
present in the basement membrane sack-like structures. Malignant tumours spread beyond 
the boundaries and metastasise to the other body organs (Mahadevan and Hart, 1990). 
Studies carried out previously have proved that different components that may cause 
cancer, where transformation of a single cell into a cancer cell occurs due to genetic 
alteration as a result of physiological and/or environmental and /or genetic alterations 
(Baylin and Jones, 2011; Sharma et al., 2010; Sandoval and Esteller, 2012).  
1.3 Causes of cancer 
 
Induction of cancer involves alterations in the genome giving rise to uncontrolled cell 
proliferation, potential to “infect” any organ of the body and metastasise (Zingde, 2001). 
Cancer arises from a single cell and is described as a multistage process. It has been 
observed in preclinical studies that the initiation process of cancer is irreversible, after 
which further phenotypic alteration occur (Zingde, 2001). The causes of cancer initiation, 
development and progression of disease is represented in figure 1.1.  
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Figure 1.1.  Causes of cancer. Transformation of normal cells into cancerous due to genetic, epigenetic, 
environmental factors, and/or viral or bacterial infections. 
 
1.3.1 Environmental carcinogens 
 
Human beings are continually exposed to different types of agents which can cause genetic 
alterations leading to cancer.  Chemical carcinogens, eg., asbestos, arsenic, aflatoxin  found 
in food items), and tobacco smoke [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) and benzo(a)pyrene (BaP)] can lead to lung and skin cancer (Hecht et al.,994; 
www.cancerresearchuk.org).  Physical carcinogens, e.g., ultra-violet rays, and ionising 
radiations can lead to malignancies (Belpomme et al., 2007).  
1.3.2 Infectious pathogens 
 
Biological carcinogens such as viruses, e.g., Human Papilloma Virus (HPV), Hepatitis C 
Virus (HCV), and Hepatitis B Virus (HBV) can cause cell transformation. HPV inhibits 
apoptotic signals by inhibiting the host cell signaling cascade of p53 and retinoblastoma 
(Rb) genes which control cellular proliferation, via interaction with E6 and E7 viral 
proteins (Song et al., 1999). HBV is responsible for the induction of Reactive Oxygen 
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Species (ROS) that leads to tumourigenesis (Jackson and Loeb, 2001).  Furthermore, some 
bacteria, such as Helicobacter pylori, cause chronic ulceration with links to the 
development of gastric cancer (Eslick et al., 1999; www.cancerresearchuk.org). Some of 
the viruses causing of human cancers are listed in Table 1.1.  
Table 1.1.  Viral infections causing cancer in humans 
Virus Virus family Targeted cells Type of malignancy References 
EBV1 Herpesviridae B cells, 
oropharyngeal 
epithelial cells, 
lymphoid 
Burkitt’s lymphoma 
Nasopharyngeal 
carcinoma 
de-The et al., 1991 
HTLV-12 Retroviridae T-cells Non-Hodkin’s 
lymphoma 
de-The et al., 1991 
HHV-83 Herpesviridae Endothelial cells Kaposi’s sarcoma, body 
cavity lymphoma 
Chang et al., 1994 
HBV4 Hepadnaviridae Hepatocytes Hepatocellular 
carcinoma 
IARC, 1994 
HCV5 Flaviviridae Hepatocytes Hepatocellular 
carcinoma 
Read et al., 1963; 
Joske et al., 1972 
HPV6 Papillomaviridae Cervical epithelial Cervical carcinoma Wong and Gruber, 
1994; Galloway, 1994 
JCV7 Polyomaviridae Central nervous 
system 
Astrocytoma, 
glioblastoma 
Richardson, 1961; 
Enam et al., 2004 
1Ebstein Barr Virus, 2Human T-Lymphotropic Virus, 3Human Herpes Virus, 4 Hepatitis B Virus, 5Hepatitis C Virus , 
6Human Papilloma Virus, 7John Cunningham Virus 
 
1.3.3 Disruption of epigenetic processes 
 
Aberrations in the epigenetic mechanisms given the integrity of chromatin are capable of 
malignant transformation (Sharma et al., 2010). Along with genetic alterations, epigenetic 
aberrations are also required for initiation and progression towards cancer and modifying 
events include DNA methylation, covalent modification of histones, nucleosome 
positioning and microRNA gene silencing, which often impacts on the activation of 
oncogenes and the silencing of tumour suppressor genes (Sharma et al., 2010). Epigenetic 
events are reversible and may be important in developing new cancer therapies. Some 
cancer treatments linked to epigenetic events include: reversing inversed methylation 
patterns in leukaemia and lymphoma using 5-azacytidine and 5-aza-2’-deoxycytidine 
Chapter 1: Introduction                                                    
5 
 
(Kantarjian et al., 2006), and the use of FDA approved histone deacetylase inhibitors, 
Vorinostat and Romidepsin, in cutaneous T-cell lymphoma (CTCL) and acute myeloid 
leukaemia (AML) (Marks & Breslow, 2007; Klimek et al., 2008). 
1.4 Genetics of cancer 
Under normal circumstances, cells constantly divide and proliferate, and cell 
transformation leading to uncontrolled cell growth, and cancer, is a relatively rare event. In 
normal cell division and proliferation the events are tightly regulated via different 
checkpoints at different cell cycle stages. The genetic material of the “mother cell” is 
copied and transferred to the descendant cells in the process of cell division and 
proliferation. Any alteration in the genetic material or sign of cellular damage is monitored 
on a regular basis by checkpoint events. If the genetic damage is irreversible and further 
proliferation may lead to a potential threat to the body, the cells undergo programmed cell 
death or apoptosis (Wyllie et al., 1980). The concept of programmed cell death to control 
cancer growth was established by functional studies (Adams and Cory, 2007; Lowe et al., 
2004; Evan and Littlewood, 1998). To maintain tissue integrity, cells undergo senescence 
and with every replication cycle the non-coding DNA sequence on the telomeres undergo 
partial degradation. These events are under close surveillance by the immune checkpoints, 
and cancer cells acquire the capacity to overcome these checkpoint surveillance 
mechanisms through further mutations. Genetic alterations are therefore the cause of 
cancer, where the cell is programmed to escape mechanisms such as apoptosis and gain the 
ability to divide uncontrollably. Hence, cancer is accepted as clonal where a primary cell 
may gain further mutation with subsequent division (Stratton et al., 2009) and acquire the 
classical hallmarks of a cancer cell. It was shown by Fearon and Vogelstein (1990) in a 
colon carcinoma model that the cell must obtain mutation in at least 5 genes, each of which 
should enable the cell to adapt and grow in the host. Some examples are, down regulation 
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of NKX3.1 homeobox gene through promoter methylation in prostate cancer (Asatiani et 
al., 2005) that leads to oxidative stress and DNA damage (Ouyang et al., 2005; Bowen & 
Gelmann, 2010); the loss or reduction of cell cycle associated PTEN tumour suppression 
proceeds to gradual progression to an androgen independent phenotype in prostate cancer 
(Mulholland et al., 2006), and up-regulation of a histone-lysine N-methyltransferase 
encoded by EZH2 gene has been associated with late stage metastatic disease promoting 
Ras and NF-κB pathways found deregulated in many cancers (Chiaradonna et al., 2008; 
Sun & Xiao, 2003). The development of PrCa is slow and asymptomatic and may reach an 
advance stage before symptoms are apparent. 
Various stages are involved in carcinogenesis, including: irreversible cell initiation 
process, promotion facilitating the expression of commenced phenotype and progression 
are shown in pre-clinical models (Zingde, 2001) and further programming towards a 
malignant phenotype through a series of gene mutations. All stages encompass subtle point 
mutations and chromosomal alterations (Zingde, 2001). The genes responsible for the 
cancerous transformation of the cell are known as “oncogenes” (Zingde, 2001) and 
promote cellular growth by various mechanisms.  Tumour suppressor genes suppress the 
uncontrolled cellular growth and control tumourigenesis, but when mutated they act in a 
similar way to oncogenes (Zingde, 2001).  
 
1.4.1 Proto-oncogenes and oncogenes 
In the 1970s, the genomes of mammals and birds were shown to contain a group of proto-
oncogenes that regulate normal cell proliferation and differentiation (Stehelin et al., 1974). 
Alterations in these genes affect the function or structure of the proteins encoded and leads 
to over-active growth-promoting genes causing cancer and were subsequently termed 
oncogenes (Bishop, 1985). Oncogenes were first identified in 1969 (Huebner and Todaro, 
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1969) associated with avian sarcoma virus B77 and the src gene. Various oncogenes were 
later identified to have viral origins (Toyoshima, 1983), and oncogenes present in the DNA 
of human tumour cells were found in a diverse range of malignancies including 
neuroblastoma, leukaemia, carcinomas and sarcomas (Slamon et al., 1984). Oncogenes 
were primarily identified in transforming retroviruses: Rous sarcoma virus, avian 
erythroblastosis virus, Harvey sarcoma virus (Bishop, 1991). Although genetic mutations 
caused by exposure to chemical or physiological carcinogens and were found to be related 
to those carried by transforming retroviruses, a common repertoire of the proto-oncogenes 
could be activated by either retrovirus or via somatic mutations (Der et al., 1982 and 
Parada et al., 1982). Somatic mutations could be further divided into two categories: one 
that causes structural alterations in encoded protein and another that causes deregulation 
expression of the encoded protein (Der et al., 1982 and Parada et al., 1982). 
Normal proto-oncogenes gives rise to controlled cell division whereas mutated ones, called 
as oncogenes, give rise to cancerous cell growth. These concepts are represented 
diagrammatically in figure 1.2, and transformation of proto-oncogene into oncogene due to 
retroviral infection is shown in figure 1.3. 
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Figure 1.2.  Proto-oncogenes when mutated to oncogenes gives rise to cancerous cell growth with the help of 
hyperactive growth promoting protein. (Figure is adapted from www.bio.utexas.edu)       
  
 
 
Figure 1.3.  Conversion of normal cell into cancerous cell due to transforming retroviruses. Diagrammatic  
representation of cancer cell formation from normal cell due to transforming retro virus mediated proto-oncogene 
conversion into oncogene. (Diagram is adapted from  http://www.britannica.com/EBchecked/topic-
art/101396/58074/Cancer-causing-retroviruses). 
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Normal cells require growth signals such as, diffusible growth factors, extra cellular matrix 
(ECM) components or cell-to-cell adhesion molecules (Zingde, 2001). These factors help 
transformation from a dormant G0 state to proliferative state (Zingde, 2001). In some 
cancers, oncogenes are over-expressed, coding for growth factors such as, sis, platelet-
derived growth factor β (PDGFβ) required by the cancer cells. These signals transduce 
growth stimulatory signals resulting in cell proliferation (Zingde, 2001). Some of the 
growth factors encoded by oncogenes are EGF-R/erbB-2 which is overexpressed in breast 
cancer (Zingde, 2001). Structural changes in the growth factor receptors (e.g., c-fms) are 
capable of ligand independent signaling and cancer induction (Zingde, 2001). Cancer cells 
are also capable of switching extracellular receptors (integrins) to transmit pro-growth 
signals to the cell (Zingde, 2001) and oncogenes are capable to act across tissue and 
species boundaries to induce cell transformation (Stehelin et al., 1976).   
1.4.2 Tumour Suppressor Genes (TSG) and inhibition of tumour suppression 
 
The proteins encoded by proto-oncogenes are responsible for providing growth stimulating 
signals and promoting cell proliferation (Heldin and Westermark, 1984). When proto-
oncogenes transform into oncogene (due to genetic aberrations) cell growth stimulating 
signals regulation gets disrupted leading to uncontrolled cell proliferation (Barbacid, 
1987). To control cell proliferation, another mechanism operates, mediated by tumour 
suppressor genes (Perry and Levine, 1993). TSG when present in their normal state control 
cell growth and respond to DNA damage. The protein activities of TSGs are intrinsic to the 
cell cycle checkpoint responses, inhibition of cell growth, induction of cellular senescence, 
cell differentiation, DNA damage and repair, promotion of apoptosis and the prevention of 
tumour progression (Jakobisiak et al., 2003; Sherr, 2004). Loss of function mutation in 
TSG results in uncontrolled cell proliferation which leads to various types of cancers. The 
“two-hit” mutation theory proposed by Knudson (1971) stating that a germline mutation of 
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one allele of a gene predisposes an individual to cancer following somatic mutation in the 
second allele holds true for most TSGs. Fifteen years later, the discovery of the first TSG 
isolated from retinoblastoma, and termed the Rb gene (Friend et al., 1986; Peters and 
Vousden, 1997) is commonly found to be defective in multiple cancers through its role as a 
checkpoint control element during cell transition into S phase of the cell cycle. Germ line 
mutation along with somatic mutation in the second Rb allele leads to cancer formation 
(Peters and Vousden, 1997). Chromosome 13 may be damaged or a part of this 
chromosome, containing the Rb locus, is deleted, which alters the normal role of Rb in 
mitosis. Normally Rb prevents the cell from entering into the synthesis phase by binding to 
the transcription factor, E2F. During cell cycle phosphorylation of Rb is regulated 
periodically and hyperphosphorylation of Rb inhibits its interaction with E2F, as a result of 
which uncontrolled cell growth occurs and tumours form (Peters and Vousden, 1997).  
In contrast to proto-oncogenes, genetic mutations in both alleles of a tumour suppressor 
gene results in alteration of normal protein function through processes such as loss of 
hetrozygosity, methylation, cytogenic aberrations, and polymorphisms (Teh et al., 1999). 
In hereditary cancer syndromes, defective TSG expression pre-disposes individuals to a 
further mutation of the gene that leads to cancer. Patients with familial adenomatous 
polyposis have an increased risk of developing colorectal cancer due to mutations that 
reduce the activity of the adenomatous polyposis coli (APC) gene. APC operates within the 
Wnt signalling pathway, targeting free β-catenin for ubiquitination, preventing the 
transcription of cyclin D1 and MYC genes which are responsible for cell cycle 
advancement to S phase (Vogelstein & Kinzler, 2004). Germline mutations in the stability 
genes BRCA1 and BRCA2 also predispose individuals to breast and ovarian cancer (King et 
al., 2003). Various TSGs identified are given in Table 1.2 (adapted from Fearon, 1997 and 
Marsh and Zori, 2002).  
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               Table 1.2.  Tumour suppressor genes and types of cancer induced 
Tumour Suppressor Genes Cancer Type 
Rb1 Retinoblastoma 
p53 Many types of cancer 
BRCA1/BRCA2 Breast and ovarian cancers 
p161NK4a Oesophageal squamous cell carcinoma 
THY1 Nasopharyngeal carcinoma 
NF12 Many types of cancer 
                         1Retinoblastoma tumour suppressor gene, 2Neurofibromatosis type 1 
 
From the above, it can be stated that cancers develop by acquiring mutations in growth 
promoting oncogenes. On the other hand cancer inactivates recessive mutations in TSG 
along with epigenetic abnormalities which are important in the expression of these 
suppressor genes (Weinstein, 2000). All of these changes demonstrate the lethal effects of 
mutagens, germline mutations and genomic uncertainties attained in the process of tumour 
development (Weinstein, 2000). Both proto-oncogene and tumour suppressor genes are 
involved in signal transduction pathways and act in synergy. Any alteration in these genes 
affects the pathway, giving rise to uncontrolled cell proliferation which leads to cancer. 
Gene mutations leading to the loss or functional impairment of the p53 protein represents 
perhaps the most frequent genetic alteration event observed in cancer. The p53 gene acts as 
a transcription factor controlling the activation and inhibition of many genes and functions 
at the nexus of all cell cycle signalling pathways. The importance of p53 and Rb as TSG 
and their network of associated proteins are important as they are both commonly defective 
across several types of cancer and virtually all oncoviruses directly or indirectly inactivate 
both p53 and Rb TSG pathways leading to tumour formation (Vogelstein & Kinzler, 2004). 
1.5 p53, the guardian of genome and executioner: an ideal candidate for cancer 
immunotherapy 
 
p53 is a nuclear protein which shuttles to the cytoplasm, becomes degraded by the 
proteasome into peptides, some of which are presented on the cell surface in the context of 
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MHC antigens (O’Keefe et al., 2003, Townsend et al., 1985). p53 protein is encoded by 
the p53 gene which is located on chromosome 17p13.1 (Vogelstein et al., 2000; Petitjean 
et al., 2007b) and was originally discovered as a complex along with simian virus 40 
(SV40) large T antigen (Lane and Crawford 1979 and Linzer and Levine, 1979). Initially 
suggested as a pro-oncogene, wild type and mutant forms of p53 were shown to possess 
several functions subsequently (Freed-Pastor et. al, 2012).  It is widely accepted that 
mutations in p53 are very common genetic events in cell transformation in human cancers 
(Levine and Oren, 2009).  
Wt p53 controls cell division through different mechanisms such as repair of DNA 
damage, apoptosis or cell cycle arrest, acting as a transcription factor. p53 in its active 
form promotes the production of  p21, which forms a complex with the cell division- 
stimulating protein, cdk2. On formation of this complex, cells cannot progress to the next 
stage of cell division. Any damage or mutation to p53 due to alteration in the environment 
due to hypoxia, stresses, DNA damage, onco-gene activation can alter the function of 
tumour suppression which in turn leads to uncontrolled cell proliferation. Mutation in p53 
prevents DNA binding and lack of p21 production leads to failure in p21-cdk2 complex 
formation. The cells no longer receive the “stop” signal and divide uncontrollably (Harper 
et al., 1995). Figure 1.4 gives the overview of the mechanism. 
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Figure 1.4.  Functions of p53 in the cell cycle. Shows rescue of damaged cells by p53 by activating p21 gene 
under normal circumstances. Mutation in p53 abolishes the binding site of the protein to the DNA. Lack of 
p21 causes uncontrolled cell division. 
 
p53 is activated in response to diverse cellular stress signals including nucleotide 
deprivation, oncogene activation and hypoxia following which p53 orchestrates stress-
specific pathways. Most significantly p53 is instrumental in conserving cell function via 
protein activation essential for DNA repair by initiating cell cycle arrest in the event of 
DNA damage or triggering programmed cell death if the damage is too great (Bertram, 
2000; Horn & Vousden, 2007).  
1.5.1 Mutations in p53 
 
There are different types of mutations found in the p53 gene, at different locations such as; 
position 273, 248, 196, 213, 245, 282, and 306 (Olivier et al., 2010) which can be divided 
into two categories: one that affects the structure and the other affects the conformation of 
the p53 protein. In the present research, the two types of mutations are represented by: 
p53-175 (structural alteration) and p53-273 (conformational alteration) (Liu et al., 2010). 
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Mutation at the location 175 changes the arginine to histidine (R-H) and linearises the 
protein. Mutation at the 273 location abolishes the binding site of the protein to the DNA, 
thus losing the tumour suppressor function of the protein. Mutation in the p53 gene gives 
rise to the accumulation of the protein within the cell (Rivlin et al., 2014). Mutations in 
p53 give rise to tumour initiation, promotion, aggressiveness and metastasis while going 
through the multistep process of malignant transformation (Rivlin et al., 2014). Mutant p53 
protein not only loses its tumour suppressive character but has been shown to gain 
oncogenic function leading to cells growth and survival (Olivier et al., 2010).  
1.5.1.1 Somatic mutations 
Somatic mutations occur in more than 50% of human cancers (Wang  et al., 2013) with 38-
50% of ovarian, oesophageal, colorectal, head and neck, larynx and lung cancers, 
demonstrating p53 mutations.  5% of primary leukaemias, sarcomas, testicular cancer, 
malignant melanoma and cervical cancers also possess mutated p53 (IARC TP53 database; 
Pititjean et al., 2007b; Olivier et al., 2010). Somatic mutations appear to be more frequent 
in advanced or aggressive cancer subtypes (Wang et al., 2004a; Langerod et al., 2007). 
Within the DNA binding Domain, 175, 145 and 173 hotspot codon mutations represent 
60% of the CpG mutations and 196, 213, 245, 282, 306 residues represents 26% of 
mutations (Olivier et al., 2010). 
1.5.1.2 Germ line mutations 
Germ line mutations are located in highly conserved regions of exons 5-8 (Kleihues et al., 
1997).Germline mutations are distributed similarly to that of the somatic mutations located 
at the “hot spots” regions (Olivier et al., 2010). In germ line mutations, point mutations are 
most common followed by splice mutations and insertions. G:C-A:T are the most 
commonly found transitions followed by G:C-T:A and A:T- G:C (Kleihues et al., 1997). 
Germ line mutations arise spontaneously compared with somatic mutations (Olivier et al., 
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2010).  P53 is found to be mutated in 50% of breast cancers, soft tissue and bone cancers. 
These are followed by adrenocortical sarcomas, brain tumours, gastric, colorectal and 
ovarian cancer that occurs at early age within the general population (Oliver et al., 2003). 
Some other less frequent types of cancers associated with germ line mutations are choroid 
plexus carcinoma, papilloma, Wilms’ tumour, and malignant phyllodes tumours (Birch et 
al. 2001; Gonzalez et al., 2009).  
Individuals with deleterious mutation in the p53 gene are 15% more likely to develop 
cancer at the age of 15 years, 80% or more in 50 year old women and 40% in 50 year old 
men (Soussi, 2000). In the case of p53, one allele is lost and the second undergoes 
mutation (Esrig et al., 1993). Wild type p53 has a half-life of 6-30 mins whereas the 
mutated p53 forms the complexes with heat-shock protein (hsp70) and can be stable for 
hours (Esrig et al., 1993). P53 mutations are frequently found in the conserved regions of 
the central DNA binding domain of the protein (Attardi and Jacks, 1999). Residues within 
the “hot spot" mutations are responsible for maintaining the integrity of DNA-binding 
surface structure or in initiating DNA contact. On this basis they are classified as “contact 
mutants” (residues R248 and R273) or “structural mutants” (residues R175, G245, R249, 
R282) (Joerger et al., 2007). The protein possesses an acidic N-terminal transactivation 
subdomain, containing proline-rich regions that contains a secondary transactivation 
domain, DNA-binding domain, an oligomerisation domain which contains a nuclear export 
signal and a C-terminal regulatory domain that contains three nuclear localisation signals. 
The great majority of mutations are clustered in the central most conserved region (Freed-
Pastor et al., 2012). The most frequently found “hot spot” mutations are listed in the table 
3.1. The different p53 mutations, their frequency of alteration and their categories are 
given in Table 3.2. 
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Cancer peptide vaccines 
van Der Bruggen et al., introduced the cDNA cloning technique to identify genes and 
peptides from tumour-antigens in 1991 followed by the technique to identify genes and 
peptides by host immune system using autologous antibodies by Chen et al., 1997. These 
reports resulted in providing a large number of antigens and peptides as cancer vaccines. 
Melanoma antigen gene-1 (MAGE-1) derived peptide vaccine came up as the first peptide 
vaccine in the clinical trials (Hu et al., 1996). Earlier generation of peptide vaccines were 
composed of one to several MHC-class I restricted peptides of a single HLA type. The 
peptides were imulsified in a clinical grade incomplete Freund’s adjuvant,  Montanide 
ISA51,  or pulsed on antigen presenting cells and used for vaccination (Yamada et al., 
2013). Various types of peptide vaccines have been developed since then targeting various 
cancer antigens. Multivalent long peptide vaccine/ synthetic long peptide vaccines, as the 
name suggests are pool of long peptide vaccines which are taken up by APCs for 
processing and presentation by MHC class I and class II (Yamad et al., 2013).   Kenter et 
al., carried out a phadse I study of high risk HPV 16 E6 and 7 overlapping long peptides in 
end stage cervical cancer patients using a cocktail of long peptide covering entire proteins 
in montanide ISA51. At 12 months of follow up patients showed clinical responses to the 
peptide vaccine (Kenter et al., 2008). Different types of peptide vaccines have since been 
in use in cancer therapy including multipeptide vaccines (consisting of both CTL and Th 
peptides), peptide cocktail vaccines (different peptides with different peptide binding 
affinities loaded onto APCs), hybrid peptide vaccines (a peptide fused with two peptides, 
eg., Ii-Key ⁄ HER-2 ⁄ neu), personalised peptide vaccines (to match the pre-existing 
immunity of each patient) and peptide pulsed dendritic cell vaccines (Rahma et al., 2012). 
P53 targeting acnecr vaccines  
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Since p53 is found to be mutated/over-expressed in more than 50% of different types of 
cancers (Vogelstein et al., 2000), there have been various attempts to develop a p53 cancer 
vaccine. In all of these trials either whole p53 gene and/or overlapping p53 peptides/ 
synthetic long peptides from the immunogenic regions of the protein were used for vaccine 
development (Table 1.3, adapted from Vermeiji et al., 2011). For the current study, the 
main focus was to identify the immunogenic p53 class I and class II wt peptides in silico 
and assess their immunogenicity in the selected p53-175 and p53-273 mutants of interest 
and develop cancer vaccination strategy targeting p53 by recruiting wt p53 in prostate 
cancer (PrCa). Levels of p53 are controlled by Mdm2 and p19ARF, the upstream regulators. 
MDM2 is a E3 ligase which is specific to p53 and is the cellular antagonist of the protein 
(Moll and Petrenko, 2003). MDM2 monoubiquitinates p53, a crucial step in degradation of 
the protein by both nuclear and cytoplasmic proteasome (Moll and Petrenko, 2003). 
Apoptosis is a complex cellular mechanism which can be activated either by p53 or by 
extracellular signals (Drake et al., 2006). Alterations in the apoptotic function allow cancer 
cells to escape several types of physiologic stresses (Drake et al., 2006). Cancer cells find a 
number of mechanisms to inactivate the apoptotic function in order to survive, including 
activation of Akt/PKB firing, increase in anti-apoptotic Bcl-2 related proteins, inactivation 
of p52 via alterations in the p53 gene or its upstream regulators, methylation of pro-
apoptotic promoters, inhibition of caspases (Drake et al., 2006). p53 mediated signal 
transduction pathway is shown in figure 1.5. It has also been found that mutated and wt 
p53 can give rise to same types of tumours. Interestingly, mutant p53 has found to have 
more lifespan and dominant over that of wt.  
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Table 1.3.  p53 targeting cancer vaccines 
Immunisations with Protein/ 
Peptides 
Type2  Patients Clinical 
trial  
Reference 
full length wt1 p53 Wt a recombinant 
replication-defective 
adenoviral vector encoding  
rAd/hup53, to 
urogenital-, lung cancer, 
malignant schwannoma 
Pilot 
study 
Kuball et al., 
2002 
full length wt p53 Wt recombinant virus colorectal cancer Phase I/II Menon et al., 
2003 
Idiotypic vaccine, CDR regions of human anti-p53 antibody CDR8 
regions of 
human anti-
p53 antibody 
Idiotypic p53 vaccine breast, colorectal, non-small-
cell 
lung, renal, prostate, head- and 
neck, hemangiopericytoma, 
esophageal cancer 
Phase I Lomas et al., 
2004 
 65–73 (RMPEAAPPV), 264–272 (LLGRNSFEV), 187–197 
(GLAPPQHLIRV) 
Wt DC based (CTL epitopes) 
 
Advanced breast cancer Phase I Svane et al., 
2004 
149–157 (SLPPPGTRV), 139–147 (KLCPVQLWV), 103–
111 (YLGSYGFRL) 
modified     
P53 gene Wt recombinant virus small cell lung cancer Phase I/II Antonia et 
al., 2006 
 65–73 (RMPEAAPPV), 264–272 (LLGRNSFEV), 187–197 
(GLAPPQHLIRV) 
Wt DC based (CTL epitopes) 
 
Advanced breast cancer Phase II Svane et al., 
2007 
149–157 (SLPPPGTRV), 139–147 (KLCPVQLWV), 103–
111 (YLGSYGFRL) 
modified     
70-99 (APPVAPAPAAPTPAAPAPAPSWPLSSSVPS) 
86–115 (APAPSWPLSSSVPSQKTYQGSYGFRLGFLH) 
102–131 (TYQGSYGFRLGFLHSGTAKSVTCTYSPALN) 
126–155 (YSPALNKMFCQLAKTCPVQLWVDSTPPPGT) 
142–171 (PVQLWVDSTPPPGTRVRAMAIYKQSQHMTE) 
157–186 (VRAMAIYKQSQHMTEVVRRCPHHERCSDSD) 
174–203 (RRCPHHERCSDSDGLAPPQHLIRVEGNLRV) 
190–219 (PPQHLIRVEGNLRVEYLDDRNTFRHSVVVP) 
206–235 (LDDRNTFRHSVVVPYEPPEVGSDCTTIHYN) 
224–248 (EVGSDCTTIHYNYMCNSSCMGGMNR) 
Overlapping 
wt 
SLPs3 emulsified in 
Montanide ISA-51 
Ovarian cancer patients Phase II Leffers et al., 
2009 
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p53.1: 1-78; p53.2: 70-115; p53.3: 102-155; p53.4: 142-203; 
p53.5: 190-248; and p53.6: 241-393. 
Overlapping 
wt 
SLPs emulsified in Montanide 
ISA-51 
Metastatic colorectal cancer Phase I Speetjens et 
al., 2009 
full-length wt p53 
gene 
Wt Ad.p53DC vaccine plus 
indoximod. 
Adult patients with metastatic 
solid tumors that were p53+ 
(>5% nuclear staining by 
IHC), 
Phase I/II Soliman et 
al., 2010 
264-272 Wt 1. Peptide admixed with GM-
CSF and emulsified in 
Montanide ISA-51 
2. CD-40 ligand matured DCs 
pulsed with p53-264-272 
peptide 
Stage III, IV or high 
recurrence risk ovarian cancer 
patients 
Phase II Rahma et al., 
2010, 2011 
aa 70-248, 25–30 amino acid long overlapping 
peptides 
Wt SLPs in Montanide ISA-51 
with low dose 
cyclophosphamide  
Ovarian cancer Phase II Vermeij et 
al., 2011 
Aa4 70-235 (224-248 excluded due to low yield and purity) Wt SLPs with IFNγ Colorectal cancer patients Phase I/II Zeestraten et 
al., 2012 
full-length wt p53 
gene 
Wt Ad.p53DC5 vaccine with or 
without ATRA6 
Extensive stage SCLC7 Phase II Iclozan et al., 
2013 
1Wild type, 2type of vaccine, 3synthetic long peptides, 4amino acid, 5Autologous DCs expressing p53 after infection with adenovirus encoding full-length wtp53, 6all trans retinoic acid, 7small 
cell lung cancer, 8complementarity determining regions 
 
 
 
 
Chapter 1: Introduction                                                    
20 
 
           
Figure 1.5.  p53 mediated signal transduction pathway. In the presence of transcription factor protein that  
inhibits cell growth is produced after transcription and translation processes.  When non-functional 
transcription factor is presented due to mutations in p53 gene, it cannot trigger transcription due to which 
protein which inhibits cell division cannot be produced and uncontrolled cancerous cell division occurs. 
(Diagram is adapted from www.gopixpic.com) 
 
1.6 The immune system and cancer 
 
The immune system is the body’s natural shield against invading pathogens and consists of 
different cells (figure 1.6) which recognise foreign antigens and invading pathogens. But 
the gradual realisation of the importance of the immune system in cancer etiology arose 
from observations in immuno-deficient animals and in patients with immuno-suppressive 
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therapy (Hanahan and Weinberg, 2011). In the late 19th century Dr. William Coley devised 
the first anti-cancer vaccine that involved triggering the immune system using bacterial 
toxins (Coley, 1893) and in 1909, the concept of immunosurveillance was first formulated 
by Dr. Paul Ehrlich who suggested that cell transformation is a frequent occurrence in 
humans and such cells are recognised and eliminated by the immune system before they 
become clinically apparent. In more recent times, several studies have confined the 
importance of both innate and adaptive immunity against tumours with the identification of 
tumour-specific circulating T lymphocytes as well as tumour reactive antibodies in the 
blood of cancer patients (Valmori et al., 2000; Schlichtholz et al., 1992). Similarly, the 
release of cellular stress induced signals and the loss of surface MHC class I expression 
appear to activate natural killer (NK) cell-mediated tumour cell lysis (Long & 
Rajagopalan, 2002). With knowledge of the complicated processes that orchestrate the 
anti-tumour response, several strategies to utilise the immune system in therapy have been 
proposed. 
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Figure 1.6.  Diagrammatic representation of different types of cells involved in induction of immune 
responses against invaders.  (Diagram has been adapted from www.uta.edu/chagas/images/immusys.jpg)  
 
1.6.1 Adaptive and Innate immunity and cancer 
 
The innate immunity is considered to be the “non-specific” arm of the immune system that 
includes defences present constitutively, capable of responding rapidly against pathogenic 
infection and eliminating any invaders. Several natural effector cells have been identified, 
such as NK cells, NKT cells and γδ T-cells originating from lymphoid progenitor and 
phagocytic cells e.g., macrophages and DCs derived from a myeloid lineage. These cells 
perform their function through interaction of cell-surface pattern recognition receptors 
(PRRs) with pathogen-associated molecular patterns (PAMPs) (associated with a wide 
range of conserved surface molecules of microbial origin). On the other hand, damage-
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associated molecular patterns (DAMPs) are also recognised by PRRs during cellular 
damage (Seong & Matzinger, 2004) followed by phagocytosis. Likewise, NK cells release 
cytotoxic granules to induce either apoptotic or osmotic lysis of target cells. A family of 
transmembrane protein structures, considered to be most important types of PRRs, toll-like 
receptors (TLR), are common among vertebrates and invertebrates. Ten functional 
members have been classified according to their known agonists in mammalians: TLR 
recognition of peptidogylans (TLR2), double stranded RNA (TLR3), lipopolysaccharide 
and viral proteins (TLR4), flagellin (TLR5) and unmethylated CpG DNA motifs (TLR9) 
(Imler et al., 2001; Akira & Takeda, 2004). TLR mediated signalling pathways include 
NFκB and mitogen-activated protein kinases (MAPK) capable of inducing pro-
inflammatory cytokines, chemokines and expression of co-stimulatory molecules essential 
for the induction of adaptive immunity via APCs (Kawai et al., 2001; Medzhitov, 2001).  
It has been suggested that cells of the innate immune system are comparable to adaptive 
immune responses in detecting nearby tumour cells and that endogenous danger signals 
released by damaged cells, principally uric acid (Shi et al., 2003) or through exposure to 
certain inherent biological signals of the tumour itself (Seong & Matzinger., 2004) are 
implicated in the activation of innate immune responses. Pro-inflammatory responses may 
be induced through the activation of TLRs by agonists, eg. heat-shock proteins (HSPs), 
high-mobility group protein B1 (HMGB1) and ECM derivatives (hyaluronic acid and 
heparin sulphates) (Dunn et al., 2004) and a number of danger signals produced by 
tumours. In NK cells, NKG2D acts as an activation receptor capable of triggering NK 
mediated tumour cell lysis and induce NK cells to secrete IFNγ, a potent pro-inflammatory 
stimulator, which is capable of inhibiting angiogenesis, metastasis and induces the 
recruitment of lymphocytes. IFNγ also activates the adaptive T lymphocyte response 
through the maturation of macrophages and DCs which in turn release IL-12 which 
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enhances anti-tumour CD8+ CTL and further promotes NK cytotoxicity. NKG2D serves as 
a co-stimulatory receptor for TCR-activation of CD8+ T- cells (González et al., 2008). NK 
cells have also been found to recognise MHC class I molecules via specific surface 
receptors (Killer inhibiting receptors (KIRs), lectin-like receptor 1 (LIR-1) and CD94-
NKG2A) that all act to inhibit NK cytotoxic activity. A frequent immune evasion 
mechanism, known as “the missing-self”, the absence or insufficient concentration of 
MHC class I expression on the cell surface, leads to NK mediated cell lysis (Moretta & 
Moretta, 2004).  
“Unconventional” T-cell populations have been studied recently with regard to their role in 
bridging innate and adaptive immune responses. NKT cells represent a subset of CD3+ T 
lymphocytes expressing CD1d-restricted TCR on their surface, which differ from the 
conventional αβ TCR that are limited to recognise glycolipid antigens via PRR from 
bacterial origin rather than peptide/MHC. Phenotypically, NKT cells closely resemble cells 
of the innate immune system with NK-like features: rapid production of IFNγ, IL-4 and 
GM-CSF upon activation, exhibit NK-like killing, and fail to generate immunological 
memory (Berzofsky & Terabe, 2009; van Kaer et al., 2011). Similarly, mature γδ T-cells 
form a functionally distinct subgroup that provides them with both innate and adaptive 
characteristics. These cells are capable of recognising microbial invaders (Vδ2 T-cells) and 
transformed cells (Vδ1 T cells) independent of antigen presentation and MHC antigen-
expression, eliciting both NK cell and CTL anti-tumour effector responses, and appear to 
have immunological memory (Holtmeier & Kabelitz, 2005; Kalyan & Kabelitz, 2013). 
These two populations provide evidence for an overlapping component that encompasses 
both the innate and adaptive arms of the immune system (Kim et al., 2007). Figure 1.7 
represents the overview of the immune system. 
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The most effective cross-talk between the innate and adaptive immune systems occurs 
through B lymphocytes, macrophages and DCs, via antigen capture, processing and 
presentation. DCs are considered to be the “professional” antigen presenting cells (APCs) 
that have been intensely researched to establish their identity and clinical utility. DCs are 
derived from bone-marrow progenitor cells and are designated as the sentinels of the 
immune system, positioned at the antigen entry points of the body. Due to surface 
projections (dendritic processes) similar to those found on neurons, the cells are named as 
Dendritic Cells (DCs). DCs were discovered by Steinman et al., in 1972 and efficiently 
present proteins and peptides to T and B lymphocytes (Steinman, and Cohn, 1973). DCs 
are key to the primary immune response induction (Kushwah and Hu, 2011) which leads to 
the development of immunological memory (Hart, 1997). DCs reside in the periphery in an 
immature state. On encounter with damaged or infected cells, DCs begin to engulf cellular 
debris by phagocytosis and following antigen uptake, migrate to the draining lymph nodes. 
They undergo maturation which culminates in the upregulation of surface MHC antigen 
and co-stimulatory molecules, CD40 and B7. In addition, DCs process captured proteins 
into short peptides which are then displayed onto MHC molecules present on the cell 
surface. In the lymph nodes, DCs activate naive CD4+ and CD8+ T-cells differentiating 
them into antigen-specific effectors T-cells. The maturation status of DCs is important in 
generating functional effector T-cells (Steinbrink et al., 2009; Palucka & Banchereau, 
2012).  
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Figure 1.7.  The overview of the  of the immune system. (Adapted from Biology by Campbell and Reece, 
2008)  
 
1.6.2 The humoral response  
Humoral immunity is generated through antigen-dependent activation of B lymphocytes by 
DCs leading to either memory B cells or their clonal proliferation and terminal 
differentiation into antibody-secreting plasma cells. Circulating antibodies (Ab) can 
facilitate the ingestion of cells by phagocytic macrophages through antibody opsonisation, 
a process involving FAb mediated binding of antigen and activation of Fc receptors on the 
surface of macrophages. Similarly antigen bound antibodies can attract complement 
molecules to induce cell clearance via macrophages. Critically, B lymphocytes are 
Chapter 1: Introduction                                                    
27 
 
themselves able to recognise and engulf soluble forms of their cognate antigen and display 
processed antigens bound to MHC class II molecules on their surface to T lymphocytes 
(Noeile et al., 1992; Spriggs et al., 1993). Following B lymphocyte and CD4+ T-cell 
interactions, a further co-stimulation signal (via CD40/CD40L) activate B cell proliferation 
(Noeile et al., 1992; Spriggs et al., 1993). Meanwhile CD4+ T-cells begin secreting 
cytokines to drive the development of a Th2 (CD4 phenotype) response. Plasma cells are 
unable to generate a high-titre of antibodies without of cognate CD4+ T-cells. This has led 
to the identification of numerous TAA through serological identification of antigens by 
recombinant expression cloning (SEREX), suggesting that humoral responses are capable 
of inducing antibody mediated anti-tumour responses concomitant with T-cell activation 
(Li et al., 2004). During their development, B lymphocytes undergo negative selection to 
antigens in the bone marrow. Studies have demonstrated that an increase in B cell tumour 
infiltrates correlate with a poor prognosis in patients with metastatic disease (Dong et al., 
2006), contrary to other findings which associate them with improved survival (Nzula et 
al., 2003; Kotlan et al., 2005). Although it is evident that the humoral response is 
detrimental to the effectiveness of the anti-tumour responses, it is becoming clear that the 
correct Th1/Th2 CD4+ T-cell balance relative to CD8+ and B-cell responses is critical to 
promote tumour rejection (Kao et al., 2006; DiLillo et al., 2010).  
 
1.6.3 The cell mediated response  
The cell mediated response is comprised of three functional classes of T lymphocytes 
which are capable of inducing antigen-specific responses following their activation by 
APCs. Cytotoxic T lymphocytes or CD8+ T-cells recognise and eliminate infected or 
transformed cells. T helper lymphocytes (Th) or CD4+ can differentiate into two further 
subtypes of effector cells: T helper 1 lymphocytes (Th1 cells, involved in promoting CTL 
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responses through APC signalling and drives the activation of macrophages) and T helper 
2 lymphocytes (Th2 cells, promote the development of a humoral response via B-cell 
interaction) (Fearon and Locksley, 1996).  
On interacting with CD4+ T-cells DCs undergo further maturation which facilitates 
differentiation and expansion of CD8+ T-cells into antigen specific CTL (Schoenberger et 
al., 1998). This helps activated CTL and Th cells to migrate to the site of the tumour and 
initiate antigen-specific killing of tumour cells expressing the same antigen through the 
release of cytolytic toxins or through the activation of death-inducing signal receptors on 
the cell-surface of targets. This represents the mobilisation of cellular components involved 
during the adaptive response (Schoenberger et al., 1998).   
 
1.6.4 MHC and antigen presentation (exogenous and endogenous pathways) 
In the early 1950s, Gorer and Snell found that every mammalian species possesses a tightly 
linked cluster of genes that constitutes the Major Histocompatibility Complex (MHC). 
These are important in intercellular recognition and in discrimination between self and 
non-self. These genes are organised within a continuous stretch of DNA, localised on 
chromosome 6 and are known to as the HLA complex in humans and H-2 complex in mice 
(located on chromosome 17) (Trombetta et al., 2005). In both species, the genes are 
classified into class I, class II and class III MHC genes (Trombetta et al., 2005). MHC 
class I and class II antigens function as highly specialised antigen presenting molecules. 
They present the class I or class II peptides to the T-cell and are responsible for activating 
the immune system (Trombetta et al., 2005). MHC class III antigens are not related to class 
I and class II proteins and are responsible for the secretion of proteins that form the 
complement system (Trombetta et al., 2005). The structure of MHC class I and class II 
molecules is shown in figure 1.8. 
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Figure 1.8.  Structure of MHC class I and MHC class II molecules. They are structurally distinct, but 
homologous proteins. Both are characterised by presence of an extracellular, peptide-binding cleft and pair 
of Ig domains and is anchored to the cell membrane through transmembrane segments. (Figure is adapted 
from Airaldi, 2014). 
 
Exogenous and endogenous processing of antigens 
The immune system continuously assesses the intra and extracellular proteins for 
indications of infection or transformed cells. This process is mediated through MHC class I 
and class II molecules which present peptide fragments to T-cells and activates the 
immune system to invade the infection. These MHC-peptide complexes are generated 
within APCs and presented to T-cells. The peptides and MHC molecules are generated in 
one of two classical antigen presentation pathways. Typically, MHC class I molecules bind 
peptide fragments from intracellular sources (e.g. viral and altered self proteins) and are 
presented to CD8+ T-cell whereas MHC class II molecules present proteins arising from 
extracellular sources as a consequence of phagocytic activity by the APCs (Bevan, 1976; 
Shen & Rock, 2006). The processing and presentation of antigens via MHC class I and 
class II pathways are illustrated in figure 1.9.  
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Endogenous peptides destined for surface presentation by MHC class I molecules undergo 
degradation by a multi-catalytic complex, proteasome. Proteasomes are responsible for the 
ubiquitination of all miss-folded, damaged or foreign cytoplasmic proteins that have been 
covalently tagged with ubiquitin molecules (Michalek et al., 1993). Proteasomes contain 
three IFNγ-inducible immunoproteasome subunits, LMP2, LMP7 and MECL-1 which 
induce proteasomal protease activity allowing transportation of peptide fragments to the 
ER via transporters associated with antigen processing (TAP) molecules. MHC class I 
antigens and peptides are assembled within the ER lumen through the co-ordination of the 
peptide loading complex which consists of tapasin, ERp57, calreticulin and TAP 
molecules. The MHC heavy chain (α1, α2 and α3 components) are stabilised by the 
glycoprotein binding chaperon protein called calnexin before binding with β2m and tapasin 
mediate the editing and loading of high affinity peptides onto the MHC class I molecule 
(Praveen et al., 2010). The binding of peptides enhances the structural stability of the 
MHC molecule and the complex is exported out of the ER to the Golgi complex. CD8+ T-
cell-mediated immune response is induced after this complex is exocytosed to the cell 
surface via transporter vesicles (Praveen et al., 2010). 
Although having similar structure and intracellular function of antigen processing, the 
assembly of the MHC class II molecules is significantly different. Exogenous proteins 
enter the cell via intracellular endosomal vesicles and as endosomes advance further into 
the cell the pH environment within them falls, which activates acid proteases (such as 
cathepsins) to degrade antigens into short peptide fragments (Parham, 1999; Nordeng et 
al., 1998; Busch et al., 2000). In the ER lumen, MHC class II α and β chain are assembled 
in a dimer upon synthesis. During this stage, an additional chaperon chain molecule 
invariant chain (Ii) associates to form a heterodimer and prevents binding of polypeptides 
to the peptide binding groove (Parham, 1999; Nordeng et al., 1998; Busch et al., 2000). 
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The hetrodimer complexes are exported to the Golgi complex and trafficked through the 
cytoplasm via exocytic vesicles. Ii gets degraded leaving a small region, CLIP, inside the 
binding groove (Kasai et al., 1998). CLIP detaches from the MHC class II allowing high 
affinity peptides-MHC complex formation (Kasai et al., 1998). The vesicle containing the 
MHC class II-peptide complex shuttles towards the plasma membrane for presentation to 
CD4+ T cells leading to induction of immune response (Robinson and Delvig, 2002). 
Although the two pathways mediate extracellular and intracellular routes, these divisions 
are not strictly adhered to. Endogenous antigens internalised by DCs can generate peptide-
MHC class I complexes that are cross-presented to CD8+ T cells (Bevan, 1976; Shen & 
Rock, 2006). Similarly, endogenous proteins which are independent of the proteasome and 
TAP complexes may lead to peptide-MHC class II complexes recognised by CD4+ T-cells 
(Li et al., 2008). Although the mechanisms for cross-presentation are not fully determined, 
reports suggest that exogenous antigens escape through translocators into the cytostol or 
through phagosome-ER fusion leading to MHC class I presentation (Shen & Rock, 2006). 
Importantly, the mechanisms of cross-presentation can be exploited to induce antigen-
specific immune responses stimulating both CD4+ and CD8+ T-cells. 
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Figure 1.9.  Exogenous and endogenous antigen processing pathways. Intracellular antigens are processed 
into short peptides by the proteasome. The short peptides generated are then transported to RER by TAP to 
interact with MHC I molecules. The MHCI-loaded peptide complex is then transported to cell surface for 
recognition by CD8+ T-cells. Extracellular antigens are internalised by APC and is processed within the 
lysosomes. MHC II molecule generated at the RER is associated with Ii (Invariant chain) thereby preventing 
the class I peptides uptake by MHC class II. The MHC II-Ii complex is transported to the endosomal 
compartment where it fuses with the endosome. Once in the endosome, Ii degrades and is replaced by CLIP 
which prevents pre-mature binding of peptide to MHC II molecule. The endosomal compartment later fuses 
with the lysosome where CLIP is replaced by the peptide. The peptide-MHC complex is then moved to the 
plasma membrane for presentation to CD4+ T-cell (Image adapted from www.qiagen.com).  
 
1.6.5 Hard and soft loss of MHCs 
 
Studies by Garrido et al. (2010) showed the altered expression of MHC class I molecules 
in solid tumours and cancer cell lines. Genetic, epigenetic, transcriptional and post-
transcriptional events cause reversible regulatory abnormalities (reversed with cytokine 
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treatment) or irreversible structural defects (Garrido et al., 2010) to MHC which are 
classified as: regulatory or “soft” and “hard” defects respectively (Garrido et al., 2010).  
Three of the 6 classical normally expressed MHC class I genes can be lost in tumours in a 
somatic cell (Garrido et al., 2010). This mechanism is associated with loss of 
heterezygocity (LOH) in HLA-ABC harbouring chromosome 6, a frequently found 
mechanism in irreversible MHC class I alterations (Melano et al., 2002; Garrido et al., 
2010). Another irreversible MHC defect/ total loss of MHC class I expression is caused by 
LOH on chromosome 15 that encodes beta-2 miroglobulin and homologous gene mutation 
(Benitez 1998; Paschen, 2003; Garrido et al., 2010). Garrido et al. (1997) also indicated 
that mutations, deletions and somatic recombination can result in irreversible loss of MHC 
(Garrido, 1997). Mutations in the transporter associated with antigen processing (TAP) 
gene leads to HLA Class I loss and has been reported in lung cancer and melanoma (Chen 
et al., 1996; Seliger, et al., 2003), and resistance to IFNγ–mediated up-regulation of HLA 
class I expression may lead to tumour escape resulted due to defects in the Jak-STAT 
components of IFN-mediated signalling pathway (Rodriguez et al., 2007; Abril et al., 
1996). Thus, tumour cells express low levels of MHC class I which cannot be up-regulated 
and this helps them in immune escape mechanisms (Seliger et al., 2008).  
Defects in the gene regulation of HLA class I heavy chain, b2m and the components of the 
antigen-processing machinery (APM) results in down-regulation of MHC class I antigen 
expression (Romero et al., 2005) and can be reversed. Epigenetic modifications can be 
reversed in vitro with pharmacologic agents inducing DNA hypomethylation or inhibiting 
histone deacetylation (Serrano et al., 2001). It was proved that T-cell immune-selection 
results in the loss of MHC class I phenotype in tumours (Garcia-Lora, 2001) and 
prevalence of ‘‘soft’’ or ‘‘hard’’ MHC lesions in the tumour cells is crucial in malignant 
cell targeting by T lymphocytes (Garrido et al., 2010). 
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1.6.6 Immune evasion/immune suppression 
Tumours are capable of evading the immune system (Thakur et al., 2013) and escape anti-
tumour immune responses (Drake et al., 2006). The tumour microenvironment also support 
encourages the activity of myeloid derived suppressor cells (MDSC), T regulatory cells 
(TRegs), tumour associated macrophages (TAMs) that impede effector T-cell functions 
(Thakur et al., 2013) along with secretion of immunosuppressive cytokines that inhibit the 
DC maturation and mutated or absence of immunomodulatory molecules (Tien et al., 
2005; Miller et al., 2006 and Rabinovich et al., 2007). 
Myeloid derived suppressor cells (MDSCs) 
MDSCs contribute to immune suppression within tumour microenvironment (Ostrand-
Rosenberg & Sinha, 2009). Accumulation, activation and expansion of MDSCs is driven 
by various factors of which STAT3 is arguably the most important transcription factor 
(Gabrilovich et al., 2009; Gabrilovich et al., 2009; Bronte et al., 2007; Kozin et al., 2010; 
Levy et al., 2002). In a study conducted in PrCa patients with progressing disease 
following immunotherapy an increased immunosuppressive effect due to MDSCs 
compared to the control population was demonstrated (Vuk-Pavlovic et al., 2010 and 
Gustafson et al., 2010). It was concluded that elimination of these MDSCs may improve 
the anti-tumour response and effect of immunotherapy (Vuk-Pavlovic et al., 2010 and 
Gustafson et al., 2010). In another study it was suggested that aATC are capable of 
suppressing MDSC differentiation and their suppressive activity by down regulating 
COX2, PGE2 and ARG1. This suppression is due to Th1 cytokines and chemokines (IFN-
γ, IL-2, CXCL9 and CXCL10) (Thakur et al., 2012). MDSC and tumour cell targeting 
immunotherapies will prove beneficial in boosting the efficacy of future treatment.  
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Regulatory T-cells (TRegs)  
TRegs are critical in immune suppression against cancer cells hence promote tumour 
growth (Hurwitz et al., 1999). CD4+ TRegs (5-10%) are responsible for inducing tolerance 
against self-antigens whereas the lack of TRegs can lead to autoimmunity (Hiura et al., 
2005). Tang et al. (2012) suggested a mechanism of TReg expansion following androgen 
ablation that possibly results in tumour progression. It was shown that low-dose 
cyclophosphamide can decrease TReg activity and improve the efficacy of the 
immunotherapy. In the same study it was also shown that the increasing ratio of Teff/Treg to 
CD4+ and CD8+ T-cells may be due to cyclophosphamide inhibition of TRegs while 
stimulating the effector T-cells at the same instance (Green et al., 2009). 
Modulation of tumour microenvironment 
Components such as IL-10 and transforming growth factor-β (TGF-β), IDO, expression of 
negative co-stimulatory ligands PDL-1 and CTLA-4 and the presence of TRegs and 
MDSCs represents the biggest challenge for successful immunotherapy (Robinovich et al., 
2007; Vanneman et al., 2012). Combination strategies of vaccines with those that inhibit or 
alleviate the immunosuppressive microenvironment may prove helpful in enhancing the 
effect of tumour immunotherapy. For example, imatinib (inhibits IDO) (Balchandran et al., 
2011), sunitinib (antagonises MDSCs and TReg cells) (Ozao-choy et al., 2009), 
cyclophosphamide (eliminates TRegs) (Ghiringhelli et al., 2004) and gemcitabine (kills 
MDSCs) (Suzuki et al., 2005). 
1.7 The prostate gland and cancer 
1.7.1 Anatomy and physiology of prostate gland 
The prostate is a walnut size gland in the male reproductive system located between the 
urinary bladder and penis. The term prostate has originates from Greek word “prohistani” 
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and means “to stand in front of”. The prostate is the largest male accessory gland, which 
surrounds the urethra near urinary bladder (Kumar and Majumder, 1995), responsible for 
the secretion of semen that nourishes and protects the sperm cells and expels them through 
the urethra during ejaculation (Ross et al., 2010). Histologically, the prostate gland is 
divided into central, transition and peripheral zones. Figure 1.10 represents the structure of 
prostate gland. 
 
 
 Figure 1.10.  The structure of the prostate gland. (The figure is adapted from Hammerich et al,. 2009 and 
Dr. Andrew Yip, 2013.)  
 
The peripheral zone is comprised of 70% glandular tissue and is present at the bottom and 
the back of the prostate gland near the rectum. This zone of prostate cancer comprises of 
simple, round to oval acini and a loose stroma of muscle (Ross et al., 2010). This is the 
area most susceptible to malignant transformation (Walsh and Worthington, 2007; Ayala 
Transition zone, 20% 
Peripheral zone Central zone, 5-8% Anterior fibromuscular 
stroma 
Urethra 
Penis 
Prostate gland 
Bladder 
Rectum 
Testis 
Chapter 1: Introduction                                                    
37 
 
and Wheeler, 2006; and Zelefsky et al., 2008). The central zone is cone-shaped and forms 
25% of the prostate, found towards the base of the prostate and encompasses the 
ejaculation ducts (Hammerich et al., 2009). This zone is characterised by large and 
complex acini with papillary infoldings, and compact stroma of interlacing smooth muscle 
bundles (Ross et al., 2010). The transition zone surrounds prostatic urethra (Walsh and 
Worthington, 2007), and is made up of simple, small and round acini with a compact 
stroma (Ross et al., 2010). The prostate gland of an adult man is composed of branched 
ducts (made of stratified epithelium) separated by the basal lamina composed of a 
fibroblast stroma and a smooth muscle envelope. The prostate gland develops from the 
epithelium and mesenchyme of the urogenital sinus (UGS) (Marker et al., 2003 and Wu et 
al., 2007). The adult prostate consists of branched ducts (made of stratified epithelium) that 
are separated by the basal lamina (composed of a fibroblast stroma and smooth muscles) 
(Marker et al., 2003 and Wu et al., 2007). The luminal layer of prostate epithelium is 
characterised by cytokeratin 8 (CK8) and CK18, specific intermediate filaments, and also 
contains secretory cells that are dependent on androgen for their survival and 
differentiation (Marker et al., 2003 and Wu et al., 2007). The normal epithelium of the 
prostate is composed of: secretory, basal and neuroendocrine cells. 73% of the epithelium 
consist of secretory cells expressing PSA, PAP and androgen receptors and has the least 
proliferative capacity (Ross et al., 2010). The basal cells are flattened, attenuated cells and 
are present at the base of the prostate gland and assist in reproducing secretory cells and 
have the highest rate of proliferation (Ross et al., 2010). The neuroendocrine cells are the 
least common, and although their function is unknown, they do express PSA and androgen 
receptors (Ross et al., 2010). The prostate contains copious amount of pluripotent stem 
cells which help prostate to support cell replication, differentiation and morphogenesis 
throughout adult life (Abate-Shen and Shen, 2000 and Marker et al., 2003). Any damage to 
Chapter 1: Introduction                                                    
38 
 
these progenitor cells results in uncontrolled cell proliferation and transformation resulting 
into benign prostate hyperplasia and prostate cancer (Abate-Shen and Shen, 
2000 and Marker et al., 2003). 
1.7.2 Prostate cancer and its diagnosis 
 
Prostate cancer is the most prevalent cancer in men in UK. It is the sixth leading cause of 
mortality of men in the world (Jeman et al., 2011). In 2009, 40,800 men were diagnosed 
with prostate cancer in the UK alone, in 2010 around 10,700 men actually died of the 
disease (www.cancerresearchuk.org). Prostate cancer develops slowly; this can be an 
advantage for immunotherapeutic interventions giving more time to vaccinate patients 
when the tumour is still small. Other conditions of the prostate such as, prostatitis, enlarged 
prostate, and hyperplasia may occur and for the diagnosis of prostate cancer the prostate-
specific antigens (PSA) test is common and widely used to assess blood PSA levels. PSA 
is secreted by the epithelial glands in the prostate (Tse et al., 2014), and serves to liquefy 
the semen which helps in increasing the sperm motility (Lilja and Abrahamsson, 1988).  
Dr. Donald F Gleason assessed patients from 1960-75 with long-term follow up. The grade 
was determined using the histologic pattern of the carcinoma cell arrangement, where 9 
pathologies were integrated into 5 grades (Humphrey, 2004) as shown in the figure 1.11. 
This is the dominant method of classification used routinely world-wide.  
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Prostatic Adenocarcinoma (Histologic grades), D. F. Gleason, M. D. 
            
 
 
Figure 1.11.  Gleason grade scoring of PrCa tissue section. Dr. D. F. Gleason developed a scoring system to 
determine the disease status. GG is determined using the histologic pattern of the carcinoma cell 
arrangement. There are 9 patterns were integrated into 5 grades. Figure above shows the histology section 
of the prostate tissue.  (The diagram is adapted from Humphreys, 2004 and www.prostate.com)                           
 
The stages of the cancer are determined using the TNM system. 
(http://www.nhsinform.co.uk/Health-Library/Articles/C/cancer-of-the-prostate/staging). In 
this method stages T1-T4 represent localised tumour and assesses how much the cancer 
has spread within the prostate and surrounding tissue. N describes lymph node 
involvement and is categorised as NX, N0 and N1, whereas M describes cancer spread 
outside of the pelvis to, for example, the bone and is categorised as MX, M0 and M1. Both 
N and M are symbolic of metastatic disease 
(http://www.pcf.org/site/c.leJRIROrEpH/b.5835079/k.FF5F/Staging_the_Disease.htm).  
1. Small uniform cells 
2. Loosely packed cells, vary in 
sizes and shapes 
3. Less distinction between cells: 
larger with irregular shapes 
4. Large, irregular and fused 
cells 
5. Irregular fused cells invading 
surrounding tissue 
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Figure 1.12 shows the development of prostate cancer and its’ progression in different 
stages. 
Stage I, the initiation stage where a small cancerous lump is present in the one lobe of the 
prostate gland, but is confined to the gland. 
Stage II, the cancer has developed in both the lobes of the prostate gland. 
Stage III, the cancer has metastasised to the regional lymph nodes. 
Stage IV, where the cancer has spread to the distant organs, especially the bone. 
 
Figure 1.12.  Stages of prostate cancer. (Figure adapted from www.bladdercontrol.com) 
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1.7.3 The pathophysiology of PrCa 
 
The pathophysiology of PrCa is poorly understood and complex interaction between 
genetic and environmental factors, such as, infectious agents, dietary carcinogens and 
hormonal imbalances, have been reported to play a fundamental role in PrCa 
pathophysiology, which can result in chronic inflammation which drives prostate 
carcinogenesis and neoplastic progression (Balistreri et al., 2014).  Although PrCa is 
diagnosed in older men, evidence suggests that the process of malignant transformation is 
initiated much earlier on (Merrimen et al., 2013). PrCa incidences progress rapidly in men 
over 50 years (Balistreri et al., 2014), and is classified as an adenocarcinoma when normal 
semen-secreting prostate gland cells transform to cancer cells (Merrimen et al., 2013). At 
an early onset the appearance of small ‘clumps’ of cancer cells is confined in the prostate 
gland; this condition is termed prostatic intraepithelial neoplasia (PIN), commonly found in 
peripheral zone (Merrimen et al.,2013) (Figure 1.12A). Although not all patients with 
high-grade PIN (HGPIN) develop invasive disease, PIN is characterised by ‘cancer-like 
cells’ that multiply and show metastatic characteristics (Merrimen et al.,2013). The strong 
association of PIN with progressive abnormalities has excited researchers to propose its 
use as an intermediate marker in the development of PrCa (Sakr et al.,1999). The most 
common site of metastasis of PrCa are the bones, lymph nodes, lungs, liver, the rectum and 
the bladder (Bubendorf et al., 2013) a process which is associated with the recruitment of 
mesenchymal stem cells (MSC) (Jung et al., 2013). The recruitment of MSC into the 
prostate tumours is facilitated by CXCL16, a ligand for CXCR6. CXCR6 is responsible for 
converting MSCs into cancer associated fibroblast secreting CXCL12 (Jung et al., 2013), 
and the interaction between CXCL12 on CAFs and CXCL4 (present on tumour cells) is 
responsible for epithelial-to-mesenchymal transition and metastasis to distant organs (Jung 
et al., 2013).  
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1.7.4 Conventional cancer treatments 
 
Cancer has been treated with traditional therapies to date including surgery, chemotherapy, 
radiotherapy and most recently with hormonal therapy. Even after using these therapies on 
large scale to treat cancer patients, these therapies could not prove themselves to be the 
ultimate remedy for cancer.   
 1.7.4.1 Chemotherapy  
Chemotherapy involves usage of cytotoxic drugs to inhibit rapidly growing cancerous 
cells. These drugs target cancerous cells and uses characteristic of cell to undergo 
apoptosis. Around 50 different types of drugs which are available for cancer chemotherapy 
which can either be given alone or in combinations. For example, Methotrexate can be 
used for the treatment of Acute Lymphatic Leukaemia (ALL) along with some 
lymphomas, osteosarcoma, choriocarcinoma (Chabner and Roberts, 2005) and vincristine 
can be used in combination with other drugs for the treatment of ALL, hodgkin’s and non-
hodgkin’s lymphoma (Moxley et al., 1967). There are high chances of cancerous cells to 
become resistant to certain type of drug. To avoid this, combination of different drugs is 
used. Chemotherapy also has severe side effects on the normal cells of patients. 
1.7.4.2 Radiotherapy  
Cancerous cell can also be targeted by using ionizing radiations in small doses of 1.8-2.0 
Gray given at specific time intervals (Kim and Tannock, 2005). Radiotherapy uses the 
method of attacking the DNA of the cancerous cells to kill them. But this therapy is 
seemed to be effective on well-oxygenated cells and not on hypoxic cells which can 
proliferate in near future. It has also been observed in some of the cancer cases that chemo 
and radiotherapeutic regimes can increase the proliferation rate of cancer in contrast to 
decrease them (Kim and Tannock, 2005). 
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1.7.4.3 Surgery 
 Surgical removal of cancer is most effective method used till now to remove cancerous 
cells from cancer site. Surgery can prove to be effective when used in combination with 
chemo and/or radiotherapy. Yet being widely used to treat tumours, this treatment also has 
its own drawbacks. Even after advances in the treatment there are high chances of 
recurrence of the tumour at surgery site as it is difficult to remove all the cancerous cells 
from tumour site, for example, brain tumours. This method of cancer treatment needs to be 
implemented at early stages of cancer as it can prove hardly palliative if the cancer 
metastasised.  
1.7.4.4 Hormonal therapy  
Hormonal therapy another method of cancer treatment. It is limited to certain types of 
cancers depending on hormone secretion such as prostate cancer. However this treatment 
has its limitation as cancer cells become resistant after specific time period. And the 
therapy cannot be used to treat cancer at advanced stage (Denmeade and Isaacs, 2002). 
1.7.5 Current treatments for PrCa and their limitations 
 
For localised PrCa, three treatment options are used routinely, watchful waiting, radical 
retropubic prostatectomy (RRP) and radiotherapy. For advanced disease, treatments such 
as chemotherapy and hormonal ablation have been preferred traditionally. RRP performed 
under general or local anaesthesia, is executed to precisely dissect the relatively bloodless 
field and facilitate optimal cancer control (Fu et al., 2011). Emerging new techniques, such 
as laparoscopic and robotic prostatectomy, are becoming more attractive due to their 
benefits of reduced surgical trauma and morbidity (Patel et al., 2007). However, this 
traditional treatments may have adverse effects on the quality of life of patients with 
advanced stage cancer. Commonly found side effects of prostatectomy include 
incontinence, sexual dysfunction, bleeding, infection, visceral injuries and deep vein 
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thrombosis in some rare cases (Patel et al., 2007). More than 60 years ago Huggins and 
Hodges identified PrCa as an androgen dependent tumour and following the discovery 
various trials have been undertaken to reduce testosterone, levels such as bilateral 
orchiectomy, LHRH (Leuteinising Hormone Releasing Hormone) agonists, anti-androgens 
and oestrogens (Shahinian et al., 2012). Although successful initially, these treatments do 
not combat androgen independent PrCa and the risk of metastasis with no cure available 
(Shahinian et al., 2012). At this stage of disease treatment options are limited. 
1.7.6 Immunotherapy for PrCa 
1.7.6.1 PrCa vaccines 
Vaccines have long been used in a prophylactic setting against infectious disease since the 
development of the smallpox vaccine 200 years ago by Jenner (Jenner, 1798). Vaccines in 
general act by stimulating protective immune responses against unique target antigens 
expressed by the pathogen (Michael et al., 2013). This approach has been adopted for 
treating various malignancies such as prophylactic vaccination against hepatitis B that 
reduced the incidence of hepatocellular carcinoma and, human papilloma virus (HPV) 
which is effective against cervical, vaginal and vulvar cancers caused by HPV (Lai et al., 
2013; Jemal et al., 2013). The application of a vaccine in a therapeutic setting is more 
challenging and in the majority of cases relies on targeting mutated or over-expressed gene 
products. Often targeting “self-antigens” leads to a state of immune tolerance and 
combating metastatic widespread requires a combination of therapies. However, a number 
of clinical trials have shown that the majority of patients with PrCa can mount a vigorous 
anti-tumour response to vaccination despite the advanced age and disease progression level 
(Sheikh et al., 2013, Gulley et al., 2013). PAP, PSMA are the antigens that have been used 
in the development of vaccines for the treatment of castration-resistant disease. 
1.7.6.1.1 Approaches to PrCa vaccine therapy 
Chapter 1: Introduction                                                    
45 
 
DC based vaccines and adjuvants 
DCs are the professional APCs and are capable of inducing T and B-cell responses via the 
mechanism of antigen processing and presentation (Liu, 2001). In developing prostate 
cancer vaccination strategies several methods have been used: peptide vaccines, virally 
packaged antigens, DNA-based antigen-expressing vectors and cell-based DCs vaccination 
promoting tumour-specific T-cell responses (Fong et al., 1997; Mcneel et al., 2001; 
Kaufman et al., 2004; DiPaola et al., 2006; Arlen et al., 2007; Higano et al., 2009; Madan 
et al., 2009 and Tjoa et al., 1998). Also, using TAA, GM-CSF, TLR as adjuvants to boost 
the immune responses have also been under investigation (Parmiani et al., 2000; Ali et al., 
2000). In addition, granulocyte macrophage colony stimulating factor (GM-CSF) and toll 
like receptor (TLR) agonists (Bacillus Calmette-Guérin [BCG] and CpG) , tumour 
modulating factors, have been used as adjuvants in DC based vaccines (Ivasaki et al., 2004 
and Iwasaki et al., 2010). 
PROVENGE® (Sipuleucel-T) 
PAP is a specific antigen having prostate restricted expression (Ross et al., 2010). 
PRPVENGE(R) is the first prostate cancer vaccine approved by FDA and consists of 
autologous DCs from the patient transfected in vitro with the expression vector encoding 
the full length human prostatic acid phosphatase gene and human GM-CSF (Thakur et al., 
2013). Although this approach was shown to be effective in improving the overall survival 
in PrCa patients, the vaccine has its limitation including the preparation time, and the cost. 
GM-CSF-Modified Tumour Cell Vaccines 
The GVAX® (Cell Genesys, Inc., South San Francisco, CA, USA) vaccine is consists of 
genetically modified tumour cells which are engineered to secrete GM-CSF, constructed 
from two allogeneic prostate cancer cell lines, LN-CaP and PC-3. The recent study showed 
a degree of efficiency phase I and phase II clinical trials but the phase III clinical trial was 
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discontinued. One of the reasons for the lack of clinical effect could be the advanced 
disease status of the patient population selected, which may have demonstrated a better 
response in low grade cancer with prior chemotherapy (Thakur et al., 2013), and a latest 
study demonstrated feasibility and safety of GVAX plus ipilimumab (monoclonal 
antibody) combination in mCRPC patients (Van den Eertwegh et al., 2012). Ipilimumab 
works by blocking Cytotoxic T lymphocyte Antigen-4 (CTLA-4) on the T-cell surface, 
which is a known negative regulator of T-cell activation (McCoy and Gros, 1999). 
ProstVac VF 
ProstVac-VF is a prostate-specific antigen (PSA) targeted therapeutic vaccine. It is 
comprised of recombinant vaccinia and fowlpox viral vaccine to PSA and three 
costimulatory signals (B7.1, ICAM-1, and LFA-3, known as Tricom) (Maan et al., 2009) 
and enhances antigen uptake by DCs which results in induction of immune response by 
presentation to T-cells. Both vectors contain the transgenes for PSA and Tricom. ProstVac 
uses a heterologous prime-boost regime, and the rationale for using two viruses in a 
strategy was to avoid neutralizing antibody effect generated against viral antigens 
following the first vaccinia virus inoculation and boost with the fowlpox virus (Madan et 
al., 2009). The study showed clinical benefits in the castration-resistant PrCa patients 
providing rationale for combination method with no clinically significant or synergistic 
toxic effects (Antonarakis et al., 2012 and Madan et al., 2012). 
DNA vaccines 
Pre-clinical studies with PAP encoding DNA vaccine immunisation have shown promising 
CD4 and CD8 responses and potent humoral and cellular immune responses (Johnson et 
al., 2007; Hawkins et al., 2002; Johnson et al., 2006; Pavlenko et al., 2004, and Saif et al., 
2013). In a study performed at our centre targeting PAP derived peptide incorporated into 
an Immnunobody vaccine (DNA-based) tumour regression in the TRAMP mouse model 
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was induced following therapeutic vaccination (Saif et al., 2013).  It has been proven 
therefore that DNA vaccines targeting PAP combined with other antigens of interest in the 
heterologous immunisation strategies could be used to enhance the immunity against PrCa 
TAAs (Thakur et al, 2013). 
HER2 “Positive” CRPC and Armed Activated T-Cell (ATC) Therapy 
Overexpression of Her2/neu (HER2) is reported to be high in PrCa patients (Sanches et al., 
2002; Visakorpi et al., 1992; and Bartlett et al., 2005). Better survival and lower relapse 
rate was shown in the patients with HER2 positive (2+ or higher on IHC) over those of 
HER2 negative prostate cancers (Nishio et al., 2006). Over-expression of HER2 is an ideal 
target in CRPC patients for ATC armed with anti-CD3 × anti-Her2 bispecific antibody 
(Her2Bi) (Nishio et al., 2006). Boosted long-lasting anti-tumour responses was observed in 
the patients immunised with this vaccine (Nishio et al., 2006). Hence this strategy on its 
own or in combination with the traditional therapies shows a promising approach to benefit 
PrCa patients. 
Immune modulators  
Chemotherapy and radiotherapy act directly on cancer cells exerting cytotoxic effects 
(Wada et al., 2009; Ghiringhelli, 2009 and green et al., 2009). Although effective, these 
traditional therapies produce side effects in patients. A phase II clinical trial was 
successfully carried out to determine if PSA encoding poxviral vaccine was capable of 
inducing PSA-specific T-cell response in combination with radiotherapy in clinically 
localised PrCa patients (Nesslinger et al., 2010). The study concluded that this vaccination 
regime was safe for the groups of PrCa patients, which showed PSA-specific T-cell 
induction (Nesslinger et al., 2010). 
In giving immunotherapy with or without combination with chemo or radio therapy, it is 
important to note that the immunotherapy effects are often seen some time after 
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immunisation and it is important to consider this in determining the scheduling of therapy 
for the PrCa patients. 
Targeting check-point inhibitors using antibody-based immunotherapy 
Cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed death-1 (PD-1), 
the two immunologic regulators are known to avert immune-mediated tissue damage 
(Pardoll, 2012; Harvey, 2012; Green et al., 1994;  Walunas, 1994; Krummel et al., 1995; 
Pentcheva-Hoang et al., 2007; Chemnitz et al., 2004), but are also known to inhibit 
immune responses to tumour antigens. Both CTLA-4 and PD-1 are up-regulated with T-
cell activation, with tumour cells expressing PD-L1, PD-L2 the ligands for PD-1. Hence in 
order to develop a successful immunotherapy, inhibition of immunosuppressive 
mechanisms is important (Whiteside, 2010). CTLA-4 is exclusively present on T-cells and 
was the first immune checkpoint receptor to be clinically targeted and regulates the 
amplitude of the early stages of T -cell activation. In a preclinical model the combination 
therapy with CTLA-4 and GM-CSF proved effective compared to the treatments with 
individual components, suggesting that this method may prove beneficial to the PrCa 
patient treatments (Fong et al., 2009). Prostate and melanoma tumour infiltrating CD8 T-
cells expressed high levels of PD-1 and impaired effector mechanisms. Notably, B7-
H1/PD-1 also formed a molecular defense against CTLs (Hirano et al., 2005) indicating 
the reversal mechanism of PD-1 signaling and its effects on the tumour cell killing 
(Freeman et al., 2000; Hamanishi et al., 2007). From all the above trials it is important to 
consider the tumour microenvironment before designing and beginning with a large scale 
clinical trial. P53 was found to be mutated in 48% of prostate cancer patients in a study 
using prostate tissue specimens and metastatic lesions (Chi et al., 1994). Frequencies of 
p53 mutations are found to be ranging from 4-60% in the localised disease (Moul, 1999). 
Studies were undertaken to investigate the upstream of androgens, such as AR and its 
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effects on p53 and prostate cancer (Rokhlin et al., 2008).  It was shown in the same study 
that microRNA-34a and 34c play crucial role in p53-mediated apoptosis in PrCa (Rokhlin 
et al., 2008). p53 have been studied in the context of its association with progression of 
prostate cancer. The prostate cancer clinical trials currently undergoing different phase 
clinical trials are listed in table 1.4 (adapted from www.clinicaltrials.gov and Bellonne et 
al., 2014). 
Tumours can avoid immunesurveillance by stimulating immune inhibitory receptors that 
turn off established anti-tumour immune response (Intlekofer and Thompson, 2013). 
According to the cancer immunesurveillance hypothesis, the sentinel thymus-dependent 
cells of the body constantly surveyed host tissue for nascently transformed cells (Burnet, 
1970). After several decades, the concept of cancer immunosurveillance expanded to 
incorporate both adaptive and innate immunity (Dunn, Old and Schreiber, 2004). 
According to the recent work , it was shown that the immune system may also promote the 
emergence of primary tumours with reduced tumerigenicity, capable of immune escape 
(Shankaran et al., 2001). The findings gave rise to new concept of cancer immunoediting 
encompassing host protective and tumour sculpting functions of the immune system 
thoughout tumour development mechanism (Dunn et al., 2002, 2004).  Cancer 
immunoediting is a dynamic process composed of 3 E’s: emilination, equilibrium and 
escape. Elimination represents the concept of immunosurveillance, equilibrium is the 
period of immune-mediated latency after incomplete tumour destruction. In this phase the 
tumour cells can be maintained chronically or sculpted by “immune editors” and produce 
new tumour cell variants (Dunn, Old and Schreiber, 2004). Escape refers to the out growth 
of the tumour cells which have crossed the barriers of the equilibrium phase (Dunn, Old 
and Schreiber, 2004).   
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CTLA-4 and PD-1Rs represent two T-cell-inhibitory receptors with independent 
mechanisms of action. Preclinical investigations revealed that CTLA-4 enforces an 
activation threshold and attenuates proliferation of tumour-specific T lymphocytes 
(Intlekofer and Thompson, 2013). In the clinical trials recruiting CTLA-4 blockade, 
Ipilumimab antibody, was  pioneer demonstrating improved survival in the stage IV 
melanoma patients  (Hodi et al., 2010). PD-1 functions primarily as a stop signal that limits 
T-cell effector function within a tumor. By blocking either of these receptors a sustained 
anti-tumour response can be generated (Intlekofer and Thompson, 2013). Anti-PD-1 
antibody, Nivolumab,  have shown promising results in diverse  range of tumours 
including  melanoma, renal cell carcinoma, and lung cancer (Hamid et al., 2013, Topalian 
et al., 2014, Brahmar et al., 2012, and Topalian et al., 2012).   Recent evidence from 
preclinical models highlights the pivotal role of the Programmed Death-1 (PD-1) T-cell co-
receptor and its ligands, B7-H1/PD-L1 and B7-DC/PD-L2, in maintaining an 
immunosuppressive tumor microenvironment. Encouraging early clinical results using 
blocking agents against components of the PD-1 pathway making it an important target for 
cancer immunotherapy (Topalian et al., 2012). After successful trials with combination of 
Ipilumimab and Nivolumab in pre-clinical  trials, the combination has also demonstrated  
distinct pattern  of atitumour immunity  with rapid tumour regression in     a substantial 
proportion of melanoma patients (Curran et al., 2010, Topalian et al., 2012) . Although 
both PD-1 and CTLA-4 act to dampen T-cell activation via shared signaling pathways, 
differences in sites of action have been proposed to help understand the differences in 
patterns of autoimmunity as well as antitumor effects with PD-1 and CTLA- 4 blockade 
(Das et al., 2015).    It was shown in the study that combining anti-CTLA-4 and anti-PD-1 
therapies have better response than the two therapies given individually (Das et al., 2015).  
Blood/tumor tissue from 45 patients undergoing single or combination immune checkpoint 
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blockade were selected for the study conducted by Das et al. It was shown that blockade of 
CTLA-4, PD-1, or combination of the two leads to distinct genomic and functional 
signatures in vivo in purified human T-cells and monocytes. Therapy-induced changes 
were more prominent in T-cells and involve largely nonoverlapping changes in coding 
genes, including alternatively spliced transcripts and noncoding RNAs. Pathway analysis 
revealed that CTLA-4 blockade induces a proliferative signature predominantly in a subset 
of transitional memory T-cells, whereas PD-1 blockade instead leads to changes in genes 
implicated in cytolysis and NK cell function. Combination blockade leads to 
nonoverlapping changes in gene expression, including proliferation-associated and 
chemokine genes. The results demonstrated that inspite of having shared property of 
checkpoint blockade, Abs against PD-1, CTLA-4 alone, or in combination have distinct 
immunologic effects in vivo (Das et al., 2015).    
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Trial no. Title Phase Patient conditions Investigators 
NCT01688492 Combining ipilimumab with abiratorone acetate 
plus prednisone in chemotherapy and 
immunotherapy-naïve patients with progressive 
metastatic CRPrCa1 
I-II chemotherapy and 
immunotherapy-naïve patients with 
progressive metastatic CRPrCa1 
Daniel C Danila, MD 
NCT01530084 Ipilimumab and GM-CSF immunotherapy for 
PrCa 
II chemotherapy-naïve patients with 
progressive metastatic CRPrCa1 
Lawrence Fong, MD 
NCT00711334 NY-ESO phase I study for PrCa I Patients with androgen-
independent prostate carcinoma 
Teresa G Hayes, MD, 
PhD 
NCT01696877 A neoadjuvant study of androgen ablation 
combined with cyclophosphamide and GVAX 
vaccine for localised PrCa 
I-II Patients with high-risk localised 
PrCa undergoing radical 
prostatectomy 
Emmanuel Antonarakis, 
MD 
NCT01420965 Sipuleucel-T, CT-011 and cyclophosphamide for 
advancedPrCa 
II Patients with advanced CRPrCa Samir Khleif, MD 
NCT01140373 Adoptive transfer of autologous T-Cells targeted to 
PSMA2 for treatment of castrate metastatic PrCa 
I castrate metastatic PrCa Susan Slovin, MD,PhD 
NCT00450463 Vaccine therapy with PROSTAVAC/TRICOM 
and flutamide vs flutamide alone to treat PrCa 
II Patients with androgen insensitive, 
non-metastatic (D0.5) PrCa 
Ravi A Madan, MD 
NCT01487863 Concurrent vs sequential treatment with 
Sipuleucel-T and abiraterone in men with 
metastatic CRPrCa 
II Patients with metastatic CRPrCa Study director: Andrew 
C Stubbs, PhD 
NCT00583024 Phase II study of adenovirus/PSA vaccine in men 
with hormone-refractory PrCa (APP22) 
II Patients with hormone-refractory 
PrCa 
David M Lubaroff, PhD 
Table 1.4.  The prostate cancer immunotherapy clinical trials currently ongoing 
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NCT01322490 A phase 3 study of a recombinant vaccinia virus to 
treat metastatic PrCa 
III Patients with few or no symptoms 
from metastatic, CRPrCa 
James L Gulley, MD and 
Philip Kantoff, MD 
NCT00583752 Phase II study of adenovirus/PSA vaccine in men 
with recurrent PrCa after local therapy APP21 
II patients with recurrent PrCa after 
local therapy 
David M Lubaroff, PhD 
NCT01477749 Sipuleucel-T manufacturing demonstration study II Patients with metastatic CRPrCa 
referring to European 
manufacturing facility 
Study director: Andrew 
C Stubbs, PhD 
NCT01338012 Sipuleucel-T in metastatic CRPrCa patients 
previously treated on dendreon study P-11 
(NCT00779402) 
II patients previously treated on 
dendreon study P-11 
Study director: Robert 
Sims, MD 
NCT01685489 A phase 1b dose escalation trial of PSK® /placebo 
with docetoxel to treat metastatic CRPrCa 
I Patients with metastatic CRPrCa Celestia Higano, MD 
NCT01436968 Phase 3 study of ProstAtakTM with standard 
radiation therapy for localised PrCa (PrTK03) 
III Patients with localised PrCa Several PI 
NCT01522820 Vaccine therapy with or without sirolimus in 
treating patients with NY-ESO-1 expressing solid 
tumours 
I Patients with recurrent PrCa Kunle Odunsi 
1castration-resistant prostate cancer 
2prostate-specific membrane antigen 
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1.8 Boosting immune responses: adjuvants and agonists   
Adjuvants are the substances admixed or given along with vaccine to enhance the 
immunogenicity of the vaccine as they are capable of boosting the immune response of weak 
antigens (Dubensky et al., 2010). This also allows reduced use of antigen in the vaccine and 
the total number of vaccinations (Banzoff et al., 2009; Schwarz et al., 2009). They are 
particularly of interest in the context of cancer immunotherapy in order to boost the vaccine-
specific T- and B-cell responses and to engage components of the innate immune system 
(McCartney et al., 2009; O’Hagan et al., 2009) by enhancing the magnitude, breadth, quality, 
and longevity of antigen specific immune responses with minimal toxicity. Adjuvants are 
being used clinically targeting general population for increasing vaccine response, increasing 
the mean antibody titeres and/or the fraction of subjects that develop protective immunity, 
concomitant with an increase in seroconversion (Coffman et al., 2010).  
Freund’s incomplete adjuvant (IFA) is the most commonly used adjuvant in animal models, 
known to induce a weak, Th2 immune response. Various adjuvants have been trialed along 
with cancer vaccine administration to date and are listed in table 1.5. Adjuvants may achieve a 
qualitative alteration of the immune response (Coffman et al., 2010), provide conversion of a 
Th1 response to Th2, enhance CD8+ and CD4+ T-cell responses, and increase the generation 
of the effector T-cell memory response with some of them promoting the speed of immune 
response post prime (Galli et al., 2009; Khurana et al., 2010; Vandepapeliere et al., 2008; 
Galli et al., 2006; Khurana et al., 2010). 
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Table 1.5.  List of potential adjuvants 
 List of potential adjuvants Innate receptor pathway 
activated 
Immune responses 
Alum (licensed) NLRP3 inflammosome Th1 and Th2 
AS04 (licensed) TLR4 and inflammasome Th1 
MF59 and AS03 (licensed) Tissue inflammation Th1 and Th2 
Incomplete Freund’s adjuvant (IFA) p24 stimulation Induction of T-cell responses 
against HLA-A2 
restricted epitopes in melanoma 
patients 
Montanide ISA51  Strong T-cell lymphoproliferative 
response 
Microbial derivatives (natural and 
synthetic) 
  
Monophosphoryl lipid A (MPL) TLR4 Enhanced Th1 responses 
Detox (MPL + CWS) OM-174 (lipid A 
derivative, E. coli), OM-triacyl 
In vitro maturation of 
human dendritic cells 
Induction of cellular and humoral 
responses in 
melanoma patients 
Modified LT (genetically modified 
bacterial toxins [heat-labile 
enterotoxin, cholera toxin] to provide 
nontoxic adjuvant effect) 
 Balanced Th1 and Th2 responses 
CpG ODN TLR9 Th1 immunity with CD8 T-cell 
induction 
Immunoadjuvant   
Cytokines: (IL-2, IL-12, GM-CSF, 
Flt3) 
 Enhanced antibody responses 
Accessory molecules (B7.1)  Enhanced cellular responses by 
providing 
co-stimulatory signals to T 
lymphocytes 
Poly-IC TLR3, MDA5 Th1, CD8 T cells 
Flagellin, flagellin antigens, flagellin 
Proteins 
TLR5 Th1+Th2 
Imiquimods TLR7, TLR8, or both Th1, CD8 T cells (when 
conjugated) 
CAF01 Mincle Th1, Th17 
ISCOMs and ISCOMATRIX ? Th1+Th2, CD8 T cells 
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TLR agonists are potential adjuvants, known to activate DCs, augmenting T-cell responses 
and downregulating the suppressive effects of TRegs. They promote both adaptive and innate 
anti-tumour immunity and affect the tumour microenvironment. TLR 3, 4, 7, 8, and 9 are the 
most promising TLR agonists for use alongside vaccination strategies (Cheever, 2008).  
It has also been observed that inoculation of BCG into established tumours leads to regression 
and prevention of metastasis (Zbar and Tanaka, 1971). It is being used in phase I and II 
clinical trials, targeting melanoma, colorectal and breast cancers, and neuroblastoma. It is also 
involved in phase III clinical trials targeting melanoma and colon and lung cancer (Vacchelli 
et al., 2012). Various TLR agonists approved are listed in table 1.6. Immunotherapy 
combining the use of TLR agonists together with chemotherapy or radiotherapy seems to be a 
promising approach, for example, the use of cyclophosphamide to control TRegs, anti-
androgens that enhance T-cell infiltration into the tumour, and anthracyclines that appear to 
increase the potential for antigen presentation within the tumour environment.  
Table 1.6.  TLR agonists approved by FDA for use in humans 
Agonist TLR Status/Malignancy References 
Bacillus 
Calmette-Guerin 
(BCG) 
TLR2/4 FDA approved for Bladder carcinoma, phase I and II 
clinical trials for melanoma, colorectal, breast cancers, 
and neuroblastoma. In phase III clinical trials targeting 
melanoma and colon and lung cancer 
 
Zbar and Tanaka, 
1971, Vacchelli 
et al., 2012 
Monophosphoryl 
lipid A 
TLR2/4 FDA approved, incorporated in Cervarix® in the form of 
AS07 targeting HPV-associated cervical cancer 
 
Schiffman et al., 
2012) 
Imiquimod TLR7 FDA approved targeting actinic keratosis and basal cell 
carcinoma. In phase I and II- as a single agent or in 
combination with other therapies for the treatment of 
brain, breast, cervical, and colorectal cancer, melanoma, 
neuroblastoma, sarcoma, and non-small cell lung 
carcinoma (NSCLC). Phase II and III - as a single agent 
targeting cervical cancer and head and neck squamous 
cell carcinoma (HNSCC) 
Drobits et al., 
2012, Vacchelli 
et al., 2012 
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CD40 is a tumor necrosis factor receptor superfamily member expressed broadly on antigen-
presenting cells (APC) such as dendritic cells, B cells, and monocytes as well as many non-
immune cells and a range of tumors. Agonistic CD40 mAb have been shown to activate APC 
and promote anti-tumor T cell responses and to foster cytotoxic myeloid cells with the 
potential to control cancer in the absence of T-cell immunity (Eliopolous et al., 2004; van 
Kooten and Banchereau, 2000). Signaling via CD40 to APC is thought to represent a major 
component of T cell help and mediates in alrge part the capacity of Th to license APC. 
Ligation of CD40 on DC induces increased surface expression on surface costimulatory and 
MHC molecules, production of proinflammaotry cytokines and enhanced T-cell triggering 
(van Kooten and Banchereau, 2000). Along with use of agonistic mAb, recombinant CD40L 
and CD40 gene therapy have been tested in aptients with promising primary outcomes 
(Vonderheide, 2007). CD40 agonist was first used in the clinical trial for advanced squamous 
cell cancer patients in the form of CD40L which showed long term complete remission 
(Vonderheide, 2001). Similarly, CP-870,893 have also shown clinical efficacy in advanced 
cancers (Vonderheide, 2007). Due to potential synergy between the chemotherapy (to release 
tumor antigen) and CD40 agonists (to activate APC), CP-870,893 has been tested in 
combination with carboplatin and paclitaxel and gemcitabine. Objective tumor regressions 
were observed in about 20% of patients in each study (Beatty et al., 2011). Dacetuzumab, a 
weaker CD40 agonist than CP-870,893, has shown single-agent activity when given 
intravenously every week, especially in patients with diffuse large B cell lymphoma 
(DLBCL). Stable disease but not tumor regression was observed with dacetuzumab in multiple 
myeloma and CLL (Advani et al., 2009; Hussein et al., 2010; Furman et al., 2010). The 
startegies using an anti CD40 antibody aim to activate DC, macrophages, or both. 
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Immunologically, direct tumor cytotoxicity accomplished by CD40 agonists is hypothesized to 
provide a source of tumor antigen that can be processed and presented by host APC which are 
simultaneously activated. 
 
1.9 Aims of the research 
 In the current study the main aim was to develop a vaccination strategy targeting the two 
mutant forms of p53: 175 and 273. The first aim was to identify the HLA-A2 restricted 
immunogenic p53 peptides and then develop a vaccination strategy. Next aim was to assess 
the efficacy of the developed strategy in the pre-clinical tumour model and finally, to assess 
the peptide-specific circulating T-cells in prostate cancer patient PBMCs.  
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Chapter 2: Materials and Methods 
2.1 Materials  
Reagents were stored as per manufacturer instructions and used before the expiry date. 
2.1.1 Reagents 
Table 2.1.  Reagents 
Reagents Company (Catalogue no.) 
Culture Media 
1640 RPMI Lonza (BE12-167F) 
Phosphate buffer saline (DPBS) Biowittaker (BE17-512F) 
DMEM Biowittaker (BE12-604F) 
Supplements added to culture media 
Fungizone Lonza (17518) 
HEPES Buffer Biowittaker (BE17-737F) 
Foetal Calf Serum Thermo scientific(SV30160.03) 
L-Glutamine Lonza (BE17-603E) 
Penicillin/Streptomycin Biowittaker (DE17-603E) 
2-Mercaptoethanol Sigma-Aldrich (M3148) 
Cell culture reagents 
Dimethylsulfoxide (DMSO) Sigma-Aldrich (D2650) 
Lipopolysaccharide (LPS)  Sigma-Aldrich  
Trypan blue Sigma-Aldrich (T8154) 
Incomplete Freud’s Adjuvant(IFA) Sigma-Aldrich (F5560) 
Polyinosinic polycytideylic acid 
(Poly I. C)  
Geneticin (G418)  
Gentamycin  
Sigma-Aldrich (27-4110-01) 
 
Sigma-Aldrich (A1720) 
Sigma-Aldrich (G1914) 
GM-CSF  R & D Systems (415M2-050) 
mIL-2  R & D Systems (402-ML-100)        
Bovine Serum Albumin (BSA) Advanced Protein roducts (12659)  
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Chemical reagents 
Acetic acid Fisher scientific (10041250) 
Ethanol BDH  
Vitamin E Sigma-Aldrich (47786) 
Dextran Sulfate Sigma-Aldrich (42867) 
Isoton Beckman Coulter (8546859) 
Gold microcarrier BioRad (165-2263) 
Liquid Nitrogen British Oxygen Company  
Presept Johnson and Johnson (13GD585) 
Tween 20  Promega (P1379)  
PVP (Poly Venyl Pyrolidine) 
Isopropanol 
Magnesium chloride (MgCl2) 
Paraformaldehyde 
Phenyl/Chloroform/Isoamyl alcohol 
Potassium acetate (KOAc) 
Sodium azide (NaN3) 
Sodium chloride (NaCl) 
Spermidine 
Tris 
Trizma base  
2-methylbutane (Isopentane) 
CpG Oligonucleotide    
Staphylococcal enterotoxin B (SEB) from 
Staphylococcus aureus                                                  
Sigma-Aldrich (PVP40) 
Sigma-Aldrich (19516) 
Fisher Scientific (M2670) 
Sigma-Aldrich (F1635) 
Sigma-Aldrich (P2069) 
Sigma-Aldrich (P1190) 
Sigma-Aldrich (S-8032) 
Fisher Scientific (7760) 
Sigma-Aldrich (S0266) 
Fisher Scientific (9310) 
Sigma-Aldrich (T3253) 
Acros Organics (1264-70010) 
MWG 
Sigma-Aldrich (S4881) 
 
2.1.2 Media:-Culture media was prepared and used within a month. 
T cell media- RPMI 1640 media supplemented with 1% glutamine, 10% FCS, 20mM HEPES, 
50 M 2-ME, 50 U/mL penicillin, 50 g streptomycin and 0.25 g/mL fungizone 
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BM-DC media- RPMI 1640 media supplemented with 1% glutamine, 5% FCS, 20mM 
HEPES, 50 M 2-ME, 50 U/mL penicillin, 50 g streptomycin and 0.25 g/mL fungizone 
Cell culture media- RPMI 1640 media supplemented with 1% glutamine, 10% FCS 
Buffers- Trypan Blue: White cell counting solution: 0.1% (v/v) solution of Trypan blue in 
PBS 0.6% (v/v) acetic acid in PBS  
Table 2.2. Cell line and culture media 
Cell line Culture media used 
MC38 
TRAMP 
RMA/S 
LnCaP 
 
DU 145 
FGK-45 
RPMI 1640 + 10%  v/v FCS + 1% L-glutamine 
DMEM + 10% v/v FCS  and 5mM L-glutamine 
RPMI 1640 + 10%  v/v FCS + 1% 5mM  L-glutamine 
RPMI 1640 + 10% v/v FCS + 1% 5mM L-glutamine+ Na    
pyruvate+ Glucose+ Hepes buffer                 
RPMI 1640 + 10% v/v FCS + 1% 5mM L-glutamine 
RPMI 1640 + 10%  v/v FCS + 1% 5mM  L-glutamine 
 
2.1.3 Materials for Flow Cytometry:-  
Buffers for flow cytometry  
(i) Permeabilisation solution: Fixation solution:  
1% (v/v) paraformaldehyde in PBS 70% (v/v) ethanol in PBS 
(ii) FACS buffer:  
0.1% (w/v) BSA  
0.02% (w/v) NaN3  
1X PBS 
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Table 2.3. Antibodies for flow cytometry  
Antibody Manufacturer 
RaM CD11c (FITC) Serotec 
Purified mouse anti-p53 
Alexa fluor 568 goat anti mouse 
BD Pharmingen 
Invitrogen 
Ani mouse H2Kb (FITC) 
Mouse anti-human HLA-A2 (FITC)               
Anti-mouse CD3 (eFluor 450) 
Anti-mouse CD4 (PE-Cy7) 
Anti-mouse CD8 (eFluor 710) 
eBioscience 
AbD Serotec 
eBioscience 
eBioscience 
eBioscience 
Mouse anti-human CD3 (ECD) 
Mouse anti-human CD4 (PC5.5)  
Mouse anti-human CD8 (Alexa Fluor 700) 
Mouse anti human (Krome Orange) 
Beckman Coulter 
Beckman Coulter 
Beckman Coulter 
Beckman Coulter 
 
2.1.4 ELISpot Assay Reagents 
(i) Kits 
 Murine ELISpot assay kit 
Murine IFNγ kit                          Mabtech (3321-2A) 
Colour development kit              Bio-Rad (170-6432) 
 Human ELISpot assay kit 
Human IFNγ kit                                                R & D Systems (SEL285) 
ELISpot blue colour development module       R & D Systems (SEL002) 
 (ii) Buffers for ELISpot assay 
Wash Buffer- 0.05% Tween20 in PBS 
Reagent Diluent- 1% BSA in PBS, pH7.2-7.4, 0.2µm filtered 
Antibodies used for ELISpot assay:- 
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 2.1.5 ELISA  
 Buffers for ELISA 
Wash buffer: Stop solution:  
0.05% (v/v) Tween 20 in PBS 2N H2SO4  
Block buffer: Substrate solution:  
1% (w/v) BSA 1 volume colour reagent A (R&D Systems)  
5% (w/v) sucrose 1 volume colour reagent B (R&D Systems)  
0.05% (w/v) NaN3  
Completed to final volume with PBS  
Reagent diluent for IL-5: Reagent diluent for IFNγ:  
1% (w/v) BSA 0.1% (w/v) BSA  
Completed to final volume with PBS 0.05% (v/v) Tween 20  
Completed to final volume with PBS 
2.1.6 Materials for CTL Assays 
(i) Radio-isotope for CTL release Assay 
96 well Lumamax plates were purchased from PerkinElmer. 51Chromium (51Cr) in the form of 
sodium, Chromate was purchased from Amersham International LTD. 
(ii) Radio-isotope for Proliferation Assay 
96 Uni/Filter plates were purchased from PerkinElmer. [3H]-Thymidine (3Thy) was purchased 
from Amersham International Ltd. 
Table 2.4. Laboratory plastic ware, glassware and sharps 
Item Company 
T25 tissue culture flasks Sarstedt, UK 
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5 mL, 10 mL and 25 mL pipettes Sarstedt, UK 
20 mL Universals Sterilin, UK 
Centrifuge tubes (15 mL) Sarstedt, UK 
Centrifuge tubes (50 mL) Sarstedt, UK 
FACS Tubes Elkay, UK  
10 mL, 20 mL Syringes Becton Dickenson 
BD Microlance 3 needles Becton Dickenson 
24 well flat bottom culture dishes Sarstedt, UK 
Pasteur Pipettes Sarstedt, UK 
1.2 mL eppendorf tubes Sarstedt, UK 
0.5 mL  eppendorf tubes Sarstedt, UK 
Pipette tips <1 mL Sarstedt, UK 
Petri dishes Sterilin, UK 
Haemocytometer Weber 
Scalpels Swann Morton Ltd. 
0.2 µm filters Sartorious, UK 
0.5-10 µL tips Sartorious, UK 
20-100 µL tips Sartorious, UK 
200-1000 µL tips Sartorious, UK 
 
Table 2.5. Electrical Equipments                                                                
Equipment       
Manufacturer 
Refrigerated Centrifuge 
(Mistral 1000, MSE)    
Sanyo 
-80º C freezer Ultima II, Reveo 
Class II Safety Cabinets Walker  
37º C Incubator Forma  Scientific 
96 well plate harvester Packard 
Drying cabinet Scientific Laboratory Supplies Ltd 
Water Baths Grant Instruments 
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Confocal Microscope Leica 
Light Microscope Nikon   
Microcentrifuge, Microcentaur MSE 
Flow cytometer, Gallios Beckman Coulter 
Cell Harvester, Filtermate harvester Packard 
Gene Gun 
Nano Drop ND8000 
BioRad 
LabTech International 
 
 
2.1.7 P53 sequences  
2.1.7.1 Human p53 sequence, accession #P04637 
MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI 
EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ 
KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST 
PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN 
LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP 
ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP 
PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL 
KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD 
 
2.1.7.2 Mouse p53 sequence, accession # P02340 
 
MTAMEESQSD ISLELPLSQE TFSGLWKLLP PEDILPSPHC MDDLLLPQDV 
EEFFEGPSEA LRVSGAPAAQ DPVTETPGPV APAPATPWPL SSFVPSQKTY 
QGNYGFHLGF LQSGTAKSVM CTYSPPLNKL FCQLAKTCPV QLWVSATPPA 
GSRVRAMAIY KKSQHMTEVV RRCPHHERCS DGDGLAPPQH LIRVEGNLYP 
EYLEDRQTFR HSVVVPYEPP EAGSEYTTIH YKYMCNSSCM GGMNRRPILT 
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IITLEDSSGN LLGRDSFEVR VCACPGRDRR TEEENFRKKE VLCPELPPGS 
AKRALPTCTS ASPPQKKKPL DGEYFTLKIR GRKRFEMFRE LNEALELKDA 
HATEESGDSR AHSSYLKTKK GQSTSRHKKT MVKKVGPDSD 
 
Table 2.6. P53 class I and class II peptide sequences           
1HLA A-0201/2H2-K
b 
octamer/nonamer/ decamer 
Sequence Binding Score 
Human 263-272 N L L G R N S F E V 26 
Mouse 260-272 N L L G R D S F E V 26 
Human 245-253 G M N R R P I L T I 25 
Mouse 242-252 G M N R R P I L T I 25 
Human 322-330 P L D G E Y F T L 21 
Mouse 320-327 L D G E Y F T L 23 
Human 193-201 H L I R V E G N L 22 
Mouse 191-198 L I R V E G N L 13 
 
1HLA-DRB1*0101/2IAb - 
15mers 
Sequence Binding 
Score 
Human 108-123 G F R L G F L H S G T A K S V  31 
Mouse 105-121 G F H L G F L Q S G T A K S V  31 
Human 249-263 R P I L T I I T L E D S S G N  26 
Mouse 246-260 R P I L T I I T L E D S S G N  26 
Human 258-272 E D S S G N L L G R N S F E V  25 
Mouse 255-269 E D S S G N L L G R N S F E V  25 
 
 
2.1.8  Peptides  
All peptides used in this study, described in table 2.2, were obtained synthesised 
commercially, with >90% purity, and their identity and purity was confirmed by mass 
spectrometry (Mocell Biotec, Genscript). 
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2.2: Methods 
2.2.1 Peptides 
The p53 protein sequence was screened for predicted peptides binding to MHC class I (HLA-
A2) and MHC class II (HLA-DR1) using the SYFPEITHI (www.syfpeithi.de) algorithm. 
Peptide epitopes with high binding scores were shortlisted. Peptides p53-193-201 
(HLIRVEGNL), p53-322-330 (PLDGEYFTL), p53-245-254 (GMNRRPILTI), p53-108-122 
(GFRLGLHSGTAKSV), p53-249-263 (RPILTIITLEDSSGN) and p53-258-272 
(EDSSGNLLGRNSFEV) were synthesized and obtained from commercial sources. Class I 
(ISIWNPRL) and class II (ISIWNPRLLWQPIPV) epitopes from influenza were used as 
control peptides. All the peptides were dissolved in 100% DMSO and aliquoted with working 
concentration of 10 mg/mL. 
2.2.2 Animals 
Mouse class I (H2-Kb) knockout C57BL/6 HLA-A2.1/-DR1 double transgenic (HHDII-DR1) 
animals were used for the current study. The strain was received as a generous gift from Dr. 
Lone (via CNRS, France). C57 BL/6 mice (colonies supplied by Charles River) were bred at 
the Nottingham Trent University facilities under a Home Office approved project license and 
in accordance to UK Home Office regulations. 
2.2.3 Cell lines 
MC38 murine colon carcinoma cell line was a generous gift from Prof. Albert DeLeo  
(University of Pittsburgh). TRAMP C1 cells were derived from transgenic TRAMP (Transgenic 
Adenocarcinoma of Mouse Prostate) C57 BL/6 mice (a kind gift from Professor Matteo Belloni, 
Fondazione San Raffaele Del Monte Tabor, Italy). 
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LnCaP cell line was obtained from ATCC (ATCC CRL-1740, LnCaP clone FGC) and DU 145 
cell line was obtained from ATCC (ATCC HTB-81). The culture conditions and media used 
are listed in the table below. RMA/S cell line was a generous gift from Dr. Colin Brooks 
(Newcastle University) and FGK-45 hybridomas were a generous gift from Prof. Kees Melief 
(University of Leiden, Netherlands). 
Table 2.7.  Cell line and culture media 
Cell line Tumour Type Cell line features Adherent or 
suspension 
MC38 Murine colon 
carcinoma 
Naturally express mutated (242) 
p53 
Adherent 
RMA/S  Naturally express empty MHC I 
molecules on the cells surfaces 
Suspension 
TRAMP  Transgenic 
adenocarcinoma 
mouse prostate 
Express prostate specific genes 
PSCA, PSMA and PAP 
Adherent 
LnCaP (HLA-A2+) Hypotetraploid 
human cell line, 
human prostate 
carcinoma 
Express PAP, PSA, P53, T21 Adherent 
DU 145 (HLA-A2-) Hypotriploid 
human cell line, 
human prostate 
carcinoma 
 Adherent 
FGK-45 Hybridoma Source for anti CD-40 antibody Suspension 
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2.2.4 Immunisations 
2.2.4.1 Peptide immunisation procedure 
Mice were injected with anti-CD-40 antibody in the abdominal cavity using intraperitoneal (I.P.) 
route. Within 4-6 h after injecting anti-CD40 antibody they were immunised with the peptides (75 
μg of class I and II peptide/mouse in the same mixture) emulsified in incomplete Freund’s 
adjuvant (IFA) (Sigma-Aldrich) at a ratio of 1:1, with or without CpG Oligonucleotides CpG 
ODN1826 (5’-tccatgacgttcctgacgtt-3’) (50 μg/mouse) via an injection into the base of the tail 
using intra muscular (I.M.) route. Immunisations were given on d 1 and boost on d 14 with the 
same immunisation regime, spleens were harvested a week after the final immunisation.  
2.2.4.2 Gene Gun immunisation procedure 
Mice were immunised in the abdominal cavity with gold labeled DNA encoding p53-175 and 
p53-273 mutant proteins using the gene gun. Both the plasminds used for the gene gun 
immunization were kind gift from Dr. Stephanie McArdle (Nottingham Trent University). 
This was repeated at weekly intervals for a total of three immunisations. Between 7 to 10 days 
post final immunisation spleens were harvested for in vitro re-stimulation of splenocytes with 
relevant peptide prior to cytotoxicity assays.  
Gold ‘bullets’ containing the gold labeled DNA were produced according to kit manufacturers 
protocol with the following adjustments. DNA to be labeled was made up to a working 
concentration of 1µg/µL in dH2O in a final volume of 18µL. This gave a dose of 1µg of 
DNA/bullet/animal after production. Spermidine (1 mg/mL) was diluted to the working 
concentration of 4µL in 544µL dH2O, and 100µL was added to 8.3µg gold (1µm particles) in 
a sonicated water bath. DNA was then added to the gold in the sonicated water bath followed 
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by 100µL of 1M calcium chloride, added drop wise. The tube was then allowed to stand for 10 
min at room temperature. Meanwhile; PVP was weighed and made to a final concentration of 
0.025 mg/mL in ethanol and tubing for the bullets dried out using nitrogen gas. The tube 
containing the gold/DNA mixture was spun at 260g for approximately 15 s, the supernatant 
discarded and the pellet resuspended in ethanol in the sonicating water bath. This was repeated 
three times. After the final wash, the gold pellet was resuspended in 1 mL of 0.025 mg/mL 
PVP and transferred to a 15 mL centrifuge tube. The sample was sonicated then loaded into 
the tube using a syringe and the tubing turned through 1800 and left for 10 s. The tubing was 
rotated on the prep-station for 30 s on setting 1 prior to turning on the nitrogen gas (set to 0.3-
0.4 L/min) for approximately 15-20 min to allow the tubing to dry. Once dry, the tubing was 
cut to create the bullets which were then used in the gene gun as described previously.   
2.2.4.3 Plasmid (IB-p53)  
CDRs (Complementarity Determining Regions) within ImmunoBody® single heavy and light 
chain vectors were replaced with unique restriction sites. The p53 ImmunoBody® was 
generated using human IgG1 construct and complimentary oligonucleotides encoding the 
HLA-A2 restricted peptide of p53-322-330 (PLDGEYFTL) were annealed and incorporated 
into the CDRH2 site of the vector whereas the CD4 DR1 p53-249-263 (RPILTIITLEDSSGN) 
restricted helper epitope was inserted into the CDRL1 of the kappa chain. Sequences were 
confirmed and plasmid was amplified and isolated using a Qiagen EndoFree Maxi Prep kit 
follwoing manufacturer’s instructions. 
2.2.4.4 Spio-peptide immunisation 
Iron nano-particles containing multiple binding sites for the class I and class II peptides were 
synthesised by Dr. Gareth Cave’s group at the Nottingham Trent University. Spio coupled 
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with p53-322-330 (75µg) and p53-249-263 (75µg) were immunised at the base of the tail of 
the C57BL/6 mice in PBS only and/or with and without IFA in PBS, at the base of the tail. 
The mice were boosted on d 15 and spleens were harvested 7 ds post boost. 
                                                 
2.2.5 IFNγ ELISpot assay  
IFNγ ELISpot assays were performed according to manufacturer’s protocol, Mabtec and R&D 
systems, for murine and human respectively on the day of splenectomy using 96-well ELISpot 
plates (Millipore). For each experiment (0.5x106    or 1x105 cells per well), triplicate wells 
received 2 μg of class I and class II peptides. Triplicate control wells included irrelevant/no 
peptides at the same concentrations from the immunised mice and/or naïve control mice. The 
plates were developed after 48 h with BCIP/NBT (BioRad) for 30-45 min and were rinsed 
with tap water. Spots were quantitated with an ELISpot reader (Cellular Technology Limited). 
An animal was scored as positive when the response in the peptide containing well was at least 
twice that of control wells.  
 
2.2.6 Flow cytometry 
2-5x105 cells were used per 12x75 mm polystyrene tube (Elkay) for Flow cytometry. Cells 
were washed and incubated for 30 min with conjugated primary antibody and appropriate 
isotype controls were used in each experiment following manufacturer’s instructions for 
antibody dilutions. Following incubation with the antibody, cells were washed and re-
suspended in 500 μl of Isoton prior to acquisition and analysis using a Beckman Coulter 
Gallios® flow cytometer and Kaluza® software. 
          Intracellular staining 
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Cells were centrifuged, re-suspended and counted. They were then split into FACS tubes 
(1x10^6cells/tube) and were washed with 2mL of FACS buffer at 300g for 5min. cell surface 
markers of interest were stained at this stage prior to fixing and permeabilising the cells 
Cell fixation 
After centrifugation, supernatant was discarded and cell pellets were resuspended into the 
residual liquid. 100 μl of fixative (IntraPrep, Beckman counter, reagent 1) was added to each 
tube. Tubes were vortexed vigorously and incubated for 15min at RT. Cells were then washed 
with 3mL PBS and centrifuged again. 
Cell permeabilisation 
Supernatant was discarded and cells were resuspended in the residual liquid. 100 μl of 
permeabilisation buffer (IntrPrep, Beckman coulter, reagent 2) was added. Cells were then 
incubated for 15 min at RT in dark without mixing. After incubation, tubes were gently mixed 
and were washed with 3mL FACS buffer.  
Supernatant was discarded after centrifugation and blocking agent was added. Antibody was 
then added to cells without washing at required concentration/volume as per manufactirer’s 
protocol. Cells were gently mixed and incubated for 30min at RT in dark. Cells were washed 
again post incubation and secondary antibody was added (if primary antibody was 
unconjugated) and incubated again at RT for 30min in dark. Cells were then washed with 
FACS buffer twice, supernatant was discarded and isoton was added prior to analysis using 
flow cytometry.  
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2.2.7 Immunofluorescence  
OCT embedded tumour tissues were sectioned, fixed with 4% paraformaldehyde for 5 min at 
room temperature and blocked with 10% rat serum in 0.25% Triton-X100 in PBS for 30 min 
at room temperature. Purified primary antibodies were used for the assays (diluted as per 
manufacturer’s instructions in blocking buffer) for 2 h at room temperature. Appropriate 
secondary antibodies and isotype controls were used in each experiment. Slides were mounted 
with fluorescent mounting media containing DAPI and studied under using a 
immunofluorescence/confocal microscope. 
 
2.2.8 Human PBMCs 
A ex vivo ELISpot assay and a 10 d ELISPOT assay were performed to determine the 
precursor frequencies of peptide specific T cells.  
2.2.8.1 Ex vivo ELISpot assay 
On d 1 PBMCs were thawed using CTL-wash [10% CTL-wash supplement + RPMI-1640+ 
0.2 μl/mL benzonase (250 IU/μL stock, free RNA, DNA removal)] The cells were rested for 2 
h in complete medium [RPMI-1640 medium containing 5mM L-glutamine, 5% human AB 
serum, 0.2 μl/mL of Gentamicin (50 mg/mL stock)] in the incubator 37ºC, 5% CO2. Cells 
were counted using trypan blue in 1:100 ratio in acetic acid and plated in the pre-coated 
(capture antibody, R&D systems) ELISpot plates with and without p53 peptides and 
appropriate controls. For class I peptide assessment, T2 cells were used as targets. The cells 
were labelled with p53-322-330 class I peptide overnight and used as target for the 24 h 
ELISpot assay. After 24 h, plates were washed and detection antibody was added overnight. 
Chapter 2: Materials and methods                                                    
74 
 
Plates were developed next day according to manufacturer’s protocol and IFNγ response was 
assessed using CTL ELISpot reader. 
2.2.8.2 ELISpot assay after in vitro stimulation 
On d 1 PBMCs were plated (2x106 cells/mL) into 24 well plates in quadruplicates in 2 mL of 
RPMI-1640 medium containing 5mM L-glutamine, 5% human AB serum, 0.2 μl/mL of 
Gentamicin (50 mg/mL stock). The cells were incubated at 37ºC, 5% CO2. On d 2, the media 
was replenished with IL-2 (20 U/mL) and IL-7 (5 ng/mL). On d 3, 5 μg/mL p53 peptides were 
added to respective wells. On d 7, 500ul of supernatants were collected for ELISA. The cells 
were then washed and replenished with fresh IL-2 (20 U/mL). IFNγ ELISpot assay was 
performed on d 8 according to manufacturer’s protocol (R&D Systems) and response was 
assessed by reading plates using CTL ELISpot reader. 
2.2.9 Chromium Release Assay  
2.2.9.1 Effector cells 
(i) Generation of murine CTLs  
Spleens from immunised animals were harvested 7 days after final immunisation. Splenocytes 
were flushed from the spleen using same method mentioned above. These splenocytes were 
then washed, spun and counted to adjust concentration of cells at 5x106cells/500µL per well 
into 24-well plate. These splenocytes were plated in 24-well plate and co-cultured with peptide 
pulsed LPS Blast. For LPS blast, spleens were harvested from naïve mice and cells were flushed 
out. LPS blasts were set up in a T75 flask by culturing 60x106 spleen cells in T-cell medium 
supplemented with 1mg of LPS, 7mg/ml of dextran sulphate and 40mg/ml of Vitamin E. After 48 
hours, cells from LPS blasts were harvested, washed, re-suspended in 5ml of T-cell medium and 
irradiated with caesium for 8 minutes at the University of Nottingham. These LPS blasts were 
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washed again and pulsed with 10mg/mL of the relevant or irrelevant peptide for 1 hour at 37°C. 
After washing, these cells were used for in vitro re-stimulation of the splenocytes harvested from 
immunised mice. One week after the last immunisation, spleens were harvested, counted, re-
suspended and set up in a T25 flask at 25x106 cells/5ml. Finally, 5x106 irradiated and peptide-
pulsed LPS blasts per 5ml were added to the splenocytes to make a final volume of 10ml in each 
T25 flask. These splenocytes were then used for in vitro cytotoxicity assays after depletion of 
CD4+ T cells post 7 days in vitro culture, using a mouse CD4+ T cell depletion kit (Stem Cell 
Technologies) according to manufacturer’s protocol.  
 (ii) PBMCs 
PBMCs were stimulated with and without 1µg peptides for 10 days and used as effector cells. 
On the day of assay, peptide stimulated splenocytes were harvested, counted using trypan blue 
and cell concentration was adjusted to 5x106/mL in T-cell media. The cell suspension was 
serially diluted using T-cell media across a 96 well round bottom plate to give a range of 
effector: target ratios from a maximum of 100:1 and a minimum of 12.5:1 effectors to targets. 
The target cell suspension was then added to this at a volume of 100 µL/well in triplicate.  
 
2.2.9.2 Target cells 
RMA/S, MC38 and TRAMP cells were used as targets for the 51Cr assay using murine 
splenocyes. LnCaP and DU 145 cells were used for the 51Cr release assay using prostate 
cancer patient PBMCs. 
RMA/S cells were pulsed with the p53 class I peptide and irrelevant peptide overnight. Cells 
were peptide-pulsed by adding 1 µL/mL of relevant peptide and irrelevant peptide respectively 
into T25 flasks and were incubated at 37ºC, 5% CO2 overnight.  Cells were harvested from the 
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flasks and spun and resuspended in residual media. MC38 and LnCaP naturally express 
mutant p53, needed no pulsing with p53 peptide. TRAMP and DU 145 were used as negative 
controls. On the day of assay cells were labeled with 1.85MBq 51Cr 1 h at 37oC in a water 
bath. Cells were washed twice using CTL media and re-suspended in 1 mL of CTL media 
containing 1µL of peptide (RMA-S cells) and were incubated in a water bath at 37oC for 1 h. 
After incubation cells were washed with serum free media and spun at 300g for 3 min. Cells 
were re-suspended in 1 mL of T-cell media and were counted using trypan blue to adjust the 
concentration to 5x104/mL using T-cell media and used as targets for chromium release assay.   
2.2.9.3 Maximum and spontaneous release 
In order to calculate chromium release and effective cell lysis, the potential maximum and 
spontaneous release was measured and calculated. To simulate maximum release 100µL/well 
of targets cells were added to 70 µL/well of T-cell media and 30µL/well of 1% SDS prepared 
in triplicate. Similarly 100 µL/well of target cells were added to 100µL/well of T-cell media to 
determine spontaneous release. 
The 96 well plates were incubated for 4½ h in a lead container at 37oC, 5% CO2. 50µL of the 
supernatant was transferred to Luma plates after the incubation period, without disturbing the 
cell pellet. The Luma plates were dried in oven for overnight and then counted using a top-
count gamma counter. 
The specific percentage lysis was calculated using the following formulae: 
 
    Percentage cytotoxicity =  (Experimental release – Spontaneous release)    X 100            
                    (Maximum release – Spontaneous release)  
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Results obtained by Cytotoxicity assay were valid when maximum to spontaneous release was 
<20%.  
2.2.10  Proliferation assay 
2.2.10.1 Preparation of APCs [Bone marrow derived Dendritic Cells (BMDCs) generation] 
Bone marrow derived cells from hind limbs of naïve mice of HHDII/DR1 double transgenic or 
C57Bl/6 strain were isolated to culture and obtain DCs cells from bone marrow cells using 
GM-CSF as growth factor. Mouse hind limbs were isolated and muscles and knuckles were 
removed. Bone marrow was flushed out using BMDC media: (RPMI+5% (v/v) FCS+ 2 mM 
L-glutamine+ 10 mM HEPES+ 50 mM 2-mercaptoethanol+ 25 U/mL Penicillin/Streptomycin 
0.25 mg/mL Fungizone+ 1 ng/mL mGM-CSF). Cells were washed, counted and plated out in 
24-well plates at 1x106/mL/ well using BMDC media containing 1 ng/mL of murine GM-CSF. 
Cells were washed with fresh media every 2 days for 7days. Fig. 2.1 shows the schematic 
representation of the steps involved in the generation of BMDCs. 
Image shown in fig.2.2 shows matured DCs after 7 days culture in the BMDC media 
containing GM-CSF. 
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Figure 2.1.  BM-DC isolation and culture. The flow charts shows the steps involved in the harvesting and culture 
of BMDCs from naïve HHDII/DR1 double transgenic K/O mice and preparation of BMDCs as APCs. 
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(a)    (b) 
      
Figure 2.2.  Bone marrow derived cells under 10x/0.25 and 20x/0.40 magnification. 
 
The day before proliferation assay, BMDCs were replated at 0.5x106 cells/well and pulsed 
with 1 μg/mL of peptide of p53 class II peptide. Cells were rested for 4h and LPS was added 
at 1 μg/mL overnight for maturation of the cells. On the following day, BMDCs were washed 
twice in T cell media (RPMI+10% (v/v) FCS+ 2 mM L-glutamine+ 10mM HEPES+ 50 mM 
2-mercaptoethanol+ 25 U/mL Penicillin/Streptomycin 0.25 mg/mL Fungizone) and re-
suspended in 1 mL BMDC media containing poly-IC (12.5 μg) for 2 h at 37ºC, 5%CO2 . The 
peptide-loaded matured DCs were then used as APCs for proliferation assays. 
2.2.10.2  In vitro peptide re-stimulation of splenocytes  
Splenocytes were flushed from the spleens of immunised mice 7 days post last immunization. 
Pellet was resuspended in 4 mL of T cell media, cells were then counted and plated in 24 well 
flat bottom plates at 2x106 cells/mL per well containing 1 µL/mL of Vitamin E and 1 µL/mL 
of p53 class II peptide in each well. Plates were left to incubate at 37oC, 5% CO2.  
CD8+ T were depleted from the splenocytes after 7 days of in vitro culture using a mouse 
CD8+ T-cell depletion kit (Invitrogen) according to the manufacturer’s protocol. The cells 
were used in proliferation assays at the concentration of 5x104/well. On assessment with flow 
10X 20X 
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cytometry using a Beckman Coulter Gallios® flow cytometer, the T-cell preparations were 
shown to be typically 90% free of CD8+ T cells.  
2.2.10.3 Proliferation assay 
2.2.10.3.1 Murine splenocytes and peptide pulsed BMDCs proliferation 
For the assay, cells were co-cultured with 5x103 BMDCs pulsed with either the immunogenic 
or control peptide in quadruplicates in round-bottom 96-well plates. Cultures were incubated 
for approximately 60 h at 37oC, 5% CO2 and 
3H thymidine was added at 37 kBq/well for the 
final 18 h. Plates were harvested onto 96 Uni/Filter plates (Packard Instrument) and counted 
after addition of scintillation liquid (Microscint 0, Packard) using a Top-Count counter 
(Packard). Results are presented as counts per min (cpm) as means of quadruplicates.  
2.2.10.3.2 PBMCs proliferation assay in response to p53 class II peptides 
PBMCs were cultured in the RPMI1640 media and plated at 5x104 cells/ well in the 96 well 
round bottom plated for approximately 60 h with and without peptides of interest. Cultures 
were incubated for approximately 60 h at 37oC, 5% CO2 and 
3H thymidine was added at 37 
kBq/well for the final 18 h. Plates were harvested onto 96 Uni/Filter plates (Packard 
Instrument) and counted after addition of scintillation liquid (Microscint 0, Packard) using a 
Top-Count counter (Packard). Results are presented as counts per min (cpm) as means of 
quadruplicates. 
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Chapter 3: p53 peptide screening and the mutants of interest, 175 
and 273 
3.1 Introduction 
Loss of the tumour-suppressive activity in p53 is a frequent event in human cancer, occuring 
in more than 50% of all types of human cancer (Petitjean et al., 2007b; Rivlin et. al., 2011; 
Wang et al., 2013). P53 acts to suppress tumour development in a variety of ways, including: 
cell cycle arrest, DNA repair, senescence and apoptosis (Aylon et. al., 2011) (Figure 1.1). 
After several trials it was confirmed that not only wild type p53 but its subtype and /or 
mutations are responsible for the varying function of the p53 protein (Freed-Pastor et. al, 
2012).  It is also widely accepted that mutations in p53 are very common genetic events in 
human cell transformation (Levin and Oren, 2009). This “guardian of genome” is inactivated 
through missense mutations caused by alteration of single amino acid in the DNA binding 
domain of the p53 protein and carcinogenesis involves the concomitant loss of tumour 
suppression and gain of oncogene activity. P53 mutations in cancer progression are associated 
with trans-dominant suppression of wt p53 or gain of oncogenic function independent of wt 
p53. These two characters may be simultaneous events and their effects can be difficult to 
separate (Sigal and Rotter, 2000). P53 mutations are frequently found in the conserved regions 
of the central DNA binding domain of the protein (Attardi and Jacks, 1999).  
P53 mutations that occur in the “hot-spot” regions are categorised into two types: class I 
mutations that occur in the DNA contact region either on the L3 loop or loop-sheet-helix motif 
of p53 protein, which support the structure of the DNA-binding surface and are hence 
classified as “contact mutants”, usually involving residues R248 and R273. Contact mutants 
can also demonstrate conformational changes (Wong et al., 1999), which results in alterations 
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in the way protein folding occurs (Bullock et. al., 2000). Class II mutations are those which 
occur in the areas important in maintaining conformational stability of the protein involving 
the L2 loop in the zinc region. These are also called “structural mutants”, involving residues 
R175, G245, R249 and R282 (Cho et al., 1994; Joerger et al. 2007), known as the “demons” 
of the guardian of genome and an acidic N-terminal transactivation subdomain, which 
contains a proline-rich region that has a second transactivation domain, DNA-binding domain 
and oligomerisation domain harbouring a nuclear export signal and C-terminal regulatory 
domain containing three nuclear localisation signals. The majority of mutations are clustered 
in the central most conserved region (Freed-Pastor et al., 2012). Figure 3.1 (A) shows the p53 
DNA binding domain and subdomains with hotspot mutations highlighted. The two regions 
circled in red, 273 and 175, are the two mutants selected for the current study as they represent 
the two categories of mutants discussed above (class I, contact mutants and Class II, 
conformation mutants). The most frequently occurring “hot spot” mutations are listed in the 
Table 3.1. and the different p53 mutation frequency and their category is summarised in Table 
3.2. 
 
Figure 3.1 (A). p53 hotspot mutations. The figure shows P53 protein transactivation domain, central DNA 
binding domain, tetramerisation domain and the C-terminal regulatory domain. Hotspot mutations are present 
on the DNA binding domain of the central region of the p53 protein. Different mutations have different 
frequencies. The two mutant proteins of interest, 175 and 273, are highlighted with red circles (the figure is 
adapted from Somasundaram et al., 2000). 
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Table 3.1. Mutations in p53 amino acid positions and frequency of alteration in the top 6 “hot spot” mutations. 
Position Frequency of alteration1 
248 
278 
175 
245 
249 
282 
7 
6.7 
5.1 
3.3 
2.9 
2.9 
The table is adapted from (Freed-Pastor et al., 2012). 
1 shows the percent frequency of alteration. 
 
Table 3.2. Common missense mutations at “hot spot” residues within the p53 gene sequence. 
Amino acid 
residue 
Frequency of 
alteration 
Wild-type codon Mutant 
codon1 
Category 
R175H 
R248Q 
R273H 
R248W 
G245S 
R273C 
R282W 
R249S 
G245D 
4.6% 
3.5% 
3.1% 
2.8% 
2.85% 
2.75% 
2.4% 
1.8% 
0.68% 
CGC 
CGG 
CGT 
CGG 
GGC 
CGT 
CGG 
AGG 
GGC 
CAC 
CAG/CAA 
CAT 
TGG 
AGC 
TGT 
TGG 
AGT 
GAC 
Conformation 
DNA contact 
DNA contact 
DNA contact 
Conformation 
DNA contact 
DNA contact 
Conformation 
Conformation 
The table is adapted from (Freed-Pastor et al., 2012). 
1 the underlined codon bases represent the mutated residues. 
 
3.2 Differences in the two categories of the p53 mutants 
It was observed that the presence of the conformational mutant protein (p53-175) results in 
immortalisation of mammary epithelial cells (Cao et al., 1997). This category of mutants 
showed a particularly high level of protection against etoposide drug-induced apoptosis as 
compared to DNA contact mutants (p53-273) (Blandino et al., 1999). Conformational mutants 
have also been shown to be involved in disrupting the spindle check-point and polyploidy in 
Colcemid-treated Li-Fraumeni fibroblasts as opposed to the DNA contact mutants (Gualberto 
et al., 1998), however no difference was observed in the protective effect of either categories 
of mutants against cisplatin-induced apoptosis (Blandino et al., 1999). Also when assessed for 
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wild type (wt) p53 transcriptional activity, only the p53-273 mutant displayed activity, as 
opposed to other p53-175, 156, 248 and 280 mutants (Park et. al, 1994). Some of the key 
differences in the two mutants used in the present study are shown in the Table 3.3. 
 
Table 3.3. Comparison of structure and some functions of p53 175 and 273 mutants. 
 273 (R       H) 175 (R       H) References 
% folded 98 30 Bullock et. al., 2000 
Protection from apoptosis Low High Blandino et al., 1999 
Spindle check-point disruption ND1 Yes Gualberto et al., 1998 
The table is adapted from (Sigal and Rotter, 2000). 
1ND, not done 
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In this study high scoring peptides for HLA-A0201 and HLA-DR0101 molecules were 
selected and evaluated for their immunogenicity in HHDII/DRI mice. HHDII/DRI mice, 
which combines the classic HLA transgene (HLA-A2.1/Db-h2m single chain, DR1) with 
selective knockdown of murine H-2 that restricts the whole MHC class I- derived T-cell 
repertoire to HLA-A2.1 and MHC class II repertoire to HLA-DR1 (figure 3.1 B) (Anthony et 
al., 2004). 
  
Figure3.1 (B). Genetically engineered HHDII/DR1 mice represent HHDII, chimeric MHC classI molecule 
(diagram adapted from Anthony, 2004). 
 
3.3 Rationale of the study 
A wide range of p53 mutations occur and are responsible for promoting carcinogenesis. Two 
categories of p53 mutations were chosen for this study (figure 3.1-A), p53-175 and p53-273. 
Both categories of mutations lead to loss of tumour suppression function of the protein (Sigal 
A and Rotter V, 2000). Mutation at position 175 changes the arginine to a histidine (R-H) and 
linearises the protein whereas mutation at position 273 abolishes the DNA binding site of the 
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protein. It was therefore of interest to study these two mutants and assess their ability to 
induce anti-p53 immune responses (if any) following immunisation of HHDII/DR1 double 
transgenic K/O mice.  
3.4 Results 
3.4.1 Murine and human p53 protein sequence homology 
In this study a HLA-A2  transgenic mouse model was used to identify the most immunogenic 
p53 peptides suitable for a vaccine candidate. HHDII/DR1 double transgenic K/O mice were 
selected for the study; these genetically engineered mice are also “knocked-out” for murine 
class I and class II gene. These represent human MHCs and are ideal pre-clinical models for 
the studies with clinical relevance. In order to identify immunogenic p53 peptides relevant for 
use in humans, murine and human wt p53 protein sequences were aligned in order to assess 
their sequence. The alignment is shown in figure 3.2, where sequence 1 is the wt human p53 
protein sequence and sequence 2 is the wt murine p53 protein sequence. After aligning the 
murine and human p53 protein sequences, homology between the two sequences was assessed 
and was found to be >80%.  
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Key: 
Sequence 1: Human p53 
Sequence 2: Murine p53 
Figure 3.2. Homology between human and murine p53 sequences. Figure shows the alignment of human and 
murine p53 sequences. The “ * ” indicates the similarities and the “.” indicates the difference in the amino acid 
residues between the human and murine sequence. The murine N-terminal sequence contains three additional 
(MTA) amino acids. 
 
3.4.2 Identification of immunogenic p53 peptides in silico using syfpeithi algorithm  
 
SYFPEITHI is an algorithm widely used for peptide prediction on the basis of the MHC class 
I and class II binding. In the current study human and murine wt p53 sequences were analysed 
using the syfpeithi software (www.syfpeithi.de) for peptide binding to human HHDII-DR1 
and murine H2Kb as both human and murine p53 sequences are homologous (figure 3.2) and 
the tumour model was developed in the C57BL/6 mice. The highest binding peptides were 
then selected for in vitro screening. 
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Table 3.4.  p53 wt class I peptides grouped according to their HLA A-0201 binding score 
1HLA A-0201 
octamer/nonamer/ decamer 
Sequence Binding Score 
Human 245-253 G M N R R P I L T I 25 
Human 322-330 P L D G E Y F T L 21 
Human 193-201 H L I R V E G N L 22 
1HLA A-0201, human MHC class I 
 
 
Table 3.5. p53 class II peptides ranked according to their HLA-DR1 binding 
1HLA-DRB1*0101 15mers Sequence Binding 
Score 
Human 108-123 G F R L G F L H S G T A K S V  31 
Human 249-263 R P I L T I I T L E D S S G N  26 
Human 258-272 E D S S G N L L G R N S F E V  25 
1HLA-DRB1*0101, human MHC class II 
 
3.4.3 Assessment of immunogenicity of the p53 peptides in the HHDII/DR1 double 
transgenic K/O mice 
 
After screening the murine and human p53 protein sequence in silico, high binding score 
murine and human p53 peptides were selected and obtained commercially synthesised. These 
are listed in Tables (3.4) and (3.5). Lyophilised peptides were diluted to a 10 mg/mL final 
concentration in 100% DMSO. Peptides were stored in the -800 C and were used for the in 
vitro stimulation. In order to screen the p53 peptides from the two p53 protein mutants of 
interest (p53-175 and p53-273), HHDII/DR1 double transgenic K/O mice were immunised 
with gold carrying either pcDNA 3.1 p53-175 or pcmvneoBam p53-273 gene. Mice were 
immunised with 1μg of pcDNA per mouse via the intradermal route using the gene gun 
method of immunisation and received two booster immunisations at one week intervals. 
Splenocytes were harvested 7 days following the last boost. An ex vivo ELISpot assay was 
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performed on these freshly prepared splenocytes; 0.5x106 splenocytes were plated per well in 
the ELISpot plate and 2 μg of class I and class II peptide (final peptide concentration) was 
added per well. Splenocytes (0.5x106) from the same preparation were stimulated for 5-7 days 
in vitro with 2 μg of class I and class II peptides/well in 24 well plate. ELISpot assays were 
repeated using these stimulated splenocytes. The ex vivo and in vitro stimulation methods are 
described in detail in methods chapter and are schematically represented in figure 3.3. 
 
 
 Chapter 3: p53 peptide screening and the mutants of interest, 175 and 273 
           
90 
 
 
 
Figure 3.3. Schematic representation of the experimental design. HHDII/DR1 double transgenic K/O mice were 
immunised with p53-175 and/or p53-273 mutants using gene gun immunisation. The figure shows the different 
stages involved in the immunisation of HHDII/DR1 and /or C57BL/6 mice. Mice were immunised on day 1 and 
boosted twice at 7 days interval. Splenocytes were harvested and cultured 7 days post last booster immunisation. 
Splenocytes were used for ex vivo IFNγ ELISpot assays. Splenocytes from same source were divided for class I 
and class II stimulation using LPS blasts and peptide alone respectively. Splenocytes were stimulated for 5 days 
with class I peptides and for 7-10 days for class II peptides. IFNγ ELISpot assays and thymidine incorporation 
proliferation were performed using class I and class II restimulated splenocytes respectively. BMDCs generated 
form naïve mice were used as APCs for the proliferation assay to represent the class II peptides.  
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3.4.3.1 Assessment of immunogenicity of selected p53 peptides in the HHDII/DR1 double 
transgenic K/O mice immunised with p53-175 cDNA 
 
To assess the immunogenicity of wt p53 class I and class II peptides (predicted by syfpeithi 
algorithm) from the p53-175 mutant of interest, HHDII/DR1 double transgenic K/O mice were 
immunised with pcDNA p53-175 mutant gene using gene gun immunisation and boosted 
twice at 7 days interval. Spleens were harvested 7 days after last booster.  An ex vivo IFNγ 
ELISpot assay was performed immediately after splenectomy. The selected p53 class I 
peptides (on the basis of syfpeithi binding scores), p53-322, p53-245, p53-193 were used at 2 
μg/well working concentration together with an appropriate irrelevant peptide control or 
unstimulated splenocytes alone. P53 class II peptides were also assessed for immunogenicity 
by ELISpot assay using splenocytes from immunised mice. An ex vivo IFNγ ELISpot assay 
was performed using class II p53 peptides, p53-108-123, p53-249-264 and p53-258-272, 
added at 2μg/ well of final concentration. An appropriate irrelevant peptide control or 
unstimulated splenocytes alone were used as controls. Figure 3.4 shows the response obtained 
from the ex vivo IFNγ ELISpot assays towards p53 class I and class II peptides.  In parallel 
splenocytes were plated at 4x106 / well and cultured with the respective class I respective class 
I peptides, p53-322, p53-245, p53-193 and class II peptides, p53-108-123, p53-249-264, p53-
258-272 at 2μg/ well of final concentration for 5-7 days. These in vitro stimulated splenocytes 
were then harvested and the IFNγ ELISpot assay was repeated using the same peptides. The 
results obtained are shown in the figure 3.5. 
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Figure 3.4. The IFNγ response obtained from the splenocytes (0.5x106/well) of the mice immunised with p53-175 
cDNA using gene gun. Mice were boosted twice at 7 days interval and spleens were harvested 7 days post last boost. 
Splenocytes were cultured on the same day of harvest and IFNγ ELISpot assay was performed. P53-322-329, and p53-
245-253, both class I peptides (A) and p53-108-123, p53-249-264 and p53-258-272, class II peptides (B) at 2μg/well 
final concentration in ELISpot plate were used for stimulating the splenocytes. Significant difference was observed in 
the immune response obtained after in vitro stimulation of cells compared to the irrelevant Flu peptide control and 
unstimulated splenocytes. P53-193-201 (class I) was also used but this peptide did not show any significant IFNγ 
response. Comparisons of the means (± SEM) between groups (T cells pulsed with the peptide or control) are made 
with an unpaired t test. The experiments were repeated twice with 3 mice per group. *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.5.  The IFNγ response obtained from splenocytes (of the mice immunised with p53-175 cDNA using 
gene gun) after in vitro stimulation with peptides for 5 days. The IFNγ response obtained from the splenocytes 
(0.5x105 / well) of the mice immunised with p53-175 cDNA using gene gun. Mice were boosted twice at a 7 day 
interval and spleens were harvested 7 days after the last boost. Splenocytes were cultured and re-stimulated with 
p53-322-329, p53-245-253, and p53-193-201, both class I peptides (A) and P53-108-123, p53-249-264 and p53-
258-272, class II peptides (B), at 2 μg/well final concentrations in ELISpot plate in vitro. IFNγ ELISpot assay 
was performed after 5and 7 days of in vitro stimulation with class I and class II peptides respectively. A 
significant different was observed in the immune response obtained after in vitro stimulation of cells as compared 
to the irrelevant Flu I/II peptide control and unstimulated splenocyte control. Comparisons of the means (± SEM) 
between groups (T cells pulsed with the peptide or control) are made with an unpaired t test. The experiments 
were repeated twice with 3 mice per group.  *p<0.05, **p<0.01, ***p<0.001 
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The experiment was repeated twice using 3 mice per immunisation group and comparison of 
the IFNγ response made between peptide-specific responses and controls. It was observed 
using HHDII/DR1 double transgenic K/O mice, that the overall frequency of the T 
lymphocyte response obtained following immunisation towards the class I and class II HLA-
restricted p53 peptides in the ex vivo assay was low, especially towards the p53-193-201 (class 
I) and p53-258-264 (class II) peptides. A summary of the data and frequency of ELISpot 
response against p53 class I peptides (p53-193-201, p53-322-329, and p53-245-253) and p53 
class II (p53-258-283, p53-108-123 and p53-249-264) peptides is given in the table (3.6). 
 
Table 3.6. 1Summary of the total number of mice responding to p53-specific peptides in in vitro ELISpot assays 
following immunisation with p53-175 cDNA. 
p53 peptides1 ex vivo IFNγ ELISpot 
assay2  
IFNγ ELISpot assay after3 in vitro 
peptide stimulation  
108-123 (class II) 4/9 8/9 
249-264 (class II) 3/9 6/6 
322-331 (class I) 5/9 5/9 
245-253 (class I) 5/9 8/8 
193-201 (class I) 0/9 2/9* 
258-272 (class II) 0/9 3/9* 
1 p53 class I and class II peptides 
2 total no of mice responding in the ex vivo IFNγ ELISpot assay performed immediately after splenectomy 
3 total no of mice responded in the IFNγ ELISpot assay performed after in vitro splenocyte stimulation with 
peptides 
* No statistical significance difference compared to control 
 
3.4.3.2 Assessment of immunogenicity of selected p53 peptides in HHDII/DR1 double 
transgenic K/O mice immunised with p53-273 cDNA 
 
To assess the immunogenicity of wt p53 class I and class II peptides (predicted by syfpeithi 
algorithm) from the p53-273 mutant of interest, HHDII/DR1 double transgenic K/O mice were 
immunised with p53-273 mutant gene using gene gun immunisation. Mice were boosted twice 
at 1 week intervals and splenocytes were harvested and cultured 7 days after the second 
 Chapter 3: p53 peptide screening and the mutants of interest, 175 and 273 
           
95 
 
booster immunisation (method section). Splenocytes were then used to perform ex vivo IFNγ 
ELISpot assays. Selected (on the basis of syfpeithi binding score) p53 class I peptides (p53-
193-201, p53-322-329, and p53-245-253) and class II peptides (p53-258-264, P53-108-123 
and p53-249-264) were used at 2μg/ well in ELISpot plates. Figure 3.6 shows the response 
obtained from the ex vivo IFNγ ELISpot assays towards p53 class I and class II peptides. 
Splenocytes were plated at 4x106 / well in the 24 well plates together with the respective class 
I peptides (p53-322-329, p53-245-253, p53-193-201) and class II peptides (p53-108-123, p53-
249-264 and p53-258-272,) at 2μg/ well of final concentration and stimulated for 5-7 days. 
These stimulated splenocytes were then harvested and the IFNγ ELISpot assay was performed. 
The IFNγ secretion response obtained is shown in the figure 3.7. Appropriate irrelevant 
peptide control or unstimulated splenocytes alone was used as control. P53-322-329, p53-193-
202, p53=245-253 (all class I) and p53-108-123, p53-249-264 and p53-258-272 peptides 
(class II), significantly enhanced the IFNγ secretion response in ELISpot assay compared with 
the Flu I/II and unstimulated cells alone controls. 
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Figure 3.6.  The IFNγ response obtained ex vivo from the splenocytes from the mice immunised with p53-273 
cDNA using gene gun. Mice were boosted twice at 7 day intervals and spleens were harvested 7 days post second 
boost. Splenocytes were harvested and IFNγ ELISpot assays were performed. P53-322, p53-245, and p53-193-
201 (class I peptides) (A)  and P53-108, p53-249 and p53-258, class II peptides (B),  were used at 2μg/  well final 
concentration in ELISpot plates for stimulating splenocytes. A significant difference was observed in the immune 
response obtained after in vitro stimulation of cells with p53 peptides compared with the irrelevant Flu I peptide 
control and/or unstimulated splenocyte control. Comparisons of means (± SEM) between groups (T cells pulsed 
with the peptide or control) were made using an unpaired t test. The experiments were repeated twice with 3 mice 
per group. A response was considered positive if the number of spots for splenocytes stimulated with specific 
peptides was 2 fold higher than the number of spots in the control wells. *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.7.  The IFNγ response obtained after in vitro stimulation from the splenocytes of the mice immunised 
with p53-273cDNA using gene gun. Mice were boosted twice at 7 day intervals and spleens were harvested 7 
days post second boost. Splenocytes were cultured and restimulated with p3-322-331, p53-245-253 and p53-193-
201 class I peptides (A) and with P53-108, p53-249 and p53-258, class II peptides (B) at 2μg/ well final 
concentration. IFNγ ELISpot assays were performed after 5 days of in vitro restimulation. A significant 
difference was observed in the ELISpot response obtained following in vitro stimulation of cells with all the three 
peptides assessed compared to the irrelevant Flu I peptide control and/or unstimulated splenocytes control. 
Comparisons of means (± SEM) between groups (T cells pulsed with peptide or control) were made using an 
unpaired t test. The experiments were repeated twice using 3 mice per group. A response was considered positive 
if the number of spots obtained with cells stimulated with specific peptides was 2 fold higher than the number of 
spots in the control wells. *p<0.05, **p<0.01, ***p<0.001 
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The overall frequency of the T lymphocyte response obtained towards the class I and class II 
p53 peptides in the ex vivo assay was higher compared to the response obtained from the mice 
immunised with pcDNA p53-175. The mice immunised with pcmvneoBam p53-273 also 
responded well towards the p53-193-201 (class I) and p53-258-264 (class II) peptides as 
opposed to the mice immunised with pcDNA p53-175. A summary of the number of response 
frequency using p53 class I peptides (p53-193-201, p53-322-329, and p53-245-253) and p53 
class II (p53-258-264, P53-108-123 and p53-249-264) peptides is given in the table 3.7. 
 
Table 3.7. Summary of the frequency of IFNγ ELISpot response following  
immunisation with p53-273 cDNA. 
p53 peptides1 ex vivo IFNγ ELISpot 
assay2  
IFNγ ELISpot assay after3 in vitro 
peptide stimulation  
108-123 (class II) 4/9 6/9 
249-264 (class II) 3/9 6/8 
322-331 (class I) 6/9 6/9 
245-253 (class I) 
258-272 (class II) 
193-202 (class I) 
6/9 
4/9 
5/9 
4/8 
6/9 
7/9 
1 p53 class I and class II peptides. 
2 total no of mice responding in the ex vivo IFNγ ELISpot assays. 
3 total no of mice responding in the IFNγ ELISpot assay performed after 7 day 
 in vitro splenocyte stimulation with peptides. 
 
3.5 Discussion 
P53 is found to be mutated/over-expressed in more than 50% of different types of human 
cancers (Vogelstein et al., 2000). Mutations in p53 occur at different phases of the multistep 
process of malignant transformation contributing to tumour initiation, promotion, 
aggressiveness and metastasis. Mutant p53 protein loses its tumour suppressive properties and 
is shown to gain oncogenic function leading to enhanced cell growth and survival (Oliver et 
al., 2010). Different types of genetic mutations of p53 occur leading to inactivation of the 
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protein that leads to cell transformation. Most frequently found mutations are referred to as 
“hot spot” mutations, present in the DNA binding domain of which two, p53-175 
(conformation mutant) and p53-273 (DNA contact mutant) were selected for the current study. 
Both types of mutation lead to inactivation of the p53 protein (Joerger and Fersht, 2007) and 
are expressed in different types of cancer. The first objective of the current study was to 
identify immunogenic p53 class I and class II peptides in silico and secondly to assess the 
immunogenicity of high binding score peptides (predicted in silico by syfpeithi algorithm) by 
immunising HHDII/DR1 double transgenic K/O mice with pcDNA carrying either p53-175 or 
p53-273 mutation of interest.  
The overarching objective was to develop a prostate cancer vaccination strategy against 
tumours expressing mutant p53 protein by targeting wt p53 peptide sequences expressed by 
cell surface MHC antigens. This required the identification of MHC class I and class II 
peptides from the wt p53 sequence that could be used to promote T cell immunity. P53 is 
found to be conserved among different species including anemone, flies, worms, clams, fish, 
mice and human (Belyi et al., 2010). In the current study out of 7, first variant was selected, 
and human (accession number P04637) and murine (accession number P02340) wt p53 
sequences (shown in 2.1.6.1 and 2.1.6.2 respectively) were aligned and assessed for sequence 
homology, which was found to be >80% (figure 3.2-b). this shows that the p53 sequence in 
human and murine is highly conserved inspte of difference in the species. Subsequently both 
human and murine wt p53 sequences were analysed using the syfpeithi software to predict 
class I and class II sequences binding to HLA A-0201 and HLA-DRB1*0101 respectively. A 
ranked order of class I and class II peptides was obtained from the in silico analysis 
(www.syfpeithi.de) and the highest binding score peptides were selected and assessed for 
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immunogenicity in vitro by IFNγ ELISpot assays. The selected peptides, listed in the table 3.3 
and 3.4 were homologous for human and murine wt p53 peptides sequences and hence studies 
in mice would have some clinical relevance in humans.  
There have been several reports identifying the immunogenic p53 peptides binding to different 
HLA haplotypes. Some were identified as immunogenic on the basis of their Syfpeithi binding 
score and in binding assays using, for example, using T2 cell line (Stuber et al., 1994). p53 
peptides (Table 1.3) have been used in vaccination trials, for example targeting ovarian cancer 
in a phase II clinical trial and in metastatic colorectal cancer (Leffers et al., 2009, Speetjens et 
al., 2009). The p53 peptide vaccines used for these studies were in the form of a pool of 
overlapping synthetic or long peptides (SLPs) spanning most of the p53 protein (Leffers et al., 
2009, Speetjens et al., 2009) but without taking account of the p53 mutational status of the 
tumour as from the current study it showed that the response obtained was different towards 
the same p53 peptides by the splenocytes form the mice immunised with two different mutants 
of p53, 175 and 273. In trials to date, the mutant form of the p53 protein (DNA contact vs 
conformational) has not been considered. It was hypothesised that these two p53 mutants may 
give rise to different peptide repertoire. In the current study wt p53 peptides were identified in 
silico and their immunogenicity was assessed against T cells generated by the two p53 mutant 
forms of the protein: 175 (conformation mutant) and 273 (DNA contact mutant). To the best 
of my knowledge this approach to the analysis of mutational status versus immunogenicity has 
not been previously undertaken. 
In order to screen the immunogenic p53 peptides from the p53-175 and p53-273 mutants, 
HHDII/DR1 double transgenic K/O mice were divided into two groups. The first group (n=3) 
was immunised with pcDNA carrying the p53-175 mutant and the second group (n=3) was 
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immunised with pcDNA carrying the p53-273 mutant using the gene gun method of 
immunisation. ELISpot was performed ex vivo and after in vitro stimulation of splenocytes 
from immunised mice to assess the immunogenicity of selected p53 class I and class II 
peptides.  
For mice immunised with pcDNA carrying p53-175 mutant, immunity against class I peptides, 
p53-322-329, p53-245-253, and p53-263-272 (data not shown) was demonstrated. The p53-
193-201 (class I) peptide demonstrated a lower IFNγ response by ELISpot (figure 3.4). 
Peptides p53-322-329 and, p53-245-253 demonstrated strong IFNγ responses compared to 
either, unstimulated splenocytes or Flu I peptide stimulated controls (figure 3.4). In parallel, 
p53 class II peptides were also assessed using ex vivo IFNγ ELISpot assays performed 
immediately after splenectomy. Peptides p53-108-123, and p53-249-253, but not p53-258-272 
showed significantly high IFNγ responses. After in vitro stimulation, a comparable T cell 
activation profile was obtained. In these assays, the IFNγ response was considered positive 
when the number of spots obtained from the test peptides was at least twice that of 
unstimulated or naïve controls. 
In comparison, mice immunised with pcmvneoBam p53-273 mutation, p53-322-329, p53-245-
253, p53-193-201 (all class I) showed a significant ELISpot response in the ex vivo ELISpot 
assays and following stimulation in culture prior to ELISpot assay compared with controls. 
For class II peptides, assessed by ex vivo IFNγ ELISpot assays and following stimulation, 
peptides p53-108-123, p53-249-264, and p53-258-272 all demonstrated a strong IFNγ 
ELISpot response. In addition, when splenocytes from the naïve mice were assessed for 
response to selected p53 class I and class II peptides, no significant T cell responses were 
observed. This shows that immunity to both p53-322-329 and p53-245-253 class I peptides 
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occurs in mice immunised with either p53-175 mutant or p53-273 mutant. The mice 
immunised with the p53-175 mutant failed to generate significant IFNγ response towards p53-
193-201 class I peptide, while mice immunised with the p53-273 mutant did not show an IFNγ 
response to the p53-263-272 peptide. It is known that the p53-273 mutation abolishes the 
ability of p53 to bind to DNA and it was reported that this mutant protein was unable to 
process and present p53-263-272 peptide via MHC class I antigen (Hoffmann et al., 2000), 
which confirms the results presented here and provides one explanation for the data obtained.  
It was observed that p53-108-123 and p53-249-264 class II p53 peptides induced a strong 
IFNγ response in ELISpot assays, both in the ex vivo assay and assays performed after in vitro 
stimulation of splenocytes with the same peptides; a previous report demonstrated the p53-
108-123 class II p53 peptide to be a potent inducer of T cell immunity (Rojas et al., 2005). An 
immune response to the p53-258-273 class II peptide was generated in mice immunised with 
p53-273 pcmvneoBam but not p53-175 pcDNA3.1. This differential response and apparent 
difference in the repertoire of immunogenic class II p53 peptides from the two mutant forms is 
an important consideration in the design of immunotherapy targeting p53.  
Over the past decade several studies have been conducted targeting p53 in various types of 
human cancers. Peptide based vaccines consisted of either short MHC-restricted peptide 
vaccines or synthetic long peptide (SLP) vaccines, as shown in Table 1.4. Even though peptide 
loaded-DCs and SLPs could induce a strong CD4+ response, they failed to induce a potent 
anti-tumour response (Vermeij et al., 2011), suggesting that the lack of MHC class I –
restricted T lymphocyte responses might be critical in promoting tumour rejection. Several 
other peptide based vaccine strategies have been trialed. In metastatic colorectal cancer, 10 
SLP p53 peptides were assessed in phase I and II clinical trials with Montanide ISA adjuvant 
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and were shown to successfully induce p53 specific T cell responses without inducing 
tolerance. In other complementary studies it was shown that 9 out of 10 patients could induce 
p53- SLP specific immunity. Also, the responses against these SLPs were restricted by 
multiple HLA class II molecules and no HLA association with patient response (Speetjens et 
al., 2009). In the current study the peptides were HLA A-0201 and HLA-DRB1*0101 
restricted and were shown to successfully induce both CD4+ as well as CD8+ responses. There 
was a difference observed in the peptide repertoire in the mice immunized with the two p53 
mutants. This difference could be due to the two different vectors used to for immunization of 
the two mutants. In a study conducted on the SaOS cell line transfected with either p53-175 or 
273, both cloned in the same plasmid vector pBR322, different rate of the protein processing 
via DCs was observed (unpublished data) suggesting that the vector may not be responsible 
for the production of different peptide repertoire from the two mutants of p53. The differences 
in the peptide repertoire could be analysed using massspectrometry analysis of the cell surface 
eluted peptides. In the current study, on the basis of the IFNγ responses obtained in the 
ELISpot assay from splenocytes of mice immunised with p53-175 and p53-273 mutants, 
peptides p53-322-329, p53-245-253 (both class I) and p53-108-123 and p53-249-264 (both 
class II) were selected for the development of a vaccination strategy for further analysis. 
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Chapter 4: p53 as a potential candidate for cancer 
immunotherapy 
4.1 Introduction 
Following the first report in 1991 demonstrating that vaccinations with a single MHC class 
I binding CTL peptide epitope in IFA protected mice against a subsequent challenge, many 
studies focused on the efficiency of this mode of vaccination for producing tumour 
immunity (Schulz et al., 1991). The identification of the first human tumour antigen has 
paved the way for targeted immunotherapy (Boon and Van den Eynde, 2003), with 
specificity to destroy cancer cells and inducing long lasting immune memory without 
eliciting lethal side effects. Targeting MHC class I and class II epitopes of the tumour 
antigen has achieved some clinical success. Cancer immunotherapy and peptide 
therapeutics especially have demonstrated improved responses over that of the 
conventional therapies in patient groups where treatment options are limited (Rane et al., 
2014). But there are still obstacles to combatting advanced cancer, where the immune 
system of the host is compromised. Thus implementing ways of overcoming states of 
immune tolerance, anergy or suppression concomitant with a vaccine strategy to enhance 
adaptive immunity, offers an attractive route for clinical intervention. Targeted therapies 
against defined tumour antigens involving the use of peptide-based vaccination therefore 
offers potential for the future, where novel therapeutics relies on knowledge of peptide 
epitopes and awareness of how these can be used to activate appropriate anti-tumour 
immune responses.  
4.1.1 Development of a vaccination strategy 
P53 HLA-restricted class I and class II peptides were selected using in silico analysing 
(SYFPEITHI algorithm) and screened subsequently to assess their immunogenicity in vitro 
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by immunising HHDII/DR1 double transgenic K/O mice with mutant p53 proteins (p53-
175 and p53-273). These peptides, when used alone to immunise mice, failed to show a 
strong IFNγ response by ELISpot assays and it was therefore decided to adopt a peptide 
delivery system. The peptide incorporated ImmunoBody (IB) vector was the first method 
used for immunisation alongside peptide immunisation in this study. After the discovery of 
anti-idiotypic antibodies which can stimulate both antibody and T-cell responses (de Cerio 
et al., 2007)  it was also shown that incorporation of T-cell epitopes within 
complementarity determining regions (CDRs) can be efficiently presented to DCs in vivo 
(Pudney et al., 2010). This technology gave rise to the DNA vaccine known as 
ImmunoBody developed by Scancell technology Ltd. The light and heavy chains of the 
antibody were replaced by the class I and class II peptides of interest without affecting the 
DNA integrity or stability of the vector system (Pudney et al., 2010). Figure 4.1 shows the 
structure of the DNA vaccine and the ImmunoBody in which the light and heavy chains 
were replaced with the class I p53-322-329 and class II p53-249-264 peptides. It has been 
shown that DNA encoding CTL antigens from a variety of TAAs within the variable 
regions of antibody to induce immune responses in different strains of mice including 
Balb/c, HHD, DR4 and C57BL/6. The responses are mediated by CD8+ T cell subsets 
(Metheringham et al., 2009). On immunisation the peptide epitopes are known to be taken 
up by the DCs which get processed and presented on the cell surfaces via MHC. With the 
Fc receptors present on the cell surfaces they help to elicit and enhance the stronger 
immune response (Metheringham et al., 2009). 
In the current study HHDII/DR1 double transgenic mice were immunised with the IB 
harbouring p53-322-329 (class I) and p53-249-264 (class II) peptides, but they failed to 
induce a strong immune response when assessed in vitro using ELISpot assays after co-
culture with the same peptides. Similar approach was used to immunise C57BL/6 mice, but 
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these mice also failed to show a strong immune response when assessed in vitro in 
comparison with the peptide immunisation.  
                            
Figure 4.1. Schematic representation of the ImmunoBody vector. The double expression vector pDCOring 
used for vaccination. In the ImmunoBody the light was replaced with the CTL epitope of the p53, p53-320 
(LDGEYFTL) and the heavy chain was replaced with the Th epitope of the p53 (RPILTIITLEDSSGN). Once 
epitope have been incorporated into the VH and VL sites within the single vectors they are transferred into 
the double expression vector utilizing HindIII/AfeI and BamHI/BsiWI in frame with their respective human 
constant regions. High-level expression of both the heavy and light chains in mammalian cells is driven from 
the CMV immediate early promoter. CDR regions of the vector are designed to pen easily for the insertion of 
T cell epitope. The image is adapted from Metheringham et al.,2009 and www.scancell.co.uk. 
 
Chapter 4: p53 as a potential candidate for cancer immunotherapy     
107 
 
Superparamagnetic Iron Oxide (Spio) nanoparticles were the next delivery vector that was 
used for immunisation. Spios are the nanoparticles and proven to be non-toxic when 
injected into mice (Dr. Victoria Mundell’s PhD thesis, NTU 2013). These nanoparticles 
possess binding site (-OH) for peptides, and have been shown to have adjuvant-like effects 
(Dr. Victoria Mundell’s PhD thesis, NTU 2013). The p53 peptides attached spios were 
obtained synthesised. Access to further details about the spios are restricted for disclosure 
due to patent applied. Spios were used in this study in an attempt as to boost the 
immunogenicity of the selected p53 peptides. However, spio nanoparticles coupled with 
p53 peptides also failed to induce strong immune responses and did not show any adjuvant 
effects. It was subsequently decided to choose an alternative approach using anti-CD40 
antibody and CpG TLR agonist in the p53 peptide immunisation with IFA to condition the 
DCs and boost the immune response.  
4.1.1.1 Anti-CD40 antibody and CpG agonist combination as an adjuvant for T-cell 
activation 
The CD40 receptor, a transmembrane protein, is a member of TNF super family, and is 
expressed on different cell types including: B cells, macrophages, DCs, epithelial, stromal 
and endothelial cells, and platelets (Grewal and Flavell, 1998; Young et al., 1998; van 
Kooten and Banchereau, 2000, and Quezada et al., 2004;  Eliopoulos and Young, 2004; 
Grewal and Flavell, 1998; van Kooten and Banchereau, 2000; Khalil and Vonderheide, 
2007). APC signalling via CD40 ligand promotes T-cell activation, B lymphocyte 
responses and improves the expression of MHC and co-stimulatory molecules on the 
surface of APCs, increasing cytokine production and T-cell signalling (Vonderheide and 
Glennie, 2013). CD40 ligand (CD154 or CD40L) that binds to CD40 present on DC 
surface leads to activation of these professional APCs. The ligand for CD40 is found to be 
expressed on activated T-cells and platelets (van Kooten and Banchereau, 2000; Armitage 
et al., 1992). Activation of DC via CD40 binding results in the up-regulation of surface 
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molecules. The ligation results in enhanced expression of MHCs and co-stimulatory 
molecules, production of pro-inflammatory cytokines, essential for the complete 
stimulation and activation of T-cells and induction of potent immune response (Grewal and 
Flavell, 1998; Young et al., 1998; van Kooten and Banchereau, 2000, Albert et al., 2001, 
and Mackey et al., 1998). In addition, the magnitude of innate immune responses strongly 
influences adaptive immunity (Ahonen et al., 2004). Activation of specific immunity is 
one of the most enticing avenues in immunotherapy of cancer. Induction of maturation of 
DCs leads to specific downstream T-cell response which reduces the risks arising due to 
autoimmunity (Banchereau and Steinman, 1998). Studies have shown the potential of 
agonist CD40 antibodies in overcoming T-cell tolerance in murine tumour models, evoking 
cytotoxic T-cell response and enhancing the efficacy of cancer vaccines (French et al., 
1999, Diehl et al., 1999, and Sotomayor et al., 1999). 
Toll-like receptors (TLR) are crucial for the induction of innate immune responses and 
synergy between TLR and CD40 induces a strong and long lasting immunity, by inducing 
innate and adaptive immune responses respectively (Ahonen et al., 2004). It has been 
shown that stimulation of CD40 can generate CD4+-independent CD8+ T cell responses 
(Lefrancois et al., 2000, Bennett et al., 1998, Ridge et al., 1998, Schoenberger et al., 1998) 
and it was shown that CD40 can induce long-term T cell survival (Lefrancois et al., 2000, 
Sotomayor et al., 1999, Diehl et al., 1999), tumour antigen specific T-cells could be 
induced when administered in combination with viral or tumour antigens. (Kedl et al., 
2001, Mauri et al., 2000, Ahonen et al., 2002).  In this study TLR-9 was used as an agonist 
in combination with anti-CD40 antibody to enhance antigen presentation and to stimulate 
CD8+ and CD4+ T-cell responses to p53.  
The tumour model was developed in the C57BL/6 syngeneic mice. Although the peptides 
were selected by the assessment in HHDII/DR1 mice, the selected p53 peptides are similar 
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in human and mouse. Hence further assessment of efficacy of this vaccination strategy 
using therapy experiments was performed in the C57BL/6 mice, and this chapter focuses 
on results obtained using this system. 
4.2 Rationale of the study 
The aim of cancer immunotherapy is to induce long lasting and potent immune responses 
against cancer by targeting tumour antigens expressed by tumour cells without inducing 
lethal side effects. This therapy has the potential to be used in combination with 
conventional cancer treatments such as chemotherapy, radiotherapy, and surgery. After 
identifying immunogenic class I and class II p53 epitopes using the syfpeithi algorithm 
(chapter 3, table 3.3 and 3.4), it was considered important to develop a vaccination strategy 
using the selected p53 peptides to induce a potent immune response in a pre-clinical model 
and optimise their potency through the use of adjuvants. In the current study class I p53-
320-327 and class II p53-249-264 peptides were used in combination with anti-CD40 
antibody and CpG (TLR-9 agonist) to develop an anti-cancer vaccination strategy, 
effective in causing tumour rejection. To assess the efficacy of the vaccine, an in vivo 
tumour model was developed in C57BL/6 mice.  
4.3 Results 
4.3.1 Development of the tumour model 
4.3.1.1 The MC38 murine colon carcinoma as a model for immunotherapy 
The MC38 murine colon carcinoma was used as a target for this study, since cells naturally 
express mutated p53 (242) (Vierboom et al., 2000), are tumourigenic (Pajtasz-Piasecka, et 
al., 2001), and express H-2Kb MHC class I antigen, which is required for MHC class I-
restricted peptide expression at the cell surface.  
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The expression of p53 and H-2Kb in MC38 murine colon carcinoma cells is shown in 
figure 4.2(A) using flow cytometry (anibody details in table 2.3), compared with unstained 
cells alone as control. MC38 murine colon carcinoma cells expressed p53 (91.86% of 
cells) and H-2Kb (95.9% of cells). In vitro cultured cells expressed nuclear p53 as seen in 
figure 4.2(B) whereas in tumour sections p53 localised to the cytoplasm (figure 4.3). Since 
the MC38 murine colon carcinoma cell line is known to naturally express mutated p53, this 
cell line was used to develop the tumour model for the assessment of a p53 peptide-based 
vaccine. From earlier experiments (data not shown) we found that a 5 fold change in 
cellular concentration resulted in a halving of tumour uptake. Four different concentrations 
of cells; 4x103, 2x104, 1x105, 5x105; were injected in C57BL/6 mice and tumour size was 
recorded twice per week. Tumour size vs time was plotted as shown in (figure 4.4). Mice 
were euthanised after the tumour reached 100 mm2 size. 2x10 4 number of cells was the 
dose chosen and ten times the cell number was subsequently used as a challenge dose and 
to establish tumours in C57 BL/6 mice resulting in 100% tumour take within the 7-15 days 
allowing enough time for vaccine administration.  
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Figure 4.2. p53 and H-2Kb expression in MC38 murine colon carcinoma cells.  (A) MC38 murine colon 
carcinoma cells were assessed for expression murine class I MHC H-2Kb (i) and p53 (ii) by flow cytometry 
analysis. 91.86% of cells expressed P53 and 95.9% cells expressed H-2Kb. (B) MC38 murine colon 
carcinoma cells were assessed for expression of mutated p53 using immunofluorescence assay. (a), (b),(c) 
and (d) shows the cells in in vitro culture, nuclei staining with Dapi in blue, mutated p53 expression in red 
and co-expression of the nuclei and mutated p53 respectively (n=3). 
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Figure 4.3.  p53 expression in MC38 murine colon carcinoma tumour sections. MC38 murine colon 
carcinoma cells induced tumours were harvested and frozen immediately. MC38 murine colon carcinoma 
tissue sections were stained and assessed using immunofluorescence for the expression of mutated p53 in 
vivo.  The images show the harvested tumour in (a), nuclear staining with Dapi in blue in (b), p53 expression 
in red in (c) after staining with p53 antibody by immunofluorescence assay and co-localisation (dual 
staining)  in (d) (n=4).  
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Figure 4.4.  Determination of the tumour growth rate using MC38 murine colon carcinoma cells in C57BL/6 
mice. Four different doses, 4x103, 2x104, 1x105 and 5x105, of the MC38 murine colon carcinoma cell were 
used to assess the tumour growth rate in C57BL/6 mice. The cells were injected subcutaneously on the right 
side flank of the mice in serum free media. Tumour size was monitored twice per week. Mice were euthanized 
after the tumour reached 100 mm2 size. Tumour sizes were plotted against the number of days. (n=8).  
(a) (b) (c) (d) 
50µm 
Chapter 4: p53 as a potential candidate for cancer immunotherapy     
113 
 
 4.3.2 Development of a vaccination strategy 
 4.3.2.1 ImmunoBody and spio immunisations 
Peptide immunisation alone may not induce strong and long lasting T-cell immunity 
capable of tumour rejection, making it essential to establish a strategy incorporating either 
an efficient delivery system for peptides or including a potent immune adjuvant to boost 
the T-cells response. The p53-108-123 class II peptide, which has been reported to be 
highly immunogenic (Rojas et al., 2005), and p53-245-252 class I peptides were suggested 
for incorporation in the IB vector. However, due to incompatibility with the IB vector, 
determined by in silico assessment, p53-322-329 class I and p53-249-264 class II peptides 
were used as an alternative. The IB vector encoding p53-322-329 class I and p53-249-264 
class II peptides were used for immunisation in an attempt to achieve enhanced CD8+ anti 
p53 responses. The same IB vector was used in HHDII/DR1 double transgenic K/O mice, 
but the T-cells generated failed to show any significant enhancement in T-cell immunity 
when assessed in IFNγ ELISpot assays ex vivo or after in vitro stimulation (figure 4.5, 4.6). 
The use of Spio nanoparticles has been reported to elicit adjuvant like effects (Dr. Victoria 
Mundells’s PhD thesis, NTU 2013). Therefore spio nanoparticles coupled to murine p53-
320-327 class I (holologue of human p53-322-329) and p53-249-264 class II peptides were 
synthesised and used to immunise C57BL/6 mice. C57BL/6 mice is a syngeneic strain of 
mice which was used in further studies due to unavailability of the HHDII/DR1 mice. No 
significant enhancement in the T-cell response to the p53-320-327 class I and p53-249-264 
class II peptides was detected using IFNγ ELISpot assays (Figure 4.7, 4.8).  
Subsequently, the same peptides were used to immunise C57BL/6 mice in combination 
with anti-CD40 antibody and CpG ODN (TLR 9 agonist). The results demonstrated 
enhanced immunogenic response of T-cells, as assessed using the IFNγ ELISpot assay and 
was adopted as a potential immunotherapy for detailed analysis  ex vivo and after in vitro 
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stimulation, 51Cr cytotoxic assay and 3H incorporation proliferation assay. Figure 4.9 
demonstrates the different vaccination strategies used to immunise the selected p53 
peptides. Anti-CD40 antibody is a component of TNF receptor family and known to couple 
with CD40 ligand on APCs/DCs (van Kooten and Banchereau, 2000; Armitage et al., 
1992) and boosts CD4+ mediated immune response. The antibody was obtained from the 
FGK45 hybridomas. Flow cytometry analysis of the DCs for the expression of the CD11c 
marker after treating the cells with anti-CD40 antibody was used as an indicator of DC 
maturation in response to anti-CD40 antibody. Untreated cells alone were used as a 
negative control and DCs treated with LPS provided as a positive control (Appendix II), 
indicative of DC maturation. 
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Figure 4.5. Comparison between two methods of immunisations, peptide and immunobody immunisation. 
HHDII/DR1 mice were divided into 2 groups. First group received p53-323-331 (classI) and p53-249-264 
(class II) (each 75µg) in PBS and emulsified in IFA I.M. the other group received same peptides but in the 
form of IB vector I.P. on the abdominal cavity using gene gun method of immunistaion. The figure represents 
the IFNγ response obtained form the splenocytes of the immunised mice stimulated with p53-322-331 (class 
I) and p53-249-264 (classII) peptides compared with the unstimulated cell alone control from each 
immunisation group. Stastical significance of the results obtained was calculated using two way Anova.  
(n=4). The experiment was repeated with 4 mice per group. 
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Figure 4.6. Comparison between two methods of immunistaions, peptide and immunobody immunization 
after in vitro stimulation of splenocytes. HHDII/DR1 mice were divided into 2 groups. First group received 
p53-323-331 (classI) and p53-249-264 (class II) (each 75µg) in PBS and emulsified in IFA I.M. the other 
group received same peptides but in the form of IB vector I.P. on the abdominal cavity using gene gun 
method of immunistaion. The figure represents the IFNγ response obtained from the slenocytes of the 
immunised mice stimulated with p53-322-331 (class I) in vitro (A) for 5 days and p53-249-264 (class II) in 
vitro for 7 days (B) compared with the unstimulated cell alone control from each immunisation group. 
Stastical analysi was performed using two way Anova (n=4). The experiment was repeated with 4 mice per 
group. 
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Figure 4.7. Comparison between two methods of immunisations, peptide and spio immunisation. 
HHDII/DR1 mice were divided into 2 groups. First group received p53-323-331 (classI) and p53-249-264 
(class II) (each 75µg) in PBS and emulsified in IFA I.M. the other group received same peptides but in the 
form of IB vector I.P. on the abdominal cavity using gene gun method of immunistaion. The figure represents 
the IFNγ response obtained form the slenocytes of the immunised mice stimulated with p53-322-331 (class I) 
and p53-249-264 (classII) peptides compared with the unstimulated cell alone control from each 
immunisation group. Stastical significance of the results obtained was calculated using two way Anova. 
(n=4). The experiment was repeated with 4 mice per group. 
(A) 
     
0
20
40
60
80
100
120
140
SPIO-peptide-IFA
immunisation
SPIO-peptide-NO IFA
immunisation
Peptide-IFA immunisation
control
p53-320-327 (class I)
 
 
N
o
. 
o
f 
IF
N
γ 
se
cr
et
in
g
 s
p
le
n
o
cy
te
s/
1
x
1
0
^
6
 
 
N
o
. 
o
f 
IF
N
γ 
se
cr
et
in
g
 s
p
le
n
o
cy
te
s/
1
x
1
0
^
5
 
Chapter 4: p53 as a potential candidate for cancer immunotherapy     
118 
 
(B) 
0
20
40
60
80
100
120
140
160
SPIO-peptide-IFA
immunisation
SPIO-peptide-NO IFA
immunisation
Peptide-IFA immunisation
control
p53-249-264 (class II)
 
Figure 4.8. Comparison of IFNγ response obtained from the groups of mice immunized with spio-peptides 
with/without IFA in PBS after in vitro stimulation of splenocytes. C57 BL/6 mice were divided into 3 groups. 
First group received spio- p53-323-331 (classI) and p53-249-264 (class II) (each 75µg) in PBS and 
emulsified in IFA I.M. Second group received same peptides with spio in PBS (no IFA) and third group 
received same peptides (no spio attcahed) in PBS and IFA I.M. The figure represents the IFNγ response 
obtained from the slenocytes of the immunised mice stimulated with p53-322-331 (class I) in vitro (A) for 5 
days and p53-249-264 (class II) in vitro for 7 days (B) compared with the unstimulated cell alone control 
from each immunisation group (n=4). The experiment was repeated with 4 mice per group. 
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Figure 4.9.  p53 peptide based immunotherapy strategies. P53 peptides, class I p53-320/322-331 and class II 
p53-249-264, were selected using in silico assessment using syfpeithi algorithm and in vitro screening in 
HHDII/DR1 double transgenic K/O murine models. Three approaches were used to develop a therapeutic 
strategy. (i) These peptides were firstly incorporated in the IB cDNA vector by replacing the variable chains 
of the antibody. The IB vector possessing p53 peptides failed to induce immune response in the HHDII/DR1, 
C57BL/6 or HHDII murine models. (ii) The same peptides were then coupled with spio nanoparticles and 
used in HHDII/DR1 and C57BL/6 murine models. These spio nanoparticles coupled with the p53 peptides 
also failed to induce enhanced immune response or show adjuvant properties. (iii) An alternative therapy was 
developed where the p53 peptides, class I p53-320/322-331 and class II p53-249-264, were used for 
immunisation in combination with anti-CD40 antibody and CpG ODN TLR. This strategy successfully 
enhanced peptide specific immune responses when assessed using IFNγ Elispot assays for class I and class II 
peptides ex vivo, 51Cr release cytotoxicity assays and 3H thymidine incorporation analysis to measure cell 
proliferation as detailed in this chapter. 
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4.3.2.2 Development of an immunisation strategy using anti-CD-40 antibody and a TLR 
agonist: in vitro immune responses 
 
Since IB and spio failed to induce a strong immune response, the combination of anti-
CD40 antibody and TLR9 targeting using CpG ODN1826 were used as adjuvants in the 
development of a vaccination strategy for class I p53-320-327 and class II p53-249-264 
peptides. The method was adapted from Ahonen et. al., 2004. C57BL/6 mice were 
immunised I.P. on the abdominal cavity using anti-CD40 antibody and via the I.M.route 
with class I p53-320-327 and class II p53-249-264 peptides mixed with the CpG TLR 
agonist in IFA. In order to assess the efficacy of each of the components ie. peptides in 
combination with CpG TLR and anti-CD40, peptides with CpG TLR alone or with anti-
CD40 alone verses peptides on their own, C57BL/6 mice were separated into groups of 3 
mice and were immunised with the peptides in combination with or without CpG and/or 
anti-CD40 together with IFA and boosted on day 14. Figure 4.10 shows the  schematic 
representation of the immunisation regime and experiments performed ex vivo and after in 
vitro stimulation. The immunogenicity of the class I p53-320-327 and class II p53-249-264 
peptides, as assessed using the IFNγ ELISpot assays performed ex vivo is shown in figure 
4.11 (A) and (B). In the ex vivo assays performed the IFNγ response obtained from all the 
groups was similar (except for the control group), although higher IFNγ response was 
obtained towards the class II p53-249-264 peptides in the group that was immunised with 
the anti-CD40 antibody (no CpG). Additionally splenocytes were stimulated with the class 
I p53-320-327 and class II p53-249-264 peptides in vitro for 5 to 7 days and then assessed 
using IFNγ ELISpot assays (for both class I and class II resposes) 51Cr cytotoxicity assays 
(for class I p53-320-327) and 3H thymidine incorporation assays to measure the 
proliferative response towards the class II p53-249-264 peptides. The MC38 murine colon 
carcinoma cell line which expressed mutated p53 was used as the target cell line, and the 
Transgenic adenocarcinoma of mouse prostate (TRAMP) cell line was used as the control 
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for these assays. TRAMP cells do not express wt or mutated p53 since the cell line was 
generated by producing a K/O cell for both SV40 large T antigen and p53 (Foster et al., 
1997). Figures 4.12 (A), (B), and 4.13 show the responses responses obtained by 
splenocytes restimulated in vitro.  The group that received the peptide immunisation in 
combination with anti-CD40 and CpG demonstrated significantly high response in the 
form of IFNγ secretion (assessed using ELISpot assay and MC38 and p53-320-327 pulsed 
RMAS as target cells) and cytotoxicity towards the MC38 target cells, performed after 
p53-320-327 class I peptide stimulation in vitro. ELISpot assays and 3H thymidine 
incorporation proliferation assays were performed using splenocytes stimulated with p53-
249-264 class II peptide and DCs pulsed with the same peptide, as shown in figure 4.14 
(A) and (B) where the groups that received the peptides with CpG and with/without anti-
CD40 antibody in IFA showed better responses compared to rest of the groups.  
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Figure 4.10.  Schematic representation of the immunisation regime and experiments performed ex vivo and after 
in vitro stimulation. C57BL/6 mice were injected with anti-CD-40 antibody I.P. and immunised with P53-320-
327 (class I) and p53-249-264 (class II) with CpG TLR agonist and IFA using I.M. route within 4-6 h after 
giving anti-CD-40. Spleens were harvested and ex vivo Elispot assays were performed to assess the IFNγ 
response towards the p53 peptides. Splenocytes were restimulated with P53-320-327 (class I) and p53-249-264 
(class II) peptides and Elispot assays were repeated along with 51Cr cytotoxicity assay and 3H thymidine 
incorporation proliferation assay for class I and class II peptide response assessment respectively. 
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Figure 4.11. Comparison of IFNγ response obtained using ELISpot assay performed ex vivo immediately 
after splenectomy for mice immunised with different immunisation strategies. Four groups of C57BL/6 mice 
were immunised with p53 peptides, p53-320-327 (class I) and p53-249-264 (class II) in combination with 
anti-CD-40 antibody and CpG TLR agonist. The first group received anti-CD-40 antibody I.P. and p53-320-
327 (class I) and p53-249-264 (class II) peptides admixed with CpG and IFA. The second group received 
p53-320-327 (class I) and p53-249-264 (class II) peptides amixed with CpG and IFA. The third group 
received anti-CD-40 antibody I.P. and p53-320-327 (class I) and p53-249-264 (class II) peptides in IFA; a 
fourth group received only p53-320-327 (class I) and p53-249-264 (class II) peptides in IFA. (A) represents 
the IFNγ response obtained against the p53-320-327 class I peptide in the ELISpot assay performed ex vivo 
imediately after splenectomy. (B) represents the IFNγ response obtained against the p53-249-264 class II 
peptide in the ELISpot assay performed ex vivo imediately after splenectomy. Statistical significance was 
assessed using two way Anova. The experiments were repeated twice with 3 mice per group. *p<0.05, 
**p<0.01, ***p<0.001 
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Figure 4.12. Comparison of IFNγ response obtained using the ELISpot assay performed after in vitro 
peptide stimulation of splenocytes from mice immunised with p53 peptides and/or immune adjuvants. Four 
groups of C57BL/6 mice were immunised with selected p53 peptides, p53-320-327 (class I) and p53-249-264 
(class II) in combination with anti-CD-40 antibody and a CpG TLR agonist. The first group received anti-
CD-40 antibody I.P. and p53-320-327 (class I) and p53-249-264 (class II) peptides admixed with CpG and 
IFA; the second group received p53-320-327 (class I) and p53-249-264 (class II) peptides admixed with CpG 
and IFA. The third group received anti-CD-40 antibody I.P. and p53-320-327 (class I) and p53-249-264 
(class II) peptides in IFA, and the fourth group received only p53-320-327 (class I) and p53-249-264 (class 
II) peptides in IFA. (A) Represents the IFNγ response obtained against the p53-320-327 class I peptide 
(ELISpot assay) using splenocytes stimulated in vitro with the p53-320-327 class I peptide and then co-
cultured with MC38 murine colon carcinoma cells. (B) Represents the IFNγ response obtained against the 
p53-320-327 class I peptide in the ELISpot assay performed with the splenocytes stimulated in vitro with the 
p53-320-327 class I peptide then subsequently co-cultured with RMAS cells pulsed with p53-320-327 class I 
peptide. Statistical significance of the results obtained was calculated using two way Anova. The experiments 
were repeated on three separate occasions with 3 mice per group. *p<0.05, **p<0.01, ***p<0.001 
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Cytotoxicity assay 
 
 
Figure 4.13. Comparison of percent cytotoxicity assay performed after in vitro peptide stimulation of the 
splenocytes from the group of mice immunised with anti-CD-40 and CpG TLR agonist with p53 peptides 
strategy. The splenocytes from the group of mice immunised with anti-CD-40 and CpG TLR agonist with p53 
peptides (class I p53-320-327 and class II p53-249-264) were stimulated in vitro for 5 days with class I p53-
320-327 peptide and sytotoxicity assay was performed using MC38 murine colon carcinoma and TRAMP 
cells as targets. The targets cellls were labelled with 51Cr on the day of assay and co-cultured with stimulated 
splenocytes at varying effector:target ratios. The percent cytotoxicity was measured after 4 h using the 
formula given in the methods section. The experiments were repeated twice with 3 mice per group. 
Percentage cytotoxicity was considered specific when maximum to spontaneous release was <20%.  
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Figure 4.14.  Comparison of IFNγ response obtained using ELISpot assay and counts per minute using the 3H 
thymidine incorporation proliferation in response to in vitro peptide stimulation of the splenocytes from the groups of 
mice immunised with different immunisation/treatment strategies. Four groups of C57BL/6 mice were immunised with 
selected p53 peptides, p53-320-327 (class I) and p53-249-264 (class II) in combination with anti-CD-40 antibody 
and/or a CpG TLR agonist. The first group received anti-CD-40 antibody I.P. and p53-320-327 (class I) and p53-249-
264 (class II) peptide admixed with CpG and IFA; the second group received p53-320-327 (class I) and p53-249-264 
(class II) peptides admixed with CpG and IFA; a third group received anti-CD-40 antibody I.P. and p53-320-327 
(class I) and p53-249-264 (class II) peptides in IFA; a fourth group received p53-320-327 (class I) and p53-249-264 
(class II) peptides alone in IFA. (A) Represents the IFNγ response obtained against the p53-249-264 (class II) peptides 
in the ELISpot assay performed with the splenocytes stimulated in vitro with p53-249-264 (class II) peptides pulsed 
splenocytes co-cultured with p53-249-264 (class II) peptide pulsed DCs. (B) Represents the counts per minute obtained 
against the p53-249-264 (class II) peptide pulsed DCs in the proliferation assay performed with the splenocytes 
stimulated in vitro with the p53-249-264 (class II) peptide. . Statistical significance of the results obtained was 
calculated using two way Anova. The experiments were performed on 3 separate occasions with 3 mice per group. 
*p<0.5, **p<0.01, ***p<0.001 
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4.3.3 In vivo immunotherapy model 
4.3.3.1 Boost can be detrimental in the therapy model 
On the basis of the results obtained by in vitro assessment of the ELISpot and proliferative 
response obtained by combining CpG TLR and anti-CD40 with class I p53-320-327 and 
class II p53-249-264 (as shown in the section 4.3.2.1), it was observed that the class I p53-
320-327 and class II p53-249-264 peptides when used to immunise in combination with 
anti-CD40 antibody and CpG TLR as adjuvants elicited a strong immune response in vitro. 
The same strategy was chosen to assess the efficacy of these treatments on in vivo tumour 
growth in C57BL/6 mice using the MC38 murine colon carcinoma model. C57BL/6 mice 
were divided into two groups, the first group received developed vaccination therapy (p53-
320-327 and p53-249-264 peptides with CpG and IFA within 4-6 h after injection of anti-
CD40 antibody I.P.) on the same day of MC38 murine colon carcinoma cell injection S.C. 
on the right flank for tumour induction as described in section 4.3.1 The second group 
mice were injected with the MC38 murine colon carcinoma cells S.C. and tumour size was 
monitored. Once tumours reached the 2-4 mm in size, mice received therapy using CpG 
TLR and anti-CD40 with class I p53-320-327 and class II p53-249-264 peptides in IFA. 
Each group was further divided into two groups where one group was boosted on day 14 
with same therapy regime; the other group did not receive any further therapy. Figure 4.15 
gives the schematic representation of the experimental design and figure 4.16 and 4.17 
shows the results obtained from the experiment using survival analysis and percent of 
tumour infiltrating lymphocytes (TILs) of tumour bearer mice  following treatment. 
Tumour infiltrating lymphocytes were also assessed in tumour cells isolated from the 
tumour bearer mice that received the developed vaccination therapy. A clear CD3+, CD8+ 
and CD4+ population was observed in the TIL. The developed vaccination strategy did 
successfully reduce tumour growth in a therapeutic setting i.e. when the vaccine was 
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administered when tumours were 2-4 mm in size, the therapy showed efficacy by slowing 
the tumour growth, compared with mice that received MC38 murine colon carcinoma cells 
alone or p53 peptide vaccination at the same time as tumour cell injection, although no 
statistical significance was observed when two groups were compared. 
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Figure 4.15.  Schematic representation of the therapy experiment with immunisations at different time points. 
C57BL/6 mice were divided into two groups and both the groups received MC38 murine colon carcinoma 
cells S.C. First group received the developed therapy (anti-CD-40 antibody I.P. and p53-320-327 (class I) 
and p53-249-264 (class II) peptides with CpG TLR and IFA I.M.) on the same day of MC38 murine colon 
carcinoma injection. This group was further divided into two groups, one of which received the boost with 
the same therapeutic regime on day 14. For the second group that received the MC38 murine colon 
carcinoma cells S.C., the tumour were monitored. These tumour bearer mice received the therapy once the 
tumours reached the size of 2-4 mm. These mice were also divided into two groups and one of which received 
boost with the same treatment on day 14.  
 
Time 
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Group 1- Tumour implant and therapy on d0  (no boost)  
Group 2- Tumour implant and therapy on d0 and boost on d14 
Group 3- Therapy given when tumours reached 2-4mm2  (no boost) 
Group 4- Therapy given when tumours reached 2-4mm2 and boost on 
d14 
Group 5- Control, no therapy given 
*
*
 
** 
*
*
*
 
**** 
* 
p= 0.001 
p= 0.004 
p= 0.0008 p< 0.0001 
p= 0.0467 
Figure 4.16.  The survival curves obtained from the mice treated with the developed vaccine given at different time points. (A) 
Represents the results obtained from the mice which were given therapy on the same day of MC38 murine colon carcinomas 
cell injection in (i),and the mice that received booster on day 14(ii). (B) Represents the results obtained from the mice which 
were given therapy after the MC38 carcinomas were 2-4mm2 in size, and were compared to the control mice which did not 
receive any therapy. This group of mice were primed after the tumours were 2-4 mm2 (iii) and other group received booster on 
day 14 (iv). (C) represents the comparison between the groups of mice that received the treatment and the MC38 murine colon 
carcinoma cell injection on the same day and the group that received the therapy after the MC38 carcinomas were 2-4 mm2 in 
size. A group of mice that did not receive any treatment was used as a control (n=5). The data was analysed using Kaplan 
Meier analysis. In (A.ii), (B.ii) and (C), p value shows the oveall statistical significance between the comparison groups.  No 
statistical significance was found between group 1and 2, 3 and 4 or group 1 and 3. Experiment was performed on two 
different occasions. 
 
(A) 
(B) 
(C) 
(i) (ii) 
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Flow cytometry TIL assessment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17.  The percentage of the tumour infiltrating lymphocytes (TILs). Tumour cell suspension were 
prepared (dissociated mechanically) from excised tumours from C57BL/6 mice of the therapy [anti-CD-40 
antibody and p53-320-327(class I)+ p53-249-264 (class II) peptides with CpG and IFA], and the percent 
TILs infiltration was assessed for  CD3
+
CD8
+ 
and CD4
+ 
expression. (A) shows the TIL form the mice which 
received the therapy and (B) is the control. The TILs were assessed of 5 mice per group. 
 
 
 
 
 
 
(A) 
(B) 
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4.3.3.2 Comparison of the p53 peptide therapy with/without CpG and/or anti-CD40 
antibody in the in vivo tumour models 
 
Extending to include all the control groups used in the in vitro analysis (as shown in the 
section 4.3.2.1) the same combinations (CpG TLR and anti-CD40 with class I p53-320-327 
and class II p53-249-264) were assessed in the developed MC38 murine colon carcinoma 
tumour model established in C57BL/6 mice. C57BL/6 mice were injected with the 2x105 
MC38 murine colon carcinoma cells (10x optimum tumour dose chosen). Tumour growth 
was monitored and when tumours reached 4-16 mm2 in size, C57BL/6 mice received 
therapy with the class I p53-320-327 and class II p53-249-264 peptides with/without anti-
CD40 antibody and/or CpG in IFA. Group of tumour bearer mice immunised with peptides 
only (without anti-CD40 and/or CpG) and group of tumour bearing mice without any 
peptide and/or peptide combined with anti-CD40 and CpG were used as the controls for 
the experiment.  Figure 4.18 shows the results obtained using the MC38 murine colon 
carcinoma model. Of all the therapy groups of mice, the group that received peptides in 
combination with anti-CD40 and CpG in IFA showed better survival compared to rest of 
the groups.Tumour size was also recorded for the four therapy groups where the group that 
received the p53 peptides along with anti-CD40 and CpG and the group that received the 
peptides with CpG (no anti-CD40) showed slower tumour growth. 
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(B) Tumour size measurement                                                                                                                                                                                                                                                                              
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Figure 4.18. Comparison of tumour growth in the groups of mice treated with different immunisation regimes. MC38 
murine colon carcinoma cells were implanted subcutaneously in the right hand side flank of the C57BL/6 mice which 
were divided into five groups. Tumours were allowed to grow to the size of 2-4mm2 and were subsequently immunised 
with selected p53 peptides [p53-320-327 (class I) and p53-249-264 (class II)] in combination with/without anti-CD-40 
antibody and/or CpG TLR agonist. The percent survival from each group is shown in (A) and the data was analysed 
using Kaplan Meier analysis. The p value in (v) indicates the overall statistical significance of all the graphs. The 
groups that received the therapy in the combinations with/without anti-CD-40 and/or CpG were compared with the 
group 5 control and are shown in (i)-(v). (v) shows the overall stastical significance of among all the groups compared. 
The tumour growth curve is shown in (B). Group 1 received anti-CD-40 antibody I.P. and p53-320-327 (class I) and 
p53-249-264 (class II) peptides admixed with CpG and IFA. Group 2 received anti-CD-40 antibody I.P. and p53-320-
327 (class I) and p53-249-264 (class II) peptides admixed IFA. Group 3 received p53-320-327 (class I) and p53-249-
264 (class II) peptides in a mixture with CpG and IFA. Group 4 received  p53-320-327 (class I) and p53-249-264 (class 
II) peptides admixed IFA. Group 5 was a control group and did not receive any therapy. Experiment was performed 
twice with n=5. 
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4.4 Discussion 
With the maturing understanding of tumour biology and immunological mechanisms, we 
are now well equipped to rationally develop immunotherapy approaches against cancer. 
The identification of human tumour antigens (TA) has provided the basis for tumour-
targeted immunotherapy (Boon and Van den Eynde, 2003), especially that mediated by T-
lymphocytes recognising MHC-associated target peptides (Rane et al., 2014). The aim of a 
cancer vaccine therapy is the induction of T cell responses (stimulation of cellular 
immunity) capable of destroying tumour cells, causing tumour regression. For vaccines to 
stimulate cellular immunity, APCs, such as DCs, are required to process the antigen and 
present class I and/or class II peptides on their surfaces via class I and class II MHCs 
respectively to engage with the T cells receptors (TCRs). The CD8 T-cell effectors are 
potent effectors that target cancer cells directly, while CD4 T-cells act as amplifiers of the 
induced immune response (Metheringham et al., 2009). Cancer vaccines therefore act as 
“biological modifiers” which stimulate the immune system, which is designed to control 
infections and disease (http://www.cancer.gov/cancertopics/factsheet/Therapy/cancer-
vaccines). There are two types of immunisation strategies, prophylactic or preventive 
vaccines (given to healthy individuals to prevent the disease occurrence) and therapeutic or 
treatment vaccines (given to patients suffering with the disease) (Lollini et al., 2006). 
Three cancer vaccines have already been approved by the U.S. Food and Drug 
Administration (FDA). Two of which are prophylactic vaccines, Gardasil (manufactured 
by Merck & Company) and Cervarix (manufactured by Glaxosmithkline), that use Virus-
like particles or VLPs to target Human Papilloma Virus (HPV) types 6, 11, 16 and 18, the 
cause of cervical cancer (http://www.cancer.gov/cancertopics/factsheet/Therapy/cancer-
vaccines). In 2010, the FDA approved a therapeutic prostate cancer vaccine, Sipuleucel-T 
or PROVENGE(R) (developed by Dendreon). This vaccine is designed to induce an 
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immune response against an antigen which is commonly found on the prostate cancer cells 
called as Prostatic Acid Phosphatase (PAP) and prolonged overall survival was observed in 
the men (castration-resistant metastatic PrCa patients) who received the Sipuleucel-T 
vaccine in the phase III trial (Kantoff et al., 2010).  
In the current study a vaccination strategy has been developed targeting the tumour 
suppressor gene p53, which is present in all cell types and controls cell division and repairs 
DNA damage. Any damage or mutation to p53 can alter the function of tumour 
suppression, which in turn leads to uncontrolled cell proliferation and mutations in p53 are 
common genetic events in human cancer (Levin and Oren, 2009). p53 is found to be 
expressed in more than 50% of different types of cancers making it an ideal target and 
following the in silico identification of two immunogenic p53 peptides (chapter 3) and 
demonstrating their immunogenicity it was important to develop a vaccination strategy to 
deliver those two p53 peptides using an effective delivery mechanism and adjuvant regime 
to promote a peptide specific immune response.  
Two delivery systems were used in this study, IB and Spio, however neither system 
promoted effective immunogenic responses when assessed in the pre-clinical models. IB is 
an antibody vector which on incorporation of T-cell epitopes within complementarity 
determining regions (CDRs) can efficiently presented to DCs in vivo via Fc receptors 
(Pudney et al., 2010). In the current study the p53 peptides incorporated IB vector failed to 
generate immunogenic response in the HHDII/DR1 mice and HHDII (data not shown, 
performed by Scancell). This might be due to failure of the presentation of the peptides on 
the DCs and/or Fc receptor binding. Another vector used was the spios attached to the 
peptides which also failed to generate immunogenic response. Spios were reported to be 
non toxic in the murine models and reported to act as adjuvant in the immunisation mixture 
and enhance the immunogenicity of the peptides (Dr. Mundell thesis, Nottingham Trent 
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University). In the current study, the spio-peptides neither showed adjuvant like effects nor 
enhanced the immunogenecity of the peptides. As reported, they were safe to use in pre-
clinical models for immunistaion (did not show any side effects/anaphylaxis). The same 
p53 peptides when given in combination with anti-CD40 antibody with CpG TLR and IFA 
however induced strong immune responses and a tumour model was developed to assess 
the efficacy of the vaccine in vivo. Optimum dose of MC38 murine colon carcinomas cells 
were used to establish the tumour model, which naturally expressed mutated p53 (Pajtasz-
Piasecka, et al., 2001), as shown here.  The vaccination strategy using p53 peptides in 
combination with anti-CD40 antibody and CpG TLR targeting p53 in MC38 murine colon 
carcinomas has not been previously reported. 
The selected p53-320-327 (class I) and p53-249-264 (class II) peptides administered in 
IFA were first assessed in combination with anti-CD40 antibody and a CpG TLR agonist 
in the C57BL/6 murine model. The mice were divided into four groups which received 
peptides in varying combinations of anti-CD40 antibody and/or with CpG TLR in IFA. 
Mice treated with p53 peptides with CpG TLR and IFA within 4-6 h after injecting anti-
CD40 antibody showed stronger immune response, assessed using ELISpot, Cytotoxicity 
and proliferation assays performed ex vivo and after subsequent in vitro restimulation of 
splenocytes with the p53 peptides p53-320-327 (class I) and p53-249-264 (class II) (as 
shown in 4.3.2.1). This strategy was further used in the therapy experiment using the 
MC38 tumour model. 
It has been observed in several studies that TLR agonists possess the potential to be potent 
agonists of immunity. There are several TLRs which are located in the different cellular 
compartments and can be expressed in different types of the cancer cells. CpG ODN 
associated with TLR9 (Akira, 2003) which has been used as an agonist in vaccine trials in 
combination with CTLA-4 mAb (Draftarian et al., 2004). Depending on the cell type, 
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TLRs are known to act in concert with various cytokines and chemokines. The induction of 
innate immune response by TLRs is mirrored by the acquired immune response to antigen 
induced by CD40 (Ahonen et al., 2004). CD40 agonist was first used in the clinical trial 
for advanced squamous cell cancer patients in the form of CD40L which showed long term 
complete remission (Vonderheide, 2001). Similarly, CP-870,893 have also shown clinical 
efficacy in advanced cancers (Vonderheide, 2007). Due to potential synergy between the 
chemotherapy (to release tumor antigen) and CD40 agonists (to activate APC), CP-
870,893 has been tested in combination with carboplatin and paclitaxel and gemcitabine. 
Objective tumor regressions were observed in about 20% of patients in each study (Beatty 
et al., 2011). It has been shown in 2012, that different TLR agonists when combined with 
CD40 in a C57BL/6 mice model induce CD8+ T cell expansion to immunisation with 
ovalbumin protein and/or the SIINFEKL peptide (Ahonen et al., 2004). Different TLRs 
were compared in this study (Ahonen et al., 2004), which also showed to generate antigen 
specific T cells.   
To validate the hypothesis and to assess the efficacy of p53 peptide based vaccination, the 
C57BL/6 mice were injected with MC38 tumour cells and divided into four groups. After 
careful assessment of the percent survival and the tumour growth it was shown that the 
group that did not receive a “booster” injection showed better response and reduced 
tumour growth compared to mice receiving the p53 peptide vaccine “booster” injection on 
d14. It has been shown that a vaccine boost can be detrimental to immunotherapy 
(Ricupito et al., 2013). In the study, DC-based vaccine was used in the prophylactic and 
therapeutic setting using transplantable and spontaneous tumour models. It was observed 
that the necessity and/or efficacy of the booster dose is dependent on and should be 
determined on the basis of the status of the disease (Ricupito et al., 2013).   It was shown 
in the study that the booster immunisation has direct correlation with the CD8+ memory T-
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cells and in the therapeutic setting the booster immunisation proved detrimental (Ricupito 
et al., 2013).   Similarly, in the current study the group that did not receive a “booster” 
injection showed better response and reduced tumour growth compared to mice receiving 
the p53 peptide vaccine “booster” injection on d14. There was a longer survival observed 
in the group of mice that received the MC38 murine colon carcinoma injection and therapy 
on the same day, compared to the control group (no therapy), or the group that received a 
“booster” injection on d14. Tumour infiltrating lymphocytes were also assessed in tumour 
cells isolated from the tumour bearer mice that received the developed vaccination therapy. 
A clear CD3+, CD8+ and CD4+ population was observed in the TIL. The developed 
vaccination strategy did successfully reduce tumour growth in a therapeutic setting i.e. 
when the vaccine was administered when tumours were 2-4 mm in size, the therapy 
showed efficacy by slowing the tumour growth, compared with mice that received MC38 
murine colon carcinoma cells alone or p53 peptide vaccination at the same time as tumour 
cell injection, although no statistical significance was observed when two groups were 
compared. More number of mice per group might be helpful in determining the statistical 
significance. Of all the therapy groups of mice, the group that received peptides in 
combination with anti-CD40 and CpG in IFA showed better survival compared to rest of 
the groups. Tumour size was also recorded for the therapy groups where the group that 
received the p53 peptides along with anti-CD40 and CpG and the group that received the 
peptides with CpG (no anti-CD40) showed slower tumour growth implying that the 
synergistic effect of the anti-CD40 antibody and CpG TLR agonist along with peptide is 
responsible for the prolonged survival of the recipient group with CpG TLR playing key 
role. After careful consideration it also seems to be important to have an additional control 
group which would receive the developed peptide vaccine with anti-CD40 and CpG but 
without IFA. It has been reported that replacing water-based, short-lived formulation with 
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gp100 peptide vaccine in the presence of immunostimulatory molecules allowed T-cells to 
traffic to tumors, causing their regression (Hailemichael and Overwijk, 2014).  This 
strategy with the selected p53 peptides has been reported for the first time in the MC38 
murine colon carcinoma in syngeneic model.  
After assessing the immune responses in the pre-clinical models it is important to assess 
the immunogenicity of the peptides in the patients in order to make it a translational study. 
The peptides were assessed in prostate cancer patient PBMCs, as shown in next chapter. 
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Chapter 5: Assessment of immunogenicity of the selected p53 peptides in 
the prostate cancer patient PBMCs 
5.1 Introduction 
In the current study the p53 peptides identified in pre-clinical studies (chapter 4) were used 
to assess whether PrCa patient PBMCs processed pre-existing T-cell immunity. The 
assessment of immune reactivity was based on the potential of the p53 peptides to generate 
a specific response (IFNγ production in this instance) upon stimulation in vitro. Several 
cancer vaccine trials, targeting different tumour antigens, have been undertaken (Johnson 
et al., 2006; Small et al., 2006; Higano et al., 2009) to  demonstrate safety and efficacy of 
immunotherapy and in some cases prolonged survival has been described (Kantoff et al., 
2010; Schwartzentruber et al., 2011; Schuster et al., 2011). A phase II randomized 
controlled trial of a pox-viral-based PSA-targeted immunotherapy in metastatic castration-
resistant PrCa study showed that PROSTAVAC-VF was well-tolerated and was associated 
with reduction in death rate and improved overall survival (Kantoff et al., 2010).  To be 
eligible for clinical evaluation, the candidate antigen needs to have demonstrated a 
beneficial response in pre-clinical assessment and/or the ability to generate an immune T-
cell response from PBMCs (Timothy et al., 2001). This may include in vitro stimulation of 
PBMCs from cancer patients and/or benign/healthy donors of the appropriate HLA 
haplotype in order to expand T-cells with the potential to recognise and lyse the cancer 
cells expressing the appropriate tumour antigen target (Viatte et al., 2006). It is essential to 
use immune-assays that assess CD8+ T-cell activity or helper T-cell responses and reflect 
the true frequency and functional activity of immune response generated together with the 
optimum assay condition (Arthur et al., 2005). The immunological assay should be 
sensitive, reproducible, and more importantly accurate (Zhang et al., 2009). The ELISpot 
assay has been shown to be reliable for detecting antigen specific T-cells in PBMCs 
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(Zhang et al., 2009), and the accuracy of the assay has been improved and with the aid of 
computerised plate readers and dual colour development kits to assess more than one 
cytokine per cell type (Quast et al., 2005). The assay discriminates T-cell specific 
responses from the background (Fadi et al., 2012, Okamato et al., 1998) and has proved to 
be a most suitable assay to assess the immune response and the cytokine production profile 
of T-cells. Alongside the ELISpot assay, the 51Cr release (cytotoxicity) assay and 3H 
thymidine incorporation to assess cell proliferation are also useful in assessing immune 
function/reactivity in vitro. In the immune mechanism the key player against body’s toxic 
invaders is the Cytotoxic T-cell which can identify the antigens presented at the surface of 
the foreign cells and altered self via cell surface receptors and on activation are capable of 
killing them. The activated CTLs do not require co-stimulation for induction of 
cytotoxicity. The methods developed, such as chromium release assay, allows to quantify 
the cytotoxicity phenomena which helps to determine the number of lymphocytes being 
produced after infection and the efficiency of the cytotoxic T-cells in killing the foreign 
presenting cells. In the chromium release assay the target cells are pre-labelled with 51Cr 
and co-incubated with effector cells. Cytotoxic T-cells kill their targets by disrupting the 
cell membrane integrity, allowing 51Cr release, which is used as the indicator of the amount 
of specific lysis (Lavie et al., 2000; Mickel et al., 1988; 
mcb.berkeley.edu/courses/mcb150/Lecture16/Lecture16(6).pdf, 
http://www.perkinelmer.co.uk/resources/). Human leukocyte proliferation has traditionally 
been assessed using 3H incorporation proliferation assay to evaluate the ability of the 
stimuli (p53 peptides at this instance) to encourage or inhibit the cell proliferation.  
3H thymidine incorporation proliferation assays measure the incorporation of a 3H-
radiolabeled DNA precursor into the replication strands of DNA produced during cell 
division on stimulation with the peptide (Lee-Hoeflich et al., 2008; Munier et al., 2009). 
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Here, PBMCs from PrCa patients, were assessed for immunogenic responses towards p53 
MHC restricted peptides.   
5.2 Rationale of the study: 
 
P53-322-329 (class I) and p53-249-264 (class II) peptides were found to be immunogenic 
when assessed using HHDII/DR1 double transgenic K/O mice (chapter 4) and C57BL/6 
mice were subsequently used to develop a pre-clinical therapeutic vaccination strategy. It 
was proposed therefore, that these p53 peptides were suitable candidates for assessing T-
cell responses in PrCa patients expressing HLA-A2 antigen. The immunogenicity of p53 
class I and class II peptides was therefore assessed using IFNγ ELISpot, 51Cr release 
cytotoxicity and 3H thymidine incorporation to assess proliferation.   
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Figure 5.1.  Schematic representation of the experimental design using PrCa patient PBMCs. PBMCs were 
isolated from PrCa patient blood and frozen. The PBMCs were thawed and immune assays were performed, 
by ELISpot assay, 51Cr release cytotoxicity assay (after stimulation with peptides in vitro) and 3H thymidine 
incorporation proliferation assay (after stimulation with peptides in vitro) to assess the immune response 
against p53 class I and class II peptides. 
 
5.3 Patient details 
All of the patients selected for this study were HLA-A2 positive (assessed using flow 
cytometry) and the p53 class I peptides selected were HLA-A2 restricted. The clinical 
details of the patients were recorded on the day of diagnosis and the stage of disease 
determined according to the D’Amico classification and Gleason grade scores. The disease 
status was determined for all the selected patients using Transrectal Ultra Sound (TRUS) 
and Transperineal (TP) biopsy samples and pathological assessment. The prostate specific 
Cryopreserved PBMCs 
Thaw 
PrCa 
Patient 3H Thymidine 
Extraction of 3H 
Thymidine labelled 
DNA 
Counting radioactivity IFNγ ELISpot assay Measure 51Cr release 
51Cr labelled LnCap/                    
DU145 cells 
 Stimulus 
C
la
ss
 I
I 
C
la
ss
 I
 
 
Chapter 5: Assessment of immunogenicity of the selected p53 peptides in PrCa patient PBMCS     
145 
 
antigen (PSA) test and TRUS biopsy examination are routinely used for the diagnosis of 
patients suspected of having prostate cancer (Sharial et al., 2008). The TRUS method has 
limitations, and can only be taken from the posterior aspect of the prostate. Thus if the 
cancer is present on the anterior side of the prostate gland (which is not examined) it will 
not be detected by TRUS biopsy. On the other hand the TP pathology has proven to be a 
more accurate and reliable method (Nafie et al., 2013), where biopsies from the posterior 
and anterior of the prostate gland are taken for pathological assessment. Patients were 
divided into four groups: benign, low grade, intermediate and high grade, on the basis of 
their disease status and pathology, according to the Gleason grading (GG) system.  
A prostate cancer risk classification system was proposed by D’Amico in 1998 (D’amico 
et al., 1998). According to this criteria prostate carcinomas are categorised into low, 
intermediate and high risk cancers on the basis of the PSA, GG score or clinical stages of 
the disease (Loeb et al., 2010). The stages of the cancer are determined using the TNM 
system detailed in chapter 1 (http://www.nhsinform.co.uk/Health-
Library/Articles/C/cancer-of-the-prostate/staging).  
Table 5.1 gives details of the patients including their age at diagnosis, observations of the 
Digital Rectal Examination (DRE), Gleason grade, D’Amico classification, TRUS and TP 
pathology and figure 5.1 gives the details of the experimental design. The anonymised 
clinical data was provided by Prof. Masood Khan at Leicester General Hospital 
(Consultant Urologist, University Hospitals of Leicester, NHS Trust). The PBMC samples 
were obtained from two cohorts (depending on TRUS and TP examination) and were 
collected under ethics codes: NRES: 09/H0401/92 and local R&D: UHL10856 and NRES: 
11/EM/0312 and local R&D: UHL11068. 
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Table 5.1.  Clinical data of the prostate cancer patients used in this study1 
Patient ID2 Age at 
diagnosis 
PSA DRE Histology Gleason D’Amico 
classification 
TRUS pathology TPTP pathology 
Benign 
LE-0040 67 28 Benign Benign   Benign Benign   
LE-0044 64 3.6 T2 Benign   Benign Benign   
TP0024 67 7.8  Benign   Benign Atypia Benign Atypia 
TP0034 70 6.5  Benign   Benign Atypia Benign Atypia 
TP0047 67 15  Benign   Benign Atypia Benign Benign 
TP0055 66 14.4  Benign   Benign High PIN Benign Benign 
Low  
LE-0059 67 7.6 Benign 3+3 6 Low Cancer 3+3   
LE-0078 66 7.1 Benign 3+3 6 Low Cancer 3+3   
LE-0079 71 9.4 Benign 3+3 6 Low Cancer 3+3   
TP0040 66 8.8  3+3 6 Low Benign ASAP Cancer 3+3 
TP0022 64 4.7  3+3 6 Low Cancer 3+3 Cancer 3+3 
Intermediate 
LE-0048 76 16 Benign 3+4 7 intermediate Cancer 3+4   
LE-0050 72 3 T2 3+4 7 intermediate Cancer 3+4   
LE-0052 81 11 T2 3+4 7 intermediate Cancer 3+4   
LE-0053 70 8.4 Benign 3+4 7 intermediate Cancer 3+4   
LE-0071 86 13 T2 3+4 7 intermediate Cancer 3+4   
LE-0072 78 14 Benign 3+3 6 intermediate Cancer 3+3   
LE-0084 70 11 Benign 3+3 6 intermediate Cancer 3+3   
High 
LE-0043 88 52 T3 4+5 9 High Cancer 4+5   
LE-0061 84 118 T4 5+4 9 High Cancer 5+4   
LE-0067 71 54 T3 4+5 9 High Cancer 4+5   
LE-0068 67 27 T3 4+5 9 High Cancer 4+5   
LE-0069 73 21 Benign 4+3 7 High Cancer 4+3   
LE-0086 73 40 T3 4+5 9 High Cancer 4+5   
1 The anonymised clinical data was provided us Prof. M Khan, consultant Urologist at Leicester General Hospital (University Hospitals of Leicester, NHS Trust). The two cohorts were collected 
under 2NRES: 09/H0401/92 and local R&D: UHL10856 and 3NRES: 11/EM/0312 and local R&D: UHL11068.2LE- patient cohort with TRUS diagnosis, TP- patient cohort with diagnosis
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5.4 Assessment of PSA 
 
PSA is a serine protease produced by epithelial cells in prostate tissue (Tan, 2005), 
including benign and malignant (Duskova and Vesely, 2014). PSA helps in liquefying the 
semen which increases sperm motility (Lilja and Abrahamsson, 1988). Elevated PSA was 
correlated with progressing PrCa in 1987 by Stamey et al. and was approved as a marker to 
monitor PrCa in 1986 by FDA and is correctly used to detect PrCa in men older than 50 
years since 1994 (Duskova and Vesely, 2014). Although used routinely worldwide, the 
PSA test has its limitation and hence is not a conclusive measure of disease. It has been 
observed that the level of PSA can vary over time, it is prostate dependent and the level of 
PSA can be elevated by malignant and well as non-malignant conditions, including benign 
hypertrophy and prostatitis (Oesterling et al., 1988; Oesterling et al., 1991). The 
assessment of PSA levels and aggressive treatments have increased the survival rates of 
patients with prostate cancer. Assessment of PSA alone is insufficient for accurate 
diagnosis and more precise ways of assessment, such as TRUS and TP pathology, are 
proving more reliable (Cooperberg et al., 2011). The initial PSA threshold was proposed to 
be 4.0 ng/mL (Fitzpatrick et al., 2009) which has recently been reduced to 2.5 ng/mL by 
the National Comprehensive Cancer Network (NCCN), USA to improve the sensitivity and 
detection rate (Oesterling et al., 1988). Figure 5.2 shows the PSA levels (ng/ mL) of the 
patients at varying stages of the disease.  
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Figure 5.2.  The PSA level of the patients selected for the study. The patients were separated in four groups 
of benign, low, intermediate and high grade cancer on the basis of the Gleason grade score and D’amico 
classification. The level of PSA (ng/mL) was assessed on the day of first examination and is shown on the Y 
axis for individual patient. 
 
5.5 ELISpot performed with freshly thawed PBMCs stimulated with 
class I and class II p53 peptides 
 
The PBMCs (from HLA-A2 positive patients) were thawed as per the method described in 
the chapter 2. These cells were then plated at 5x105 cells/well and assessed by ELISpot. To 
assess the T-cell response against class I p53 peptides, T2 cells were labelled (pulsed) with 
the p53-320-327(class I) peptide, co-cultured with the PBMCs for 24 h and assessed for 
IFNγ response using ELISpot. Additionally, the IFNγ response was assessed for p53-249-
264 class II peptide by co-culturing the PBMCs with the peptide for 48 h.  Figure 5. 3 
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shows the IFNγ response obtained towards the class I p53-322-329 peptides in (A) and 
class II p53-249-264 peptide in (B). 6 patients from intermediate and high grade cancer 
showed significant IFNγ response, and low levels of responses were obtained from some of 
the benign patients. For the class II p53-249-264 peptide, 7 patients, spanning all the 
groups, showed significant IFNγ response including one benign patient. Three patients 
from the intermediate group showed high background over that of the response obtained 
from the p53-249-264 peptide stimulation. 
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(A) 
(B) 
    
    
Figure 5.3. Represents the IFNγ response obtained using ELISpot assay. (A)  represents the IFNγ response 
obtained after stimulating the PBMCs with p53-322-329 class I peptide for 24 h. (B) represents the IFNγ 
response obtained after stimulating the PBMCs with p53-249-264 class II peptide for 48h.  Comparisons of (± 
SEM) means between peptide stimulated and unstimulated PBMCs were made and paired student t test was used 
to determine the statistical significance. *p<0.05, **p<0.01, ***p<0.001 
 
 
Chapter 5: Assessment of immunogenicity of the selected p53 peptides in PrCa patient PBMCS     
 
151 
 
5.6 Stimulation of PBMCs in vitro and assessment of immune response: 51Cr 
release (cytotoxicity), 3H Thymidine incorporation assays 
 
Cryopreserved PrCa patient PBMCs were thawed (see methods section) and stimulated with 
p53-322-329 class I peptide for 1 week in vitro. A 51Cr release cytotoxicity assay was 
performed using targets LnCap and DU145 target cells, which represent HLA-A2 positive and 
HLA-A2 negative cell lines respectively, assessed using geometric mean in comparison with 
the control [Figure 5.4 (A)]. The percent specific lysis is shown in figure 5.4 (B). Cytotoxicity 
was observed in all the groups of patients towards LnCap target cells, with higher percent 
specific killing by T-cells by PBMC’s from intermediate and high grade cancer patients. 3 
benign patients also showed significant, more than 10% cytotoxicity, towards LnCap cells, 
whereas low or no cytotoxicity was observed towards DU145 cells. 3H incorporation 
(proliferation assay) was performed with PBMCs stimulated in vitro with p53-249-264 peptide 
for 48 h. Counts per minute obtained on stimulation with the peptide are shown in the figure 
5.4 (C). 11 patients from low, intermediate and high groups showed significant response 
towards p53-249-264 peptide in the proliferation assay. No peptide specific proliferation was 
observed in the patients with benign diagnosis. 
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Figure 5.4. The immune responses obtained following the in vitro stimulation of PrCa patient PBMCs. (A) shows 
the HLA-A2 status of the LnCap and DU145 cells which were used as target cells in the 51Cr release cytotoxicity 
assay. (B) represents the percent specific lysis of LnCap and DU145 respectively, by  peptide stimulated PBMCs 
from the PrCa patients. The PBMCs were stimulated in vitro with p53-322-329, PAP and T21 peptides. (C ) 
represents the proliferation of the PBMCs (counts per minute) after in vitro stimulation of the PBMCs with p53-
249-264 class II peptide in comparison with the unstimulated cells alone (control) assessed using 3H Thymidine 
incorporation.. Comparisons of percent specific lysis of LnCap and DU145 was done for 4h cytotoxicity assay 
and (± sem) means between peptide stimulated and unstimulated PBMCs (control) for proliferation assay. 
Student t test was used to determine the statistical significance. *p<0.05, **p<0.01, ***p<0.001 
 
5.7 Assessment of regulatory T-cells in PrCa patient PBMCs 
 
PrCa patients PBMC samples selected for the current study were stained with CD3, CD4, 
CD25 and Fox P3 antibodies. CD3 is the generic marker for T lymphocytes (Clevers et al., 
1988; Alvadori et al., 1994; Vernau et al., 1999), and CD4, CD25 and Fox P3 positive cells 
represent the population of regulatory T-cells (TRegs) (Wolf et al., 2003). Figure 5.5 shows 
the percent TRegs present in the PBMC population of benign and cancer patients’ blood. 
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Patient PBMCs were thawed and stained for cell surface (CD3, CD4, CD25) and intracellular  
(FoxP3) markers for flow cytometry analysis (method explained in chapter 2). For individuals 
with a benign diagnosis, classification was based on TRUS and/or TP pathology. The cancer 
cohort of patients included those with varying disease status, including low grade (n = 5), 
intermediate (n = 7) and high grade (n = 6) cancer. It was observed that the percent TRegs 
increases in cancer patients compared to the benign. Table 5.2 gives the summary of responses 
obtained from the PrCa patients in different immune-assays.   
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(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. The percentage of regulatory T-cells present  in the PrCa patient PBMCs. The percentage of regulatory T cells 
was assessed by staining PBMCs with CD3, CD4, CD25 and FoxP3 antibodies and the cells were assessed using flow 
cytometry. The patients were grouped into benign and cancer. The data represents the median of the two groups of PBMCs. 
The cancer group was then split into low, intermediate and high grade disease status in (II). The benign cohort contain 5 
patients with diagnosis as Benign depending on the TRUS and/or TP examination. The Cancer cohort contains patients with 
different disease status (low grade = 5, Intermediate = 7 and High grade = 6). (B) gives an example of the gating used for the 
analysis of the TRegs in patient cohort. The groups with varying disease status were compared with the benign group for 
presence of percent TRegs using One way ANOVA. *p<0.0249 
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Table 5.2. Summary of the immune assays performed using PrCa PBMCs stimulated with p53 class I and class II 
peptides1 
  
 
51Cr 
cytotoxicity 
assay 
 
ELISpot 
Class I 
ELISpot 
Class II 
 3H Thymidine 
incorporation 
proliferation 
assay 
 
 
% TRegs 
CD4+CD25+
Foxp3+ p53-322-329 p53-249-264  p53-249-
264 
Benign       
TP0024 +     2.99 
TP0034       5.04 
TP0047 + + +   3.69 
TP0055      2.43 
LE0040  +    2.79 
LE0044 + +    3.34 
Low       
LE0059   +  + 5.19 
LE0078 +     6.15 
LE0079      3.03 
TP0022 + + +  + 3.77 
TP0040 +    + 4.46 
Intermediate       
LE0048 +  +  + 6.11 
LE0050 +  +   2.66 
LE0052      5.37 
LE0053 + + +   6.92 
LE0071 + +    5.32 
LE0072 + +   + 3.47 
LE0084     + 10.28 
High       
LE0043 + + +  + 5.09 
LE0061  +   + 7.82 
LE0067      5.76 
LE0068 + +   + 3.7 
LE0069 +    + 6.27 
LE0086 +    + 3.52 
Responders 15/24 10/24 7/24  11/24  
1The table represents the summary of all the patients responded to the immune assays performed. 
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5.8 Discussion 
 
Pre-clinical trials are required to assess the immunogenicity of peptides, derived from tumour-
associated antigens, as a potential target antigen for clinical evaluation. The potential immune 
response in the patients can be predicted by stimulating PBMCs from cancer patients or 
normal subjects with the peptides of interest in vitro (Nastke et al., 2012; Kim et al., 2014). In 
the previous chapter, p53 HLA class I and class II peptides (p53-320-327 and p53-249-264 
respectively) were identified and a vaccination strategy was developed using a pre-clinical 
murine model. To further evaluate their potential as target antigen, the immunogenicity of 
these peptides were assessed using HLA-A2 positive PrCa patient PBMCs. Patients were 
further divided into benign, low grade, intermediate and high grade cancer on the basis of the 
disease status and pathology. TRUS biopsies are widely used as “Gold standard” for prostate 
cancer diagnosis (Nafie et al., 2014), although it has recently been shown that the TP/TP 
method of assessment of prostate is more accurate than TRUS/TRUS assessment for 
establishing the status of the disease (Nafie et al., 2014) and reduces risk of infection and 
patient mortality.   
In this study, all patients were diagnosed (grade and stage of disease) according to defined 
pathological criteria. Patient details, disease status/grading performed on the basis of the 
D’Amico classification, Gleason grade, and PSA level were recorded at the time of biopsy. In 
the cohort of patients selected for the current study, the PSA levels were assessed at the time 
of biopsy and which ranged from 3 to118 ng/mL. Increased level of PSA was observed in the 
patients with high grade disease compared to the other groups. Although important, PSA 
assessment has limitations. In the current study although higher PSA level was observed in the 
high grade cancer group, no significant difference in the PSA was observed in the internediate 
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and low grade cancer group compared to that in the benign patient group, giving rise to the 
need of more accurate diagnostic methods. To overcome these hurdles new technologies are 
emerging to assess the status of the prostate cancer such as using Dynamic contrast-enhanced 
(DCE)-MRI in conjunction with PSA assessment. DCE-MRI is a multi-parametric strategy 
and is an emerging technology useful in evaluating severity, location, extent of primary and 
recurrent prostate cancer (Verma et al., 2012).  
Sipuleucel-T, a DC based prostate cancer vaccine targeting Prostatic Acid Phosphatase (PAP), 
developed by Dendreon, has been approved by FDA which successfully prolonged the patient 
survival (Kantoff et al., 2010). Although approved for clinical use, a rational evaluation of the 
vaccine has raised questions about the underlying immunologic mechanism involved, and the 
prolonged time period taken in the vaccine preparation (as it’s a DC-based vaccine) which 
results in it being an expensive form of therapy (Chambers et al., 2011).  The cost per vaccine 
cycle is US$93,000 (Gupta et al., 2011), the vaccine proved ineffective in patients younger 
than 65 years of age 
(http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/Appr
ovedProducts/UCM214543.pdf). Due to these limitations, there is a need for further 
development of a more robust assessment to define immunogenic PAP peptides and immunity 
to other cancer antigens such as p53 for developing defined immunotherapy approaches to 
treat prostate cancer patients, especially those patients with castration-resistant disease.  
In order to assess the immunogenicity of p53 peptides in PrCa patients, cryo-preserved 
PBMCs were thawed and stimulated with the p53 class I and class II peptides prior to IFNγ 
ELISpot assay to determine the level and specificity of T-cell responses; 8/24 and 7/18 PrCa 
patients showed significantly positive responses towards the class I p53-322-329 and class II 
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p53-249-264 peptides respectively when compared with cells alone (control). Although this 
chapter presents the results obtained using p53 peptides, these patients were also assessed for 
ELISpot, cytotoxicity and proliferation responses to PAP (Saif et al., 2014) and T21 (Miles et 
al., 2006) peptides (data not shown). In these experiments PBMCs co-cultured with 
unstimulated T2 cells were used as a control. More controls such as PBMCs from healthy 
individuals or HLA-A2 negative patients needed to be added to study. In order to assess 
killing in a 51Cr release cytotoxicity assay, PBMCs were stimulated with class I p53-322-329, 
PAP and T21 peptides in vitro (due to limitation of available PBMCs, assays were sometimes 
only performed once; data not shown for PAP and T21) and LnCap (HLA-A2 positive and 
shown to naturally express p53 antigen) and DU145 (negative control: HLA-A2 negative cell 
line) cells were used as the target cells. LnCap specific lysis was observed after stimulating 
PBMCs with peptide; 12 PrCa patients out of 24 showed enhanced positive cytotoxic response 
against p53 class I peptides, with no or low cytotoxicity against DU145 cells. The non-specific 
lysis observed in the benign cohort may be due to killing mediated by natural killer (NK) cells 
rather than T-cells. NK cells are known to induce anti-tumour immune responses independent 
of the HLA status of the patient. It was also observed while performing this study that resting 
PBMCs in the in vitro culture leads to loss of PBMCs. Similar results were observed and 
published earlier by Kuerten et al. in 2012.  
11 out of 24 patients showed p53-249-264 peptide (HLA DR class II peptide) specific 
proliferation when assessed using 3H thymidine incorporation. It was observed that PBMCs 
stimulated with selected p53 class I and class II peptides showed peptide specific 
immunogenic responses and release of IFNγ, specific lysis of the targets and proliferation. 
From the responses observed in all three assays, it was concluded that the patient response 
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increased with progression of the disease when assessed using 3H thymidine incorporation 
proliferation assay, 51Cr release cytotoxicity assay and ELISpot assay for class I p53 321-331 
peptide. In addition, the percentage of regulatory T-cells was assessed in this HLA-A2 cohort, 
which showed that more TRegs percentage in PBMCs of cancer patients compared to patients 
with benign disease. Similar enhancement of TRegs was observed in a study performed by 
Clarke et al., 2006 in the colorectal cancer. It has also been shown that peripheral TReg are 
increased in PrCa patients as compared to individuals with no prostate disease pathology or 
patients with benign prostatic hyperplasia (BPH) patients (Akin et al., 2011).  From these 
results and others, it has also been suggested that PSA may have a role in the 
induction/maintenance of the increased TRegs (Koksoy et al., 2009; Akin et al., 2011). In 
contrast to these findings, a study conducted by Yokokawa et al. (2008) showed no differences 
in the TReg population in context of the PrCa disease stage/grade. In another independent 
analysis performed in our group on the larger cohort of all the PrCa (mix HLA haplotypes) 
patients diagnosed using TP biopsy showed no significance difference in TRegs in the patients 
with varying disease status. If the percent TRegs observed is truly associated with the disease 
stage/grade still remains to be determined.  
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Chapter 6: Discussion 
The main objectives of this study were to assess the peptide repertoire of two mutant forms of 
the p53 protein, 175 and 273, identify the immunogenic peptide regions and to develop a 
vaccination strategy to enhance the immunogenicity of selected p53 peptides. A mouse tumour 
model was developed to assess the efficacy of the developed vaccination strategy using 
therapy experiments in the pre-clinical setting. Following the assessment of immunogenic 
peptides in the tumour model, these peptides were assessed for their immunogenicity using 
Prostate Cancer (PrCa) patient PBMCs in order to gain insight into their clinical relevance.  
6.1 Immunotherapy for prostate cancer: general considerations and current 
status 
 
Cancer immunotherapy has emerged as a promising therapy alongside/in combination with 
traditional therapies (chemotherapy, radiotherapy and surgery) (Mishra et al., 2012). The lack 
of significant side-effects of immunotherapy, allows patients to continue with a good quality 
of life while undergoing treatment (Wolf et al., 2011).  Cancer immunotherapy targets tumour 
specific antigens and tumour associated antigens (TAAs) which are not present on any other 
organs of the body with a few exceptions, and can therefore be considered to be a cancer-
specific mode of treatment (Disis et al., 2009; Reuschenbach et al., 2009). In considering 
tumour specific antigens as therapeutic targets, several points require consideration. Cancer 
cells can express various types of antigens, and most of them are specific to the tumour with 
few exceptions (Romero and Coulie, 2014). However, not all “antigens” are “immunogenic” 
(Romero and Coulie, 2014), in part due to the impact of the tumour microenvironment on the 
antigen expression, priming, immune suppression, lytic T-cell activation and re-stimulation of 
T lymphocytes (Gajewski et al., 2006). Some tumour antigens are mutated during cancer 
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initiation or their expression is lost (Segal et al., 2008; Gajewski et al., 2006). It was shown 
that immunogenicity is still retained, in spite of loss of some antigens, as cancer cells may 
carry more than one tumour antigen as is the case with melanoma (Germeau et al., 2005; 
Lennerz et al., 2005; Romero and Coulie, 2014). The T-cell response to tumour antigens is 
considered essential for effective immunotherapy and in some instances T-cell activation 
elicits auto-immune reactions to the same antigen expressed on normal cells (Romero and 
Coulie, 2014). It has also been shown that with careful selection, the immunogenicity of the 
TAA peptides can be improved with either “agretopic” substitution (amino acid substitution to 
increase HLA binding, resulting in refined antigenicity and immunogenicity) or “epitopic” 
substitution which directly improved the binding affinity of the T-cell receptor (TCR) for the 
peptide (Romero and Coulie, 2014). Immunotherapy, combining the use of TLR agonists 
together with chemotherapy or radiotherapy seems to be a promising approach; chemotherapy 
especially promotes the potential of immunotherapy, for example, the use of 
cyclophosphamide to control regulatory T-cells (TReg) (Audia et al., 2007), anti-androgens 
that enhance T–cell infiltration into the tumour and anthracyclines that appear to increase the 
potential for antigen presentation within the tumour environment (Unadkat, 2005; 
Krishnamurthy, 2006).  It is also recognised that monoclonal antibody (mAb) therapy, directed 
towards cell surface antigens on tumour cells, promotes T–cell responses via tumour 
destruction and increased tumour antigen processing and presentation by DCs. This indirect 
mechanism, combined with targeted vaccine therapy represents a promising approach to 
immunotherapy (Rane et al., 2014). 
PrCa is the most prevalent cause of morbidity and mortality in UK males 
(www.cancerresearchuk.org) and it is therefore important to develop new therapies to treat 
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patients with castration-resistant cancer and improve the overall survival and quality of life of 
patients suffering from the disease. Sipuleucel-T (PROVENGE(R), a DC-based vaccine 
developed by Dendreon) for the treatment of PrCa has been shown to increase the life 
expectancy of the PrCa patients (Kantoff et al., 2010). Although approved for clinical use, a 
rational evaluation of the vaccine has raised questions about the underlying immunologic 
mechanism involved, and the prolonged time period taken in the preparation of this vaccine 
which results in it being an expensive form of therapy (Tombal, 2011).  The cost per vaccine 
cycle is US$93,000 (Gupta et al., 2011), and the vaccine appears to be ineffective in patients 
younger than 65 years of age 
(http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/Appr
ovedProducts/UCM214543.pdf). However, these studies have shown the clinical efficacy of 
antigen targeted immunotherapy in PrCa. Several other vaccine strategies have been or are 
being developed, including adoptive immunotherapy (infusion of tumour specific T cells) 
(Bellone et al., 2014). There are various PrCa clinical vaccine trials currently registered and 
undergoing evaluation, for example, GVAX which was engineered allogeneic tumour cell 
lines that secrete GM-CSF (Rigamonti and Belloni, 2012). There are several other trials using 
CD8+ and CD4+ specific TAA peptides or viral vectors encoding TAA alone or in 
combination with co-stimulatory molecules (for examples, PROSTVAC), using a monoclonal 
antibody against CTLA-4 or combination therapy incorporating TLR agonist (Bellone et al., 
2014). Another mode of immunotherapy is to adoptively transfer T lymphocytes, which has 
shown some benefit in treating early stage PrCa patients (Granziero et al., 1999 supported by 
recent finding that SV-40-specific redirected T-cells when adoptively transferred in transgenic 
adenocarcinoma of the mouse prostate (TRAMP) mice bearing mPIN lesions inhibit tumour 
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growth (de Witte et al., 2008). In addition, the adoptive transfer of autologous T-cells that 
target PSMA is undergoing trials at present  (http://www.clinicaltrial.gov). Although cancer 
immunotherapy faces many challenges, there appears to be patient benefit (better quality of 
life, less side effects compared to conventional cancer treatments) when this form of therapy is 
used in combination with the chemotherapeutic agents (Ramkrishanan et al., 2010). It was 
shown that with upregulation of mannose-6-phosphate receptors on tumour cells, 
chemotherapy enhances tumour cell susceptibility to CTL mediated cytotoxicity. The CTLs 
also showed a bystander effect on neighbouring tumour cells that did not express the specific 
antigen (Ramkrishanan et al., 2010).  
6.2 p53 peptide-based immunotherapy  
Loss of the tumour-suppressive activity of p53 is a frequent event in human cancer, occurring 
in more than 50% of all types of human cancers (Petitjean et al., 2007b; Rivlin et. al., 2011; 
Wang Y et al., 2013). P53, the “guardian of genome”, acts to suppress tumour development by 
various mechanisms, including, cell cycle arrest, DNA repair, senescence and apoptosis 
(Aylon Y et. al., 2011) and is inactivated through missense mutations caused by alteration of a 
single amino acid in the DNA binding domain of the p53 protein. Carcinogenesis however 
requires the concomitant loss of tumour suppression and gain of oncogene activity. In prostate 
cancer p53 is reported to be expressed in small percentage however the expression increases 
with the progression of disease and patient age. In an imunohistochemical study conducted by 
Al-Nuaimi et al. (2011), expression of p53 was detected in 29% of the patients with age 
ranged between 41 to 90 years. It was shown that expression of p53 has statistically significant 
relationship between patients’ age and  Gleason score with highest expression found in the 
Gleason score 9 and 10 (Al-Nuaimi et al., 2011). A statistically significant inverse relationship 
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was found between p53 expression and tumour differentiation with higher expression in 
poorly differentiated prostate adenocarcinoma (Al-Nuaimi et al., 2011).  
Speetjens et al., (2009) first reported on a vaccine targeting p53 and consisting of synthetic 
long peptides in IFA. It comprised of 10 overlapping peptides (25-30 amino acid long), 
spanning 70-248 amino acids of the wt p53 protein sequence. The vaccine trial was performed 
in patients with metastatic colorectal cancer (Speetjens et al., 2009) and ovarian cancer as a 
phase II clinical trial (Leffers et al., 2012). Interestingly in vaccinated patients, both Th1 and 
Th2 specific CD4+ T-cells were observed, but not CD8+ T-cells, possibly due to the inhibitory 
effect of Th2 cytokines on CD8+ T-cell activation (Yamada et al., 2013). A study by Rahma et 
al., (2012), showed that p53 specific CTL epitopes when co-injected with Montanide and IL-2 
showed a similar progression-free and overall survival when compared with peptide-pulsed 
DCs given with IL-2. In the current study two mutations of p53 were selected, mutation-
specific p53 peptides were identified and a vaccination strategy was developed for the 
treatment of PrCa. This approach of selecting mutation specific peptides for the development 
of PrCa therapy is reported here for the first time with p53-322-329 class I and p53-249-264 
class II peptides in combination with the TLR agonist. The results demonstrate that mutation 
175 and 273 mutation specific class I and class II peptides demonstrate enhanced immunity 
when used in combination with anti-CD40 antibody and TLR agonist. Currently there are no 
patient clinical trials registered targeting p53 peptide-based PrCa vaccine in combination with 
TLR agonist.  
6.3 The p53 peptide repertoire is dependent on the site of mutation  
P53 mutations in cancer progression are associated with trans-dominant suppression of wt p53 
or gain of oncogenic function independent of wt p53. These two characters may be 
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simultaneous events and their effects can be difficult to separate (Sigal and Rotter, 2000). P53 
“hot-spot” mutations are frequently found within the conserved regions of the central DNA 
binding domain of the protein and are categorised into class I and class II types depending on 
the L3 loop or loop-sheet-helix motif of the p53 protein (either support the DNA-binding 
surface structure or sustain conformational stability of the protein involving the L2 loop in the 
zinc region) (Attardi and Jacks  1999; Wong et al., 1999; Cho et al., 1994; Joerger et al., 
2007). The majority of mutations are clustered in the central most conserved region of the p53 
gene (Freed-Pastor et al., 2012) and the mutant p53 protein thereby loses its tumour 
suppressive properties and gains oncogenic function, thus leading to enhanced cell growth and 
survival as a consequence (Olivier et al., 2010). P53 mutants showing mutations at 273 and 
175, were selected for the current study as they represent the two categories of mutants, class I 
and class II, demonstrating the two extreme conformational alterations in p53 structure and 
function, that leads to protein inactivation in cancer (Joerger and Fersht, 2007). The immune 
response was assessed in the splenocytes from the mice immunised with either DNA encoding 
175 or 273 p53 mutant proteins. On the basis of the results obtained it was indicated for the 
first time that the p53 peptide T-cell response was different towards the two mutant forms of 
the protein, suggesting that the two mutants give rise to different peptide repertoires and a 
differential T-cell response. Using the SaOS cell lines (SaOS-175 mutant and SaOS-273 
mutant) differential cell morphology, rate of proliferation (unpublished data, Appendix I) and 
gene profile changes have been observed (Vadakekolathu et al., unpublished data) and it was 
suggesting from previous studies conducted in this laboratory (unpublished data) that when 
DCs were cultured with supernatants from the SaOS-175 and SaOS-273 cell cultures, they 
showed a difference in the rate of protein processing (McArdle et al., unpublished data). These 
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findings substantiate the results indicating that the mutation site determines the peptide 
repertoire generated from the p53 protein and hence qualitative and quantitative differences in 
T-cell responses may occur. This would influence the strategy that should be adopted for 
patients whose tumour express the p53 mutations. 
6.4 Enhancing the immunogenicity of the peptides 
Following the first report in 1991 demonstrating that vaccination with a single MHC class I 
binding CTL peptide epitope in IFA protected mice against a subsequent tumour challenge, 
many studies have focused on the efficiency of this mode of vaccination for inducing tumour 
immunity (Schulz et al., 1991). The identification of human tumour antigens has paved the 
way for developing targeted immunotherapy (Boon and Van den Eynde, 2003), with 
specificity to destroy cancer cells and induce long lasting immune memory without eliciting 
lethal side effects. Targeting MHC class I and class II epitopes of the tumour antigen has 
achieved moderate clinical success and cancer immunotherapy and peptide therapeutics have 
demonstrated improved responses over that of the conventional treatments in patient groups 
where treatment options are limited (Rane et al., 2014), but there are still obstacles to 
combatting advanced cancer, where the immune system of the host is compromised. Thus, 
implementing ways of overcoming states of immune tolerance, anergy or suppression 
concomitant with a vaccine strategy to enhance adaptive immunity, offers an attractive route 
for clinical intervention. Targeted therapies against defined tumour antigens involving the use 
of peptide–based vaccination, offers a potential for the future, which relies on knowledge of 
peptide epitopes and awareness of how these can be used to activate appropriate anti-tumour 
immune responses.  
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The aim of any cancer vaccine is, in most cases, the induction of T cell responses via 
stimulation of cellular immunity. In order to deliver and optimise vaccination, several 
protocols have been adopted, for example, the use of immunobodies to deliver peptide coding 
sequences within a DNA vector (Metheringham et al., 2009) and encompassing helper 
peptides that promote CD4 as well as CD8 T-cell responses (Metheringham et al., 2009) or 
using nanoparticles delivery systems. However in the present study none of these strategies 
were able to enhance the immunogenicity of selected p53 peptides. It has been demonstrated 
in 2012 by Ahonen et al., that different TLR agonists when combined with anti-CD40 
antibody in a C57BL6 mice induced CD8+ T cell expansion to immunisation with ovalbumin 
protein and/or the SIINFEKL peptide. In the present study it was demonstrated for the first 
time that, class I and class II p53 peptides (specific for 175 and 273 mutations I p53) in 
combination with anti-CD-40 antibody and TLR agonist combination, moderately enhanced 
the immunogenicity of the peptides.  
6.4.1 Agonists as efficient mediators to enhance the immunogenicity of the peptides in 
vaccination 
 
The half-life of the antigen can be significantly extended,  to several hundreds of days in some 
instances, when emulsified in the adjuvant in comparison with antigen injection alone (Rane et 
al., 2014) and TLR agonists act as potent adjuvants, activating DCs, augmenting T cell 
responses and down regulating the suppressive effects of regulatory T cells. They promote 
both adaptive and innate anti-tumour immunity and affect the tumour microenvironment. TLR 
3, 4, 7, 8 and 9 are the most promising TLR agonists for use alongside vaccination strategies 
(Cheever, 2008). Several other examples exist such as; the demonstration of the growth of 
transplanted and viral tumours can be prevented by co-administration of attenuated Bacillus 
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Calmette–Guérin (BCG) (Sjogren and Ankerst, 1969; Bekierkunst, 1971) and when inoculated 
into established tumours leads to tumour regression and prevention of metastasis (Zbar and 
Tanaka, 1971). BCG is being used in phase I and II clinical trials, targeting melanoma, 
colorectal and breast cancers and neuroblastoma. It is also involved in phase III clinical trials 
targeting melanoma, colon and lung cancer (Vacchelli et al., 2012). Monophosphoryl lipid A 
(MPL) is a chemical derivative of S. minnesotta endotoxin, which acts as a potent TLR4 
agonist and has been incorporated into Cervarix(R) (Human Papilloma Virus [HPV] associated 
cervical cancer vaccine) in the form of AS07 (MPL + aluminium salts) (Schiffman and 
Wacholder, 2012) and several other TLR agonists have been reported, including Imiquimod 
and CpG ODN (Drobits, 2012; Akira, 2003).  
The induction of innate immune responses by TLRs is mirrored by the acquired immune 
response induced by the CD40 activation and different TLR agonists when combined with 
anti-CD40 antibody induces CD8+ T cell expansion in response to ovalbumin and/or the 
SIINFEKL peptide (Ahonen et al., 2004). In the current study anti-CD-40 antibody was used 
to prime DCs and TLR 9 was used in combination with the p53 class I and class II peptides in 
the immunisation mixture to boost the CD4 and CD8 T-cell responses. When peptide 
immunisation with/without anti-CD-40 and/or CpG TLR was compared, the combination of 
anti-CD-40 antibody and TLR agonist in the peptides mixture showed comparatively strongest 
immune response suggesting the synergistic effect of the antibody and TLR agonist when used 
together with peptide. This developed vaccination strategy also successfully prolonged the 
survival of mice bearing  MC38) induced tumour (naturally expressing mutated p53). 
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6.5 Booster immunisation can be detrimental for overall survival in a 
therapeutic setting 
 
It has been observed that in general vaccination against infectious diseases or cancer aims to 
boost the CD8+ memory T cell (TCM) population to protect or irradicate disease (Seden and 
Hill, 2000). In the current study, a moderately prolonged survival was observed in the tumour 
bearing mice receiving therapy designed to promote p53 class I (322-331) and class II (249-
264) peptide specific T-cell immunity using a vaccine combined with a TLR agonist and anti-
CD40 antibody. The mice that received only one vaccination showed (statistically significant) 
longer survival compared to the group that received the vaccine plus a booster immunisation 
on day 14. The ability of homologous and heterologous prime and boost regimes to enhance 
immunity has been investigated previously using a DC-based vaccine strategy for sustaining 
anti-tumour immunity (Ricupito et al., 2013). It was found that vaccination with further 
booster injection or multiple injections at short time intervals did not sustain the TCM cells in 
the spleen, whereas a booster injection 6 weeks apart improved immune mediate protection 
against B16BL6-D5 melanoma (Ricupito et al., 2013). It was further observed that vaccination 
was important for increasing disease-free survival, but repeated homologous vaccination was 
found to be detrimental for the maintenance of the tumour-specific CD8+ T cells (Ricupito et 
al., 2013). In a similar study, it was shown that multiple booster immunisations with D5G6 
irradiated tumour cells in reconstituted-lymphopenic mice at short intervals, reduced the 
efficacy of adoptively transferred CTLs in a B16BL6-D5 melanoma model (LaCelle et al., 
2009). It has also been suggested that the death of cancer cells, as a result of therapy, may 
release TAAs (Bellone, 2000) which may provide a boost to immune system and that 
additional booster immunisations may lead to exhaustion of the immune cells or tolerance 
(Sallusto et al., 2010). From these studies it can be concluded that booster immunisations are 
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important in a prophylactic setting to sustain the antigen specific CD8+ T-cell immunity but 
may be inappropriate or even detrimental in a therapeutic setting due to exhaustion of the 
CD8+TCM cells. Hence it is important to optimise the immunisation schedule depending on the 
status of the patient and their treatment history. The results obtained in the present study 
support this promise, showing that improved T-cell responses and prolonged survival in mice 
which were primed once with the developed p53 peptide-based vaccine (in combination with 
anti-CD-40 and TLR agonist) compared to the mice which received the booster vaccination. 
Optimisation of vaccine therapy is essential to maximise and sustain anti-tumour immunity.  
6.6 Peptide specific PrCa patient immune responses to p53 
Pre-clinical investigations are required to assess the immunogenicity of peptides, derived from 
tumour-associated antigens, as potential target antigens for clinical evaluation. The immune 
responses of patients to tumour antigens can be assessed by stimulating PBMCs from patients 
with the peptides of interest in vitro (Nastke et al., 2012; Kim et al., 2014). In the final results 
chapter of this thesis, p53 HLA class I and class II peptides (p53-320-327 and p53-249-264 
respectively) were evaluated for their ability to stimulate T-cell responses using PBMCs from 
HLA-A2 positive PrCa patients at varying stages of disease: benign, low grade, intermediate 
and high grade cancers.  
Routinely trans-rectal ultrasound (TRUS) biopsies are widely used as a “gold standard” for 
prostate cancer diagnosis, but it has recently been shown that the Transperineal (TP) method 
of assessment of prostate is more accurate for assessment of disease status (Nafie et al., 2014) 
and additionally reduces the risk of sepsis and patient mortality. All patients evaluated for 
their immune status to p53 were diagnosed (grade and stage of disease) according to defined 
pathological criteria using TP and TRUS biopsies. It was observed in this cohort of patients 
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that the level of PSA increases with progression of the disease to advanced stages. Although 
important, PSA levels are organ specific, not disease specific, and so this assessment has its 
limitations when used alone or together with TRUS biopsy pathology. To overcome the 
obstacles of current diagnostic tests, new technologies are emerging to assess the status of the 
prostate cancer, such as using dynamic contrast-enhanced (DCE)-MRI in conjunction with 
PSA assessment. DCE-MRI is a multi-parametric strategy and is emerging as a useful method 
in evaluating severity, location, extent of primary cancer and recurrent prostate cancer (Verma 
et al., 2012). In assessing immunity to p53, it was important to have an accurate patient 
diagnosis of stage and grade of disease. 
Various functional assays were performed to assess pre-existing T-cell immunity and/or T-cell 
activation to p53 peptides, including ELISpot, 51Cr release cytotoxicity and 3H incorporation 
(proliferation) assays. It was also observed while performing this study that resting PBMCs, 
reconstituted from frozen stocks and cultured in vitro, decreased in number with time and this 
observation is similar to the results previously reported (Kuerten et al., 2012). This however, 
seems to occur with all PBMC samples. From the responses observed, using the three immune 
assays, it was concluded that the patient’s response increased with progression of the disease, 
demonstrating that the frequency of p53 alteration increases with progression of disease. The 
presence of TRegs was also assessed in this cohort of the patients where an increasing percent 
TRegs with progressing disease was observed. A statistically significant increase in the 
CD3+CD4+CD25+Foxp3+ cell population was observed with intermediate stage PrCa 
compared to the benign population, as has been previously reported by Clarke et al. (2006) in 
the colorectal cancer. It has also been shown that peripheral TReg are increased in PrCa 
patients as compared to individuals with no prostate disease pathology or patients with benign 
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prostatic hyperplasia (BPH) patients (Akin et al., 2011).  From these results and others, it has 
also been suggested that PSA may have a role in the induction/maintenance of the increased 
TRegs (Koksoy et al., 2009; Akin et al., 2011). In an independent study in our lab (with no 
defined HLA stuatus of the patients) showed no difference in the TRegs population. 
In the current study it was demonstrated for the first time that p53 class I and class II peptides 
(p53 175 and 273 mutation specific) when immunised with anti-CD-40 and TLR agonist, 
enhanced the immunity of the peptides and also showed moderately prolonged survival of 
tumour bearing mice. High population of patients demonstrated pre-existing immunity to p53 
peptides which would be beneficial to subsequent p53 directed immunotherapy. Further to this 
study it is important to assess the tumour tissues from these patients to assess the 
overexpression of the p53 antigen and also to determine the mutation status in order to provide 
more precise and patient specific immunotherapy. Unfortunately it was not possible to assess 
p53 mutational status and protein expression within individual tumours from this patient 
cohort. This is an important aspect of the study and is under current investigation.  
6.7 Conclusion and future work  
In the current study it was observed that the peptide repertoire produced by the two mutant 
forms of p53 (leading to extreme functional and conformational changes in the protein) is 
different and this has implications for vaccine-based immunotherapy. The immunogenicity of 
the peptides can be boosted by combining them with TLR agonist and anti-CD40 antibody at 
the time of immunisation and synergy  was observed using this adjuvant treatment. 
Furthermore, it is crucial to establish the optimum prime-boost regime which will be 
dependent on the presence of disease (or absence in the prophylactic setting), disease status 
and previous treatment history. From the results obtained in this study, the selected p53 class I 
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and class II peptides were immunogenic in the pre-clinical models and showed the ability to 
stimulate PrCa patient PBMCs in vitro. As reported in previous studies p53 is over-expressed 
or mutated in high proportion of PrCa patients. Time did not permit the assessment of p53 
over-expression by immunohistochemistry in this cohort of PrCa patients, in order to correlate 
p53 mutational/tissue expression with pre-existing immunity and T-cell functional activity. 
This is possibly the most important “follow up” study required to fully evaluate the 
significance of the findings given here. Which form of p53 mutation associates with immune 
response to immunogenic p53 peptides will be necessary to assess and comparison with pre-
clinical observations established using the 175 and 273 mutant forms will be of significance. 
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Appendix I 
Two mutants of p53 possess the potential of altering phenotype and 
genotypes of same cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SaOS Empty Vector SaOS p53-175 SaOS p53-273 
10x 
20x 
40x 
Figure II (a). Difference in the cell morphology after transfection with p53-175 and p53-273 mutants. 
SaOS cell line was transfected with pBR322 plasmid containing empty vector and/or p53-175 mutant and/or 
p53-273 mutant gene. Cells were cultured using under same conditions using G418 antibiotic (1 µg/mL) for 
selection of plasmid. The images were taken under 10x, 20x and 40x magnification suing inverted 
microscope. 
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Rate of cells proliferation changes after transfection with p53 mutants - 
p53-175 and 273 when assessed with MTT assay and (3H) incorporation 
proliferation assay and manual cell count using trypan blue 
 
(A)                                                                                 (B) 
      
(C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II(b). SaOS cell proliferation after transfection with pBR322- empty vector and/or pBR322-p53 175 
mutant and/or pBR322-p53 273 mutant. Graph (A) shows the difference in the rate of proliferation assessed 
using thymidine (3H) incorporation assay on d 3, d5 and d 7. Graph (B) shows the difference in the absorption of 
(dye) by SaOS cells transfected with pBR322-empty vector and /or pBR322-p53-175 mutant and/or pBR322-p53-
273 mutant when  assessed using MTT proliferation assay on d 3, d5 and d 7.  Graph (C) shows the number of 
cells in the 24 well plate when counted using trypan blue in 1:100 ratio on d1, 2, 3, 4, and 5. Comparisons of 
means (±SEM) between transfected SaOS osteosarcoma cell lines (aOS- empty vector, SaOS-p53-175, and SaOS-
p63-273) are made with a paired t test. The experiments performed 3 times with 3 triplicates for each cell line. 
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Appendix II 
DC maturation using LPS and anti-CD-40 antibody 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells alone 
FGK45 supernatant treated 
LPS treated 
Figure.Maturation of DCs using anti-CD-40 antibody and LPS. DCs were cultured and matured using 
LPS and were compared with the ones matured with anti-CD-40 antibody. The maturation was assessed 
on the basis of the expression CD11c marker expression. 
 208 
 
Appendix III 
Assessment of immune response obtained from the mice fed on different diet   
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Figure IV. Immune response obtained from mice fed on different diets. HHDII/DR1 mice were divided into two 
groups. First group was fed non-irradiated conventional diet whereas the second group was maintained on 
irradiated diet. Both the groups of mice received same peptide immunisation ie. p53-108 class II peptide in IFA. 
IFNγ response was assessed using ELISpot assay in vitro. The two groups showed different intensities of the immune 
responses (i)and (iii) with the only variable being food in their housing and maintenance.the ELISpot plate picture 
is shown in (ii) which shows the clear differences in the IFNg spots obtained form the mice fed on conventional (no-
irradiated) or barrier facility (irradiated)diet. All the mice were housed and maintained according to the Home 
office regulations.the experiment was repeated and similar results were obtained.  
 
Depending on these results obtained diet for all the mice in barrier facility was permanently 
changed to non-irradiated diet. 
 
 
 
(iii) 
(ii) (i) 
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